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ABSTRACT
Nanomedicine is a new field of science defined by the European Science
Foundation as “the science and technology of diagnosing, treating, and preventing
disease and traumatic injury, of relieving pain, and of preserving and improving human
health, using molecular tools and molecular knowledge of the human body” (ESF 2004).
The medical community has, however, made significant steps forward in understanding
the potential nanomaterials may have in medical treatment of certain diseases. Current
nanoparticles being evaluated include platinum, selenium, and ceria (Pt, Se, and CeO2,
respectively). While it is understood that these nanoparticles have potential medical
applications, there is a significant need to better understand both their potential
therapeutic uses as well as any adverse toxic effects they may have. Thus it is necessary
to further examine these nanoparticles and understand the full impact they have on health,
particularly at the cellular and subcellular level. Furthermore, the effectiveness of these
nanoparticles in the treatment of diseases, such as cancer and metabolic disorders
including fibrotic diseases, needs to be better understood to fully exploit their utility in
Nanomedicine. In this study, we evaluated the effects of three nanoparticles-Selenium
(Se), Platinum (Pt) and Cerium (Ce) on primary mouse embryonic fibroblast cells. NPs
were synthesized in the lab. Se NPs were produced via a chemical reduction of selenium
ions using ascorbic acid as a reducing agent. PVP-coated Pt NPs were prepared by
dissolution of Pt salts into water which chemically induced to convert to platinum atoms
by using a reducing agent such as sodium borohydride NaBH4 using the method
iv

described by Park et al.(2002); PVP-coated cerium oxide nanoparticles NPs were
synthesized as described previously by Merrifield et al. (2013). The physicochemical
properties of SE, Pt and Ce NPs, such as morphology, size distribution, and surface
potential, were determined. Cultured primary mouse embryonic fibroblast cells (MEFs)
were exposed to Se (1, 25 and 50 µg/ml), Pt (1, 25, 50 µg/ml) and cerium (1, 25 and 50
µg/ml) nanoparticles for up to 6 days and evaluated for cell viability, proliferation,
necrosis, DNA damage, and TGFB-1 signaling proteins expression by Immunoblotting.
Results indicated: (1) Se NP induced the intrinsic pathway of apoptosis in primary mouse
MEFs, at a minimal concentration of 1 µg Se/ml, without causing necrosis to the primary
cells and may provide a new therapy for some metabolic and neoplastic diseases; (2) Pt
NPs did not induce any toxicity in cell viability or lead to necrosis in MEFs, but
significantly reduce proliferation by > ~ 50% and induction of TGFb-1 canonical
pathway, causing production of endogenous collagen and a-smooth muscle actin (aSMA) thus indicating it might serve a big role in the TGFB-1 signaling pathway in early
stage cancer therapy but it may pose a hazard to patients with fibrotic diseases such as
cardiac fibrosis; and (3) Cerium oxide nanoparticles (Nanoceria) were able to inhibit
TGFB-1 signaling via inhibition of smad2/3 and downstream factors expression and
inflammation progression in MEF, without induction of adverse effect in in vitro studies.
These findings indicated the Se NPs caused cell death and show promise as a potential
for cancer therapy while Pt NPs signals tgf-b-1, which might help to limit early stage
cancer development but may have adverse effects during the later stages of cancer or
those suffering from fibrotic disease such cardiac fibrosis. Nanoceria, unlike Pt NPs,
down regulates tgf-b-1 signaling, which makes it appropriate for patients with fibrotic
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diseases, such as cardiac fibrosis. In this research, these nanoparticles showed incredible
potential as future therapies for cancer and cardiac fibrosis.
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CHAPTER 1
SELENIUM, CERIUM OXIDE AND PLATINUM NANOPARTICLES IN
MEDICINE: EFFECTS AND POTENTIAL APPLICATIONS

1.1 Chapter overview:
In recent times, the concept of nanotechnology has been widely applied in various
sectors, including healthcare, electronics, genomics, and construction. This trend can be
attributed to the impressive properties demonstrated by nanoparticles. With regard to
medicine, these properties include catalytic and antioxidant properties. Researchers have
studied various nanoparticles to determine their unique properties, effects, and potential
applications. This paper deliberates on the potential applications of nanoparticles in
medicine by examining the effects and properties of platinum, cerium oxide, and
selenium nanoparticles. Explicitly, in this chapter we examined these nanoparticles' in
terms of their toxicity, both in vivo and in vitro, as well as their sub-lethal effects
including beneficial protective, anticancer, oxidative stress, and immunostimulatory
effects. Most studies sggest that platinum, cerium oxide, and selenium nanoparticles
possess beneficial properties that enhance the treatment of various metabolic diseases,
including cancers, fibrosis and diabetes.
The paper examines these nanoparticles' protective effects, anticancer effects, oxidative
stress effects, immunostimulatory effects, and toxicity in vivo and in vitro. Most studies
insinuate that platinum, cerium oxide, and selenium nanoparticles possess beneficial
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properties that enable them to enhance the treatment of various metabolic diseases,
including cancers, fibrosis and diabetes
1.2 Introduction:
In recent years, nanotechnology has grown rapidly as an area of scientific research with
promising potential in several industrial sectors, including healthcare, electronics,
genomics, and construction. Nanotechnology denotes the tweaking of matter at the
molecular and atomic range to form nanoscale materials with extremely diverse and new
attributes. The use of nanoparticles in medicine can be described as nanomedicine.
Researches have conducted various experiments to test the efficacy of nanoparticles in
disease prevention and treatment. Even though some existing studies emphasize the
toxicity of nanoparticles, most suggest that some nanoparticles possess beneficial
properties/activities that enable them to enhance the prevention and therapy of various
diseases including different types of cancer and diabetes
1.3 Nanotechnology and medicine:
In medicine, nanotechnology encompasses the clinical applications of
nanoparticles, together with the utilization of artificial nano-robots to facilitate cellular
repairs. The manipulation of drugs and other elements at the nanometer level makes it
possible to modify their bioactivity and fundamental features. Therefore, nanomaterials
grant medical researchers and medical practitioners control over different drug properties
such as ,better regulated release over long or short periods; modification of solubility; and
blood pool retention time (Saini et al., 2010).
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In medicine, nanotechnology has exhibited potential to transform gene therapy,
drug delivery, imaging, diagnostics, as well as several other areas of research,
development and clinical application (Surendiran et al., 2009). With regard to drug
delivery, studies have established that nanoparticles can be used as drug carriers that
deliver drugs to specific types of cells. The engineering of nanoparticles is done in a
manner such that they are drawn towards disease-bearing cells, allowing for the direct
therapy of disease-bearing cells (Jahangirian et al., 2017). This method of treatment
lessens the damage to healthy body cells during treatment and makes it possible to detect
diseases earlier. There are various mechanisms for cellular uptake of nanomedicines, and
they are dependent on the nanoparticles characteristic features like size, aggregation state,
surface charge, zeta potential, and size distribution. Experimental studies have uncovered
that rod-shaped nanoparticles are more effective than spherical nanoparticles in the
delivery of chemotherapy drugs to breast cancer cells (Toy et al., 2014). Figure 1.1 below
illustrates the cellular uptake of nanoparticles.
Over the years, the integration of nanotechnology in clinical practice has resulted
in great therapeutic and diagnostic advancements in the treatment of several chronic
pathologies,

including

metabolic

disorders,

neurodegenerative

disorders,

and

cardiovascular disorders. The catalytic and antioxidant properties of nanoparticles make
them effective in the treatment of some metabolic disorders like diabetes. The antioxidant
properties of nanoparticles like selenium and cerium oxide enable them to reduce
oxidative stress. Oxidative stress describes an imbalance between the generation of
antioxidant enzymes and free radical species Reactive Oxygen Species (ROS) and
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Reactive Nitrogen Species (RNS) where free radicals production outstrips that of
antioxidants (Uttara et al., 2009).
The surplus generation of ROS can induce inflammation, which, in turn, brings
about oxidative stress and consequently, metabolic complications (e.g., diabetes
mellitus). Antioxidant nanoparticles counteract free radical species production in the cells
and thereby, prevent the development of metabolic disorders (Uttara et al., 2009). Figure
1.2 illustrates the mechanism of NPs’ antioxidant activities. Even though nanotechnology
has indisputable benefits in the biomedicine, there have emerged concerns regarding the
possible toxicity of nanoparticles. Toxicity could result from high chemical reactivity,
porosity, and the propensity to aggregate and high affinity for some biological structures
(Sharifi et al., 2012). Moreover, the minute size of nanoparticles enables them to
permeate biological membranes, obstruct enzyme proteins and ion channels, and
intermingle with genetic material (Leroueil et al., 2007). These activities can bring about
tissue and cell damage and cause oxidative stress. Although scholars have conducted
multiple studies to examine the various effects of nanoparticles, including their toxicity,
the number and quality of these studies are still insufficient to make conclusive claims.
Moreover, the findings of many existing studies have often been inconsistent. This article
presents a discussion on the protective, anticancer, and immunostimulatory effects as
well as the toxicity of selenium, cerium oxide, and platinum nanoparticles. Figure 1.3
shows the relationship between the toxicity of NPs and their therapeutic effects. This
review of the literature on each of these three NPs will evaluate the current state of
knowledge about their use in biomedicine.
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1.4 Selenium, cerium oxide, and platinum nanoparticles as antioxidants:
1.4.1Selenium
The administration of selenium (Se) as a supplement has been shown to cause a
substantial reduction in pro-inflammatory cytokines expression. Se integrates into
selenoproteins and considerably increases their antioxidative activities resulting in a
reduction of inflammatory responses in inflammatory and autoimmune illnesses (Duntas,
2009). Selenium is one of the primary compounds found in most antioxidant enzymes
like glutathione peroxidase (GPx), which inhibit oxidative stress.
Antioxidant activity is one of the biologic characteristics of selenium
nanoparticles. This property is influenced by the nanoparticle size as generally the
smaller the particle, the greater the antioxidant activity (Torres et al., 2012). Selenium
nanoparticles (Se NPs) boast improved antioxidant abilities and are generally less toxic
than other than other larger Se compounds (Mobasheri et al., 2018). (Mobasheri et al.,
2018). Selenium nanoparticles cause increased antioxidant effects by impeding the
formation of free radicals such as reactive nitrogen species (RNS) and reactive oxygen
species (ROS) (Mobasheri et al., 2018). These free radical species are responsible for
oxidative stress in cells, which results in several severe health outcomes. The antioxidant
effects of Se nanoparticles are through increasing activities of GPx and inducing less
oxidative stress (Hassanin et al., 2013). Se nanoparticles administration results in a
considerable rise in the concentrations of GPx, which, in turn, inhibits the generation of
ROS. This beneficial antioxidant activity of SeNPs can is due to the interaction between
C–N, NH, C=O, and COO– functional groups of proteins and nanoparticles (Torres et al.,
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2012). El-Ghazaly et al. (2016) revealed that the antioxidant property of selenium
nanoparticles may also reduce the gene expression of pro-inflammatory mediators like
PGE2, TBAR, and TNF-α. Therefore, the antioxidant activities of Se NPs are helpful in
the reduction of inflammation.
1.4.2 Cerium Oxide
Cerium oxide nanoparticles (nanoceria) exhibit antioxidant enzyme-mimetic
activity, together with the ability to vigorously hunt various RNS and ROS in cells (Dhall
& Self, 2018). The capacity to scavenge for ROS/RNS and the enzyme-mimetic activities
are determined partly by the inherent physicochemical characteristics of the
nanomaterials; the relative thermodynamic efficacy of redox cycling between Ce4+ and
Ce3+ ions on nanoceria’s surface; and the capacity of nanoceria to release and absorb
oxygen (Nelson et al., 2016).
Further, nanoceria's catalytic antioxidant activities are vigorous and receptive to
the chemical environment, physicochemical characteristics, and synthesis methods,
among other factors.Cerium oxide nanoparticles can function as catalysts that imitate the
enzyme superoxide dismutase (SOD) and seek and neutralize free radical species (i.e.,
RNS and ROS, hydroxides, etc.). Cerium oxide nanoparticles possess antioxidant SODand CAT-mimetic activity that make them effective in reducing levels of H2O2 and O2•−
in cells (Dhall & Self, 2018). These particles are also effective in scavenging for RNS
and ROS. In their study, Nelson et al. (2016) established that cerium oxide nanoparticles
synthesized with higher levels of Ce3+ than Ce4+ on the surface are more effective in
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scavenging for O2•− and H2O2, than nanomaterials made from a lower Ce3+/Ce4+ ratio.
The following equations show how cerium ions scavenge free radical species like ROS:
O2•− + Ce4+ → O2 + Ce3+
O2•− + Ce3+ + 2H+→ H2O2 + Ce4+
1.4.3 Platinum
Platinum nanoparticles (Pt NPs) have also demonstrated the significant
antioxidant activity by eliminating anion radicals and in a manner that resembles that of
superoxide Dismutase (SOD) and catalase enzymes (Watanabe et al., 2009). Pt NPs
scavenge free radical species and protect cells against radical damages. Conceivably, the
mechanistic pathway of Pt NPs’ scavenging activity involves protein kinase C. Onizawa
et al. (2009) postulated that treating secondary smokers with Pt NPs can increase
antioxidant activities, and inhibit the neutrophilic inflammation and the stimulation of
NF-kB in the lungs of mice. Furthermore, Pt NPs can act and function as antioxidant
enzymes in osteoclasts (OC) and safeguard against oxidative stress caused by
ovariectomy. Nomura et al. (2011) intimate that Pt NPs decrease ROS by reducing ROSgenerating NOX oxidases, NOX4, and NOX1, leading to decreased osteoclastogenesis.
Researchers have also contended that platinum nanoparticles have the potential to
safeguard against bone loss by restraining oxidative stress. Platinum nanoparticles
significantly inhibit the formation of osteoclasts, which ensure bone resorption. In their
study, Kim et al. (2012) established that exposure to platinum nanoparticles caused a
reduction in bone loss induced by ovariectomy (OVX) in animal models. The authors
contended that the high bone density facilitated by platinum nanoparticles was brought
7

about by the obstruction of osteoclastogenesis. Figure 1.4 below illuminates the
antioxidant enzyme-like activity of NPs.
1.5 Protective effects of selenium, cerium oxide and platinum nanoparticles
1.5.1Selenium
Se nanoparticles boast several protective effects in both cells and animal models.
The protective effects of Se NPs result from their antioxidant activities. Explicitly, Se
NPs stimulate increased activity of GPx, which results in the annihilation of surplus lipid
peroxides via the reduction of lipid peroxides to hydroxy acids (Mobasheri, 2018).
Multiple research studies, such Guan et al., 2018, and Rezvanfar et al., 2013, have
established that selenium nanoparticles have antioxidant properties in vivo and in vitro
via the stimulation of selenoenzymes like thioredoxin reductase (TrxR) and glutathione
peroxidase (GPx) which inhibit oxidative damage to tissues of the body (Guan et al.,
2018).
Additionally, the antioxidant activity of Se NPs enables them to prevent
gonadotoxicity caused by cisplatin (Rezvanfar et al., 2013). Mobasheri et al. (2018)
established that Se nanoparticles could prevent hepatotoxicity induced by acetaminophen.
The treatment of human endothelial cells with stabilized Se NPs causes a decrease in
oxidative stress (Hosnedlova et al., 2018). Decreased oxidative stress implies that cells
are protected against various metabolic complications, including diabetes, as well as
liver and kidney cancer.( Jang et al. , 2016) found that selenium nanoparticles can protect
against colon carcinogenesis by stopping the growth of aberrant crypt foci and tumorous
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lesions in rats. The antioxidant property of Se nanoparticles can also help to degrade and
reduce inflammation.
1.5.2 Cerium Oxide
Recent research works indicate that cerium oxide nanoparticles (nanoceria) are
capable of providing defence against radiological, biological, and chemical insults which
stimulate the generation of free radical species. According to multiple studies, nanoceria
exhibit protective effects in both in vitroand in vivo models by reducing the levels of
reactive oxygen species (Ponnurangam et al., 2014; Nelson et al., 2016; Rajeshkumar &
Naik, 2018). The antioxidant effects of intracellular nanoceria enable them to prevent the
build-up of reactive oxygen species and consequently, reduce the stimulation of apoptotic
response and cell death (Abdal Dayem et al., 2017). Nanoceria also boasts an impressive
oxygen-storage capacity, which, together with the particles' antioxidant property enable
these particles to scavenge for free radical species and provide protection against
irradiation (Gagnon & Fromm, 2015). Thus, cerium oxide nanoparticles can facilitate cell
longevity and decrease toxicity.
Cerium oxide nanoparticles’ antioxidant properties can also provide protection
against inflammation and diseases mediated by oxidative stress. These nanoparticles
scavenge and reduce the levels of ROS, which causes inflammation and increases
oxidative stress (Abdal Dayem et al., 2017). Moreover, nanoceria, through their catalytic
and oxidant activities, can also reduce toxicity levels in cells. Amin et al. (2011)
conducted an experiment on a rat model and found that nanoceria can act as an effective
hepatoprotective agent against hepatotoxicity induced by monocrotaline (MCT). In

9

another study, Moridi et al. (2018) assessed the influences of nanoceria on semen
parameters and oxidative stress in male rats after exposing them to Malathion. Their
findings intimated that the antioxidative properties of cerium oxide nanoparticles
enhanced sperm counts, viability, and motility.
1.5.3 Platinum
Platinum nanoparticles can scavenge H2O2 and O2•− and thus, reduce cellular
oxidative stress (Kajita et al., 2007). In turn, reduced oxidative stress triggers antiinflammatory responses that protect against inflammation and inflammation-induced
diseases. (Yoshihisa et al., 2010) reported that Pt NPs provide effective protection against
inflammation caused by ultraviolet (UV) by restraining the production of ROS and
preventing apoptosis in keratinocytes. In their study, (Medhat et al. ,2017) established
that Pt NPs improved the parameters under study compared to normal control animals
and thus, concluded that Pt NPs are more effective than cisplatin in the therapy of
diethylnitrosamine-induced hepatocellular carcinoma in mice.
For more than half a century, medics in Japan have treated chronic illnesses using
PAPLAL – a mixture of palladium and platinum nanoparticles. In a new study, Shibuya
et al. (2014) found that PAPLAL was capable of suppressing the production of intrinsic
superoxide both in vitro and in vivo through catalase and SOD activity. The authors
concluded that PAPLAL is possibly an effective tool for the therapy of skin illnesses
associated with aging and induced by oxidative damage. Figure 1.4 demonstrates the
mechanisms of the therapeutic effects of nanoparticles.

10

1.6 Selenium, cerium oxide and platinum nanoparticles in heavy metal intoxication
treatment
1.6.1 Selenium
Experimental studies have revealed that selenium has the capability to check for
and reduce the toxicities resulting from exposure to heavy metals. (Whanger, 1992) posits
that Se counteracts the toxicity of heavy metals like thallium, inorganic mercury,
methylmercury, and cadmium, etc. by switching the binding of these metals from low
molecular weight proteins to higher molecular proteins. (Hassanin et al. ,2013) found that
Se NPs can provide protection against thyrotoxicity caused by hexavalent chromium.
They concluded that the administration of Se nanoparticles is an effective approach of
correcting hormonal levels and oxidative stress biomarkers. Moreover, studies on DNA
damage using comet assay and those on cell viability using MTT assay have all
demonstrated that Se NPs can provide protection against DNA damage and cell death
caused by arsenite (Hosnedlova et al., 2018).
1.6.2 Cerium Oxide
Cerium oxide NPs can also be effective in the treatment of heavy metal poisoning.
Nanoceria has demonstrated strong efficacy in the adsorption of arsenic (Zeng et al.,
2018). Arsenic is a pervasive heavy metal that possesses toxicity in the environment.
Prolonged exposure to arsenic has been reported to lead to lung, bladder, urinary tract,
liver, skin, and kidney cancer as well as other non-cancerous diseases (Saha et al., 1999).
In a different study, Feng et al. (2012) examined nanoceria for arsenic adsorption and
confirmed its efficiency in the treatment of intoxication due to arsenite. Further, they
found that the efficacy of nanoceria in arsenic adsorption was pH dependent.
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1.6.3 Platinum
The catalytic properties of Pt nanoparticles make them effective in reducing
intoxication caused by heavy metals. For instance, Pt NPs have proved effective in
removing toxic heavy metal ions from aqueous solutions. In a study by Mehdizadeh et
al., (2014), Pt NP/Zeolite-4A demonstrated efficacy in removing Co (II), La (III), Ni (II),
Ba (II) ions from aqueous mixtures. The efficacy of removal of toxic metals was
dependent on contact times, solution pH, and adsorbent concentration. This study
established that the use of Pt NPs in heavy metal intoxication is heavily under-researched.
1.7 Effects of selenium, cerium oxide and platinum nanoparticles on oxidative stress
1.7.1 Selenium
Since Se nanoparticles cause an increase in GPx activity, they can be used as
antioxidants with less Se toxicity. The positive effects of SE NPs with regard to oxidative
stress can be attributed to their preventive role in oxidative tissue damage and the
integration of Se into proteins (Hosnedlova et al., 2018). They stimulate an increase in
GPx activity and scavenge free radical species, eventually resulting in a reduction in
oxidative stress. Heat shock proteins (HSPs) and HSP90 are among the parameters of
oxidative stress. Studies have established that the administration of Se nanoparticles
induces heat shock proteins, which protect the cells from fatal stress levels. Kojouri et al.
(2012) confirmed that the oral supplementation of Se nanoparticles in donkeys caused an
increase in HSP90 expression in the gluteal muscle following 24 hours of no physical
activity. Se NPs induced HSP90, which alters the buffering capacity of the cells in
response to stress levels and safeguards cells from further damage.
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Dkhil et al. (2016) found that Se NPs can considerably reduce testicular tissue
oxidative stress markers like nitric oxide and lipid peroxidation. They also established
that treating streptozotocin (STZ)-diabetic mice with selenium nanoparticles amplified
antioxidant enzyme activities and glutathione content in testicular tissues. However,
excess doses of Se NPs coupled with physical exercise, can bring about up- regulation of
oxidative stress and inhibit the induction of HSPs (Kojouri et al., 2013).
1.7.2 Cerium Oxide
Most studies report that nanoceria provides a new approach for defense against
oxidative stress. The antioxidant activity of nanoceria have been and continue to be
investigated for the treatment of illnesses related to augmented oxidative stress, like
Parkinson’s Disease and Alzheimer’s Disease. The term oxidative stress implies
augmented levels of intracellular ROS (Bartosz, 2009). Lengthy exposure to high
concentrations of reactive oxygen species destroy lipids, nucleic acids, and proteins,
leading to various metabolic disorders (Bartosz, 2009). Nanoceria can switch between
oxidation states, a feature that makes them more effective in the treatment of oxidative
stress-linked illnesses. Ceria nanoparticles have several O2 vacancies on their surface that
lead to a combination of coexisting Ce3+ and Ce4+ oxidation states (Mauricio et al.,
2018). This results in a redox couple, which triggers the catalytic activity of nanoceria.
Nanoceria exposure has demonstrated biochemical redox reactions, presenting sites for
scavenging free radical species like ROS and down regulating inflammation. Therefore,
nanoceria can provide cellular protection by reducing oxidative stress in living
organisms.
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1.7.3 Platinum
Pt NPs boast strong antioxidant activity in both in vivo and in vitro by quenching
H2O2 and O2•− through its SOD- and CAT-mimicking activity. Pt nanoparticles
demonstrate SOD- and CAT-mimetic activities, which enable Pt NPs to prevent various
oxidative stress-related pathologies like cellular transformations and inflammatory
reactions (Ferreira et al., 2018). During oxidative stress, Pt NPs assist the cells in
eliminating O2•− and H2O2, improving the resistant of cells to oxidative stress. One can
determine oxidative stress by computing the population of intracellular ROS using a
dichlorofluorescein assay. (Zhang et al., 2010) established that Pt NPs cause a reduction
in intracellular ROS in a dose-determined fashion as higher concentrations of Pt NPs
induced greater reductions in intracellular ROS.
1.8 Anticancer effects of selenium, cerium oxide and platinum nanoparticles
1.8.1 Selenium
Selenium nanoparticles have also exhibited impressive anticancer properties and
great potential as drug carriers and in cancer chemotherapy. A primary mechanism for the
chemo-preventive effect is the stimulation of glutathione S-transferase (GST). Se
nanoparticles exhibit anticancer effects via their capability to impede the cancer cells
growth by initiating a cell-cycle arrest at S phase (Luo et al., 2012). Treating cancerbearing cells with Se nanoparticles changes the biomechanical characteristics of cancer
cells. Explicitly, treatment with SeNPs causes a substantial diminution in Young’s
modulus and the adhesion force (Pi et al., 2013). Even though Se has proved effective in
neutralizing the chemical carcinogens that cause liver, mammary, and skin tumors, it is
less effective against the chemical carcinogens that induce colon, trachea, and pancreas
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and lung tumors in animal models (Kemp, 2015). Se NPs also provide better selectivity
between normal healthy cells and cancer-bearing cells compared to other Se chemical
forms (see Figure 1.5) (Guan et al., 2018). For this reason, they can be used as radiation
sensitizers to improve the effectiveness of radiotherapy and reduce its side effects.
1.8.2 Cerium Oxide
Various scholars have revealed the anticancer effects of nanoceria. Nanoceria
wields their anticancer effects through apoptosis (both intrinsic and extrinsic) and
diminution of oxidative stress in the cancer-bearing cells (Gao et al., 2014). Cerium oxide
nanoparticles destroy cancer cells while protecting normal cells at the same time.
Nanoceria can function as effective antioxidants and scavengers of free radicals and
consequently, counteract disorders associated with ROS production. ROS stimulate the
growth and development of cancer via distinctive acclimatization to oxidative stress and
down regulation of antioxidant enzymes expression (Gao et al., 2014). Scholars aver that
nanoceria is toxic to cancer-bearing cells, preventing the incursion of cancer cells, and
make cancer-bearing cells more sensitive to radiotherapy.
In their study, (Wason and Zhao, 2013) revealed that the treatment of cells with
cerium oxide nanoparticles improve the effectiveness of radiotherapy to cause the death
of cancer cells having acidic pH. Cerium oxide nanoparticles boast anti-invasive
characteristics towards specific cancer cells and cause radio-sensitization and
radioprotection of normal cells by down-regulating the quantity of ROS and controlling
antioxidant enzymes (Madero-Visbal et al., 2012). Furthermore, the antitumor properties
of CeO2 NPs enable them to reduce the intrinsic capability of cultured squamous tumor
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cells to invade, even without myofibroblast stimulation (Gao et al., 2014). Figure 1.6
shows how nanoparticles initiate different pathways of apoptosis and protect against
cancer cells.
1.8.3 Platinum
Platinum nanoparticles have great potential in cancer therapy as they can serve as
highly effective anticancer agents, a property that can be attributed to their ability to
prevent mitosis and DNA fragmentation through the addition of platinum nanoparticles to
the DNA strand. Asharani et al. (2010) reported that the uptake of platinum nanoparticles
by the cells endocytosis stimulates the discharge of intracellular Pt2+ ions from platinum
nanoparticles, which, in turn, inhibit cell fragmentation by binding to DNA and inducing
DNA damage in cancer cells. Figure 1.1 demonstrates different molecular mechanism of
NPs’ translocation by channels and endocytosis.
Platinum nanoparticles also prevent cancer cell proliferation by inducing cell
death through intrinsic and extrinsic apoptosis (as shown in figure 1.6) (Bendale et al.,
2017). Furthermore, Pt nanoparticles have a cytotoxic effect as they reduce cell viability
and cause G2M cell-cycle arrest, the build-up of hypo-diploid and inter-nucleosomal
DNA division (Alshatawi et al., 2015). All these effects emphasize the anticancer
properties of Pt NPs and their potential to enhance cancer therapy.
1.9 Selenium, cerium oxide and platinum in treatment of metabolic disorders
1.9.1Selenium
Selenium NPs have turned out effective in the therapy of various metabolic
disorders. For instance, Se NPs have proved effective in the therapy of fatty liver disease
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(FLD)/hepatic steatosis, which is a metabolic disorder that affects most dairy cows soon
after calving (Hosnedlova et al., 2018). A build-up of ectopic fat in the liver induces
FLD, which, in turn, can induce inflammatory responses in the liver leading to permanent
damage of the liver or death. Hegedüs et al. (2012) established that treating FLD-bearing
Wistar mice with Se nanoparticles resulted in low inflammation levels and free radical
species release in ailing animals. However, even though bioactive Se NPs seem effective,
there is a need for more experimental studies to confirm its therapeutic effects with
regard to metabolic disorders.
1.9.2 Cerium Oxide
The antioxidant and catalytic activities of cerium oxide nanoparticles make them
an effective therapy with regard to metabolic complications. Jahani et al. (2016) showed
that ceria nanoparticles could provide protection against diabetic nephropathy by
inhibiting oxidative stress pathways. Nanoceria substantially inhibited pathological
changes and oxidative damage in the kidney tissues of rats with diabetes. Among the
various types of diabetes, diabetic nephropathy has contributed most to the onset of endstage kidney complications globally (Gheith et al., 2016). Diabetes mellitus is a
metabolic complication that is diagnosed by hyperglycemia and limited action or
secretion of endogenous insulin (Jahani et al., 2016). Diabetic conditions typically induce
the production of hydroxyl and oxygen free radicals, ultimately bringing about oxidative
stress, which makes the most significant contribution to the growth of diabetic
nephropathy (Kashihara et al., 2010). Nanoceria has O2 defects on their surfaces, which
enable them to scavenge free radicals (Nelson et al., 2016). As shown earlier in figure
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1.2 , CeO2 NPs’ antioxidant property enables them to inhibit chronic inflammation and
pathologies linked to oxidative stress.
1.9.3 Platinum
The catalytic and antioxidant properties of Pt NPs make them suitable for treating
metabolic disorders. As an antioxidant, Pt NP detoxifies ROS by quenching H2O2 and
O2•−. Pt NPs reduce hydrogen-peroxide induced apoptosis without causing cell lysis
(Clarke et al., 2011). Moreover, the antioxidant activities of Pt NPs have proved effective
in the regulation of pulmonary inflammation in mice (Nellore, 2013). These particles
have also demonstrated an ability to extend life in C. elegans.
1.10 Selenium, cerium oxide, and platinum as immunostimulator
1.10.1Selenium
Selenium nanoparticles have demonstrated a significant boosting impact on
immune response in rats with tumors exposed to crude antigens of 4T1 cells. Th1 cells
make a significant contribution to the immune system’s fight against tumors. In their
study, Yazdi et al. (2012) established that supplementation with biogenic selenium
nanoparticles stimulates the Th1 type of immune response. Th1 slows down breast cancer
progression and extends the lifetime of mice with tumors (Yazdi et al., 2012). The
administration of Se NPs may lead to a significant induction of Th1 immune response
cells by intensifying the production of Th1 cytokines, IL-12, and IFN-γ and can thus,
improve the diagnosis of tumors in mice (Yazdi et al., 2012).
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The administration of Se NPs also results in increased amounts of neutrophil cells
in normal mice (Yazdi et al., 2013). Neutrophil cells help in the initiation of
inflammation and immune response. Further, they also migrate to the location of the
immune problem and act as the first line of defense. Thus, it is conceivable that treating
tumors-bearing mice with Se NPs can aid the innate immunity to block tumors
development. Hosnedlova et al. (2018) reported that a concentration of 500 μg/mL of Se
nanoparticles was capable of inhibiting the Aspergillus clavatus growth, which is a
pathogenic fungus.
1.10.2 Cerium Oxide
Inflammation is a fundamental immune system response. The ability to stimulate
the production of chemokines or cytokines enables nanoceria to induce inflammation
(Jiao et al., 2014). Various literary works have shown that specific doses of ceria
nanoparticles stimulate ROS generation in vivo and in vitro as well as improve
inflammatory responses or immune responses. In their study, Wingard et al. (2011)
established that treating C57BL/6 mice with 100 μg ceria nanoparticles of an 8 nm
diameter size resulted in the induction of inflammation in the pulmonary system through
the activation of mast cells.
Nanoceria can also function as adjuvants that enhance the immune activity of
vaccines. Zholobak et al. (2016) scrutinized the effect of nanoceria on the
immunogenicity of the split trivalent influenza vaccine Vaxigrip in vivo. They
established that nanoceria enhances the immune activity of the Vaxigrip vaccine.
Considering nanoceria do not possess immunogenicity, it is conceivable that the
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improvement in immunogenicity of the vaccine resulted from the influence of nanoceria
on components of the vaccine (Zholobak et al., 2016).
1.10.3 Platinum
Studies reveal that Pt NPs can trigger inflammatory and immune responses in
mammal cells. Pt NP exposure elicits a notable stress response, evidenced by increased
production of ROS. The build-up of ROS brings about an inflammatory response, which,
in turn, improves the adaptive immune response (Ahmed et al., 2018). Pt NPs boast good
antibacterial activity by stimulating an immune response against pathogens. Ahmed et al.
(2018) established that in the zebra-fish model, jacalin-capped platinum nanoparticles
promoted an adaptive immune response against the Aeromonas hydrophila pathogen.
Furthermore, the authors found that the zebra-fish could sustain repetitive infection even
after 21 days of treatment with JPt NPs. These findings insinuate that jacalin-capped
platinum nanoparticles possess not only strong but also persistent immunostimulatory
effects. It is also worth noting that jacalin enhance the efficacy of platinum nanoparticles
(Ahmed et al., 2018).
1.11 Selenium, cerium oxide and platinum toxic effect in vivo and in vitro
1.11.1Selenium
1.11.1.1 In vivo toxicity
In animals, selenium intoxication is characterized by retarded growth. Se inhibits
growth by decreasing the production of growth hormones and somatomedin C, insulinlike growth factor-I, and insulin-like growth factor-binding proteins (Shakibaie et al.,
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2013). According to some in vivo studies, the main organ targeted by selenium toxicity is
the liver (Mishra et al., 2017). It is conceivable that the oxidative state, solubility of Se
compounds, and chemical form make a significant contribution to selenium’s acute
toxicity. Shakibaie et al. (2013) established that biogenic selenium nanoparticles were
less toxic than synthetic selenium nanoparticles and even much less harmful than
selenium dioxide.
1.11.1.2 In vitro toxicity
Se NPs exhibit the least toxicity among different chemical forms of Se. Indeed, in
vitro studies have shown that Se NPs coated with dextrin is not toxic to the DNA and in
fact, provides protection against free radicals (Malhotra et al., 2016).
1.11.2 Cerium Oxide
1.11.2.1 In vivo toxicity
Nanoceria boasts a large Ce3+/Ce4+ ratio which can be associated with higher
toxicity, albeit not always (Rzigalinski, 2017). For instance, other studies have
established low toxicity of nanoceria to eukaryotic cells. One in vivo study showed that
inhaled nanoceria are more noxious than cerium oxide micro-materials with regard to
mass concentration but less toxic with regard to surface area concentration (Schwotzer et
al., 2018). Hussain et al. (2012) contended that nanoceria has several toxic effects on
human peripheral blood monocytes. The authors detected an elongation and bulging of
mitochondria after exposure to cerium oxide nanoparticles, further leading to apoptosis.
This activity can be due to an upsurge in reactive oxygen species generation and a
reduction in the antioxidant species glutathione (GSH) (Gagnon & Fromm, 2015). Figure
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1.3 illustrates the relationship between CeO2 nanoparticles toxicity and their therapeutic
effects.
1.11.2.2 In vitro toxicity
Even though it is widely acknowledged that nanoceria has a low toxicity profile,
Pešić et al. (2015) showed that nanoceria could cause cell death, as shown in figure 1.3.
Further, nanoceria can exhibit either pro-oxidant properties or anti-oxidant activities
(Mittal & Pandey, 2014). In neutral pH environments, nanoceria is cytoprotective and
exhibit antioxidant activity. However, in environments with acidic pH, nanoceria acts like
oxidases and result in cytotoxic effects (Mittal, 2014).
Forest et al. (2017) contend that the morphology of cerium oxide nanoparticles
(nanoceria) has a considerable impact on in vitro toxicity of nanoceria. It is also
conceivable that the toxicity of nanoceria is dependent on more so on the dual oxidation
state of nanoceria, and partly on the synthesis process and physicochemical properties of
intrinsic NPs like size, dispersion state, and surface chemistry (Forest et al., 2017).
1.11.3 Platinum
1.11.3.1 In vivo toxicity
Most studies tend to suggest that Pt NPs have minimal toxicity or organ stress in
vivo. Yamagishi et al. (2013) demonstrated that Pt nanoparticles did not cause
nephrotoxicity or liver toxicity. In a different study, Asharani et al. (2011) examined the
toxicity of Pt nanoparticles using a zebra fish model and established that the addition to
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platinum nanoparticles led to developmental changes and a concentration-determined
decrease in heart rate.
1.11.3.2 In vitro toxicity
Although Pt NPs are well-known scavengers of ROS, in some instances, Pt NPs
elicit negative responses like the instigation of cellular stress, genotoxicity effects, and
DNA damage in vitro (Nejdl et al., 2017). Labrador et al. (2018) determined that
platinum nanoparticles induce cytotoxicity and activate multiple stress pathways in a
dose-determined manner. Furthermore, exposure to Pt NPs occasioned a mild proinflammatory response and increased phosphorylation of the Akt protein, which is
responsible for signaling (Labrador et al., 2018). Thus, it is plausible that exposure to
chronic platinum nanoparticles can result in long-term health complications. Pelka et al.
(2009) found that 1 ng/cm2 Pt NPs compromised DNA integrity and decreased cellular
glutathione. Their results revealed a rise in toxicity as the nanoparticle size decreased.
The authors suggested that the toxicity could be attributed to Pt ions and not the
formation of ROS.
1.12 Summary:
While some studies have established the toxicity of Pt NPs, Se NPs, and
nanoceria, most studies have demonstrated the attractive properties that make them
effective in the treatment of various illnesses including metabolic disorders,
neurodegenerative disorders, and cardiovascular disorders. Often, Pt NPs, Se NPs, and
nanoceria exhibit impressive anticancer and immunostimulatory effects. Moreover, the
toxicity of nanoparticles is helpful in some cases, particularly cancer-related cases as the
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toxicity kills the cancer cells. These effects can be attributed to these particles’ catalytic
and oxidant properties, which enable them to scavenge free radicals and regulate
oxidative stress and inflammation, both of which play a significant role in the
development of various illnesses including cancers and diabetes. The capability of
nanoparticles to regulate inflammation and oxidative stress makes them effective in the
therapy of a variety of illnesses. There is an urgent need for further studies to gain insight
into the applications of nanoparticles with particular regard to their toxicity.
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Figure 1.1. Mechanism of nanoparticles' cellular uptake
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Figure 1. 2. Nanoparticles' mechanism of antioxidant activities
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Figure 1.3. Toxicity and therapeutic effects of NPs
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Figure 1.4. Antioxidant enzyme-mimetic activity of Se NPs, Pt NPs, CeO2 NPs, and
Iron Oxide NPs
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Figure 1.5. Therapeutic Applications of NPs in cancer, metabolic syndromes and
inflammatory diseases
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Figure 1.6. Initiation of intrinsic and extrinsic apoptosis by NPs
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Table 1.1 Selenium Nanoparticles
Authors

Wang et. al.
(2007)

Property of Se NPs
investigated

Type
of
study

Findings

- Antioxidant properties
of Se NPs compared to
in
selenomethionine
vivo
- Toxicity of Se NPs and
their effect on oxidative
stress

- Se NPs exhibit antioxidant
properties that increased plasma
GPx activity in a comparable
measure to selenomethionine
(SeMet).

Zhang et. al. - Effect of elemental Se
NPs on GPx activity in
(2007)
the liver of weanling pigs
in
comparison
to
in
inorganic selenium.
vivo

- Se NPs trigger significantly
higher GPx activities at a
concentration range of 0.50 and
1.0 mg Sekg-1 diet in
comparison
to
inorganic
selenium Na2SeO3.

Shi et al.

- Supplementation with Se NPs
brought about a significant
increase in the level of Se in the
testes as well as in GPx and
ATPase activity in the ejaculate.

(2010)

- Effect of Se NPs on
oxidative stress through
the examination of the
ultrastructure of the
in
testes, quality of ejaculate
vivo
and GPx activity in goats

- Se NPs exhibited lower
toxicity than selenomethionine
in mice.

-Se NPs exhibited protective
effects on the integrity of the
sperm plasma membrane.
- Se NPs reduce oxidative stress
and can be used to treat or avert
sperm dysfunction

Wu et al.
(2011)

- The antioxidant activity
of Se NPs with regard to
improving
the
development of the hair
in
follicle and promoting
vivo
fetus growth

.
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- Se NPs exhibited antioxidant
activity, which enabled them to
improve
hair
follicle
development and promote fetus
growth.
- Low level of ROS due to Se
NPs
antioxidant
activity
upregulates IGF-1R and IGF-1,
which, in turn, promote hair
follicle development in the fetus

Jang et al.
(2016)

Chan et al.
(2017)

The
inhibitory/protective
effects of Se NPs and
selenium on experimental
in
colon carcinogenesis in
vivo
mice.

- Se and Se NPs exhibit
comparable protective effects
against colon carcinogenesis by
impeding the growth of aberrant
crypt foci and tumorous lesions
in mice.

- Anticancer effects of Se
NPs

- The Auger-electron and the
Compton effects of Se atoms
enable Se NPs to impede the
growth of cancer cells and the
formation of colonies via the
stimulation of cell cycle arrest
and cell apoptosis.
in
vitro

Chen, et. al.
(2008)

- Effects of Se NPs
synthesized
in
U.
pinnatifidapolysaccharide in
solutions
on vitro
mitochondria- facilitated
apoptosis.

- Se NPs can serve as non-toxic
and effective agents for nextgeneration
cancer
chemoradiotherapy.
- Se NPs fabricated in U.
pinnatifida
polysaccharide
solutions
stimulated
mitochondria-mediated
apoptosis in A375 human
melanoma cells.
- The treatment of A375 cancer
cell line with Se NPs brought
about cell apoptosis that was
dependent on the dose and was
demonstrated
by
DNA
fragmentation
and
phosphatidylserine translocation.

Vekariya,
et. al.
(2012)

- Anticancer activity of
selenium nanoparticles
and its relationship with in
the morphology of Se vitro
NPs.

- Se NPs exhibited anticancer
activity that is linked to ERα
levels in breast cancer cells; the
higher the number of ERαpositive cells, the greater the
expression of apoptotic markers
and Se NP-induced cell death.

Yanhua, et.
al. (2016)

- Anticancer properties of
novel SeHAN (seleniumin
substituted

Novel
Se-substituted
hydroxyapatite NPs (SeHAN)
can
serve
as
beneficial
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hydroxyapatite
nanoparticles).

vivo

- Toxicity of SeHAN on
liver
and
kidney
functions.

anticancer agents that offer both
lower toxicity and survival
advantages in nude mice models
of
human
hepatocellular
carcinoma.
- SeHAN exhibited considerably
lower toxicity on the kidney and
liver functions.

Yazdi et al.
(2013)

-Anticancer&
immunostimulatory
properties of Se NPenriched
Lactobacillus
brevis.

The
administration
of
Lactobacillus brevis enriched
with Se NPs orally can help to
realize better prognosis in highly
metastatic breast cancer mice
model.
in
vivo

- The administration of lactic
acid
bacteria
(LAB)
in
combination with Se NPs
brought about a considerable
rise
in
delayed-type
hypersensitivity responses and
cell cytotoxicity, as well as
increased levels of IL-17 and
IFN-γ, in comparison to the
control mice that were enriched
with L. brevis only

Sonkusre et.
al. (2014)

-Anticancer effects of in
neutral-charged,
non- vitro
agglomerating Se NPs.

Neutral-charged,
nonagglomerating Se NPs exhibited
efficacy in stopping proliferation
and
stimulating
caspaseindependent necrosis in human
prostate adenocarcinoma cells
without setting off considerable
toxicity in human peripheral
blood mononuclear cells.

Liu et al.

-Anticancer properties of
Se NPs when used as
carriers of 5-fluorouracil. in
vitro

- The 5-fluorouracil surfacefunctionalized Se NPs (5-FU-Se
NPs)
exhibited
impressive
selectivity between normal and
cancer cells.

(2012)
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5-FU-Se

NPs

stimulated

apoptosis in A375 human
melanoma cells evinced by the
build-up of the sub-G1 cell
population,
nuclear
condensation,
and
DNA
fragmentation.
Luo et. al.

-Antiproliferative effects
of selenium nanoparticles
on
human
breast in
carcinoma cells and vitro
human
cervical
carcinoma cells.

(2012)

Prasad
al.
(2014)

et. Heavy
metal
intoxication properties of
Se NPs.

Yang et al.
(2017)

- Se NPs successfully stopped
the growth of both cancer cell
lines in a dose-determined
fashion.

- Se NPs exhibited protective
effects against cell death and
DNA damage induced by
arsenite.

Antimicrobial
properties of Se NPs.

- The decoration of Se NPs with
oseltamivir (OTV) inhibited
H1N1 influenza virus infection
and exhibited a lesser amount of
toxicity.
- The modified Se NPs inhibited
ROS generation together with
the activation of phosphorylation
of cellular tumour antigen p53
and Akt.

Srivastava
et. al.
(2015)

- Antibacterial effect of
Se NPs.

Shoeibi et.
al. (2017)

Synthesis
and
antibacterial activities of
Se NPs

- Se NPs exhibited excellent
antibacterial activity.
- Se NPs’ antimicrobial efficacy
is
comparable
to
the
commercially
available
antibiotic ampicillin.
- Se NPs synthesized by
Enterococcus faecalis can serve
as an antistaphylococcal element
to successfully treat and thwart
S. aureus toxicities.
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Stevanović
et al.

- Antibacterial activity of
Se nanoparticles

- Se NPs with the application of
PLGA
exhibits
significant
antibacterial activity against
Gram-positive
bacteria,
S.
aureus, and Staphylococcus
epidermidis.

(2015)

Estevez et. - Toxicity of Se NPs in
al.
comparison to other
organic and inorganic in
(2014)
vitro
selenospecies.
- Anticancer properties of
Se NPs.

- Se NPs only partially
restrained the expression of
Cdk1, unlike Se+IV and SeCys2,
which drastically reduced the
expression
of
Cdk1.
A
significant reduction in Cdk1
expression can be harmful to
healthy cells as its inhibition
stimulates cell cycle arrest.
- Se NPs that target Cdk1 can be
used in mitotic cell death for
cancer therapy.

Rezvanfar
et al.
(2013)

Ungvári
al.
(2014)

- Intoxication properties
of Se NPs with regard to
in
cisplatin-induced
vivo
reproductive toxicity

et - Protective effects of Se
NPs against DMBAinduced immunotoxicity
in mice.

in
vivo

- The antioxidant potential of Se
NPs enables them to thwart CISinduced gonadotoxicity.
- Co-administration of Se NPs
considerably
enhanced
the
sperm
quality,
serum
testosterone,
and
spermatogenesis
and
downregulated free radical toxic
stress induced by cisplatin as
well as spermatic DNA damage
in male rats.
- Se NPs exhibited protective
effects
against
7,12dimethylbenz(a)anthracene
(DMBA)-induced
immunotoxicity in mice.
- Se NPs also exhibited
functional dietary benefits.
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Kojouri
al.
(2012)

et - Effect of Se NPs and
Na2SeO3
on
iron
homeostasis
and in
expression of genes vivo
coding for transferrin and
transferrin receptor in
sheep.

- Group dosed with Se NPs
exhibited
considerably
augmented TIBC levels after 20
days in comparison to the
Na2SeO3,
and
drastically
decreased the iron serum levels
compared to the control group.

- Protective effects of Se
NPs against oxidative
and cellular damage in
prompted by chromium vivo
in rat thyroid

- Se NPs exhibited protective
effects
against
hexavalent
chromium-induced
thyrotoxicity.

Hassanin,
et. al.
(2013)

Trabelsi
al.
(2013)

et - Protective effects of Se
NPs against cadmiuminduced nephrotoxicity.

- Administration of Se NPs is
more effective in rectifying the
hormonal levels and oxidative
stress biomarkers in comparison
to K2Cr2O7
- Se NPs exhibited protective
effects against cadmium-induced
nephrotoxicity.
- Cadmium complexation with
Se NPs can downgrade oxidative
stress caused by cadmium in the
kidneys

Table 1. 2 Cerium Oxide Nanoparticles
Authors

Lin et. al. (2006)

Property of CeO2
investigated

Cytotoxicity
properties of CeO2
NPs in human lung
cancer cells.

Type
of
study

Findings

- Free radicals produced
by exposure to nanoceria
caused
considerable
oxidative stress in the
cells, evidenced by the
- Effects of 20-nm
reduction in the levels of
nanoceria on oxidative
alpha-tocopherol
and
stress
in
cultured in vitro glutathione.
human lung cancer
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cells.

- The toxic effects of
nanoceria are determined
by dose and time.
- Increased oxidative
stress
boosts
the
generation
of
malondialdehyde
and
lactase
dehydrogenase,
which are pointers of lipid
peroxidation and cell
membrane damage.

Farias et. al.
(2018)

Antimicrobial
activity of nanoceria.

The
antimicrobial
mechanism of nanoceria
likely occurs via oxidative
stress of components in
microorganisms’
cell
in vitro membranes.
The
antimicrobial
activity of nanoceria is
dependent
on
concentration.

Gopinath et al.
(2015)

Antibacterial
activities of nanoceria

Mycosynthesized
nanoceria
exhibited
effective
antibacterial
activity against dengue
vector and pathogenic
bacteria.
in vitro - Nanoceria’s mechanism
of antibacterial activity
may possibly be through
interference with the cell
membrane of the bacteria
and through binding with
mesosome.
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Babu et al.
(2014)

- Antibacterial activity
of
gold-supported
CeO2 NPs

Gold-supported
nanoceria exhibited strong
antibacterial activity in
monoculture systems.

- Cytotoxicity of goldsupported nanoceria

in vivo

A
dose-dependent
increase in the ROS levels
showed
that
the
cytotoxicity
of
goldsupported nanoceria to
A549 cells could be
attributed to their prooxidant activity.
- Cellular uptake showed
major localization of
nanoceria
in
the
cytoplasmic matrix and
mitochondrial damage as
a result of oxidative stress.

Pešić et al.
(2015)

Anticancer
and
cytotoxic effects of
nanoceria in cancer
and normal cell lines.
in vitro
- The intracellular
redox
activity
of
nanoceria

- CeO2 nanoparticles
exhibited low to temperate
cytotoxicity in cancer cell
lines while normal cell
lines were insensitive to
nanoceria.
Nanoceria’s
low
inhibitory potential in
normal human cell lines
implies
that
CeO2
nanoparticles
can
be
innocuous for clinical
application in cancer
treatment.
Alterations
in
intracellular redox status
caused by cerium oxide
nanoparticles
can
be
moderately attributed to
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the pro-oxidant activity of
nanoceria.

Nourmohammadi
et al.
(2019)

- Anticancer effects
and
toxicity
of
nanoceria on mouse
fibrosarcoma tumour in vivo
cells.

- Nanoceria exhibited
anticancer effects evinced
by elevated levels of ROS
and onset of apoptosis,
both of which occurred in
a dose-determined fashion
in cancer cells.
- CeO2 nanoparticles
exhibited low toxicity
levels in normal cells.

Diaconeasa et al.
(2015)

- The antiproliferative
properties of nanoceria
on
HeLa
human
cervical tumour cell

- Nanoceria inhibited the
proliferation of HeLa
human cervical tumour
cells in a dose-determined
fashion.

- The cytotoxicity of
CeO2 nanoparticles on
human cervical tumour
cells.

- Nanoceria did not
exhibit cytotoxic effects.

El Shaer, et. al. The
protective
(2017)
effects of nanoceria on
isoproterenol-induced
cardiac toxicity in rats.

- Nanoceria exhibited
promising
prophylactic
and ameliorative effects
against cardiac toxicity.
in vivo
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- Nanoceria can be
employed as a potent
antioxidant
in
prophylactic protocols for
the treatment of oxidative
stress-related
cardiac
disorders.

Kumari et al.
(2014)

Niu, et. al. (2011)

Cytotoxic
and
oxidative
stress
reactions of human
neuroblastoma
cell in vitro
line
after
being
exposed to nanoceria
and
CeO2
microparticles.

- Nanoceria demonstrated
more toxicity than CeO2
microparticles.

- Protective properties
of
CeO2
against
oxidative stress and
inflammation
prompted by cigarette
smoke
extract
in
cultured rat H9c2
in vitro
cardiomyocytes

- Nanoceria can deter
cigarette smoke extractinduced cell damage by
constraining
ROS
production, inflammatory
gene expression, NF-κB
activation, and antioxidant
depletion.

The toxicity of nanoceria
can be attributed to ROS

- Nanoceria can be highly
effective in the treatment
of
health
conditions
associated with smoking.
Rubio et al.
(2016)

- Antioxidant and antigenotoxic effects of
nanoceria

- Nanoceria exhibited
antioxidant
properties.
The pre-treatment of
BEAS-2B with CeO2 NPs
- CeO2 nanoparticles
considerably
decreased
protective
effects
the
intracellular
against oxidative stress
generation
of
ROS
in vitro
induced by KBrO3
- CeO2 nanoparticles can
serve
as
useful
pharmacological agents in
the treatment of oxidative
stress-induced conditions.
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Hashem et al.
(2015)

- The antioxidant
effects of nanoceria on
Nrf-2/HO-1 pathway
in liver models
in vitro

Cerium
oxide
nanoparticles
are
antioxidants with potential
to effectively reduce the
translocation
of
the
cytoplasmic Nrf-2 into the
nucleus.
- Nanoceria has the
potential to reduce HO-1
in D-GALN/LPS induced
hepatotoxicity effectively.

Adebayo,
(2017)

Ranjbar,
(2018)

et.

et.

al. - Toxicity of nanoceria
in the reproductive
system in male balb/c
mice

- Nanoceria considerably
decreased the levels of
haemoglobin, PCV, and
RBC count in comparison
to the controls.
in vivo

- Nanoceria significantly
reduced
prolactin,
luteinising hormone and
follicle-stimulating
hormone in mice

al. - Effects of CeO2
nanoparticles
on
oxidative
stress
indicators in the liver in vivo
of male rats.

- The effects of nanoceria
are mostly dependent on
the dose. Nanoceria may
exhibit protective effects
at a dose of 15 mg/kg.
- CeO2 nanoparticles in
doses of 30 and 60mg/kg
exhibited oxidative stress
and immunotoxicity in the
liver of rats.
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Table 1. 3 Platinum Nanoparticles
Authors

Kim et al.

Property of Pt NPs
investigated

Type of
study

Findings

-The
protective/therapeutic
effects of Platinum in vivo
nanoparticles on OVXinduced
bone
loss
through their action on
osteoclastogenesis.

- Pt NPs exhibited protective
effects against bone loss
induced by OVX.

Yoshihisa et - Protective effects of Pt in vivo
al.
NPs
against
inflammation induced
(2010)
by UV in mice

- Pt NPs effectively protected
against
inflammation
induced by UV by reducing
ROS
generation
and
impeding
apoptosis
in
keratinocytes.

Yusof et. al.

- Antioxidant properties
of
platinum
nanoparticles

- Platinum nanoparticles
reversed oxidative imbalance
and consequently affected
epithelial sodium channel
(ENaC)
activity
by
downregulating
protein
kinase C (PKC) in the lung
cells

- The protective effects
of PALPAL against skin
diseases
related
to in vivo &
in vitro
ageing in mice

in
vitro,
platinum
nanoparticles
exhibited
significant SOD and catalase
activity.

(2012)

(2015)

Shibuya et.
al. (2014)

- Pt NPs inhibited the
formation of osteoclasts from
bone
marrow-derived
macrophages in a dosedetermined fashion.

- The catalase and SOD
activity of PALPAL enables
it to steadily suppress
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intrinsic
superoxide
production both in vitro and
in vivo.
- PALPAL has great promise
in the treatment of agingrelated skin illnesses induced
by oxidative damage.
Medhat
al.
(2017)

et. - Antitumor activity of
Pt NPs in comparison to
cis-platin
in
the in vitro &
treatment
of in vivo
hepatocellular
carcinoma induced in
rats.

Clark, et. al.
(2011)

- Therapeutic properties
of Pt NPs that enable
them to detoxify ROS
and protect against
oxidant-mediated
in vitro
apoptosis.

Onizawa, et. - Therapeutic effects of
al. (2009)
PAA-Pt nanoparticles
(polyacrylic
acidprotected Pt NPs) on in vivo &
pulmonary
in vitro
inflammation
in
smoking mice
- Antioxidant effects of
Pt NPs
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- Pt NPs exhibited great
antitumor activity and were
more effective than cis-platin
in
the
treatment
of
hepatocellular
carcinoma
caused by diethylnitrosamine
in rats
- While Pt NPs exhibited
SOD catalytic activity, they
did not promote cytolytic or
hemolytic pathways in living
cells.
- Pt NPs reduced oxidantmediated apoptosis in target
cells, evidenced by caspase 3
activation. The ability to
reduce apoptosis makes Pt
NPs
suitable
for
the
maintenance
of
healthy
tissues.
- in vitro, using PAA-Pt
nanoparticles
to
treat
alveolar-type-II-like
A549
cells prevented the death of
cells following exposure to a
cigarette smoke extract.
- Pt NPs can serve as
antioxidants that restrain
pulmonary
inflammation

caused by acute smoking of
cigarettes.
Watanabe et Free
radical
al.
scavenging activity of
polyacrylic acid (PAA)(2009)
protected Pt NPs
in vitro

PAA-Pt
nanoparticles
exhibited promising and
durable scavenging activity
for free radicals
- PAA-Pt scavenged radicals
in a dose-determined fashion.
Pt served as the functional
element.

Bendale, et. - Cytotoxic activity of
al. (2017)
biosynthesized Pt NPs
against
cancer
and
normal cells
- Anticancer properties
of Pt NPs via induction
in vitro
of apoptosis.

Kim et al.
(2008)

- Anti-ageing properties
of antioxidant Pt NPs on
the
lifespan
of
Caenorhabditis elegans
as compared to EUK-8

- Biosynthesized Pt NPs
exhibited cytotoxic effects
on cancer cell lines but
demonstrated no cytotoxic
effects on normal cells even
at the highest dose.
- Platinum nanoparticles
exhibited strong anticancer
activities against PA-1 cell
line via the stimulation of
cell
cycle
arrest
and
apoptosis.
- Pt NPs exhibited more
effective
SOD/catalase
mimetic activity than EUK8.

in vitro

- Pt NPs extended the worm
lifespan, irrespective of
dietary
restriction
or
thermotolerance.
- Pt NPs exhibited intriguing
anti-ageing properties.

Yogesh, et. - Anticancer activity of
al. (2016)
biosynthesized Pt NPs.

- In in vitro, Pt NPs
constrained the growth of
in vitro & A549 cells in a dose-
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in vivo

determined fashion.
- In in vivo, Pt NPs
successfully prevented and
slowed the growth of lung
cancer in SCID mice at mid
and high doses.

Mohammadi - Effects of Pt NPs on
et al.
different cancer cell
lines (i.e., MCF-7 and
(2013)
HepG-2 cancer cell in vitro
lines)
Cytotoxicity
of
platinum nanoparticles

- Pt NPs exhibited strong
anticancer effects and can
serve as highly effective
anticancer agents.
- The anticancer property of
Pt NPs is linked to the
inhibition
of
DNA
replication
and
mitosis
through the addition of Pt
NPs DNA strand.
- The toxicity of Pt NPs is
dose-dependent.

Nejdl et al.
(2017)

- Effects of Pt NPs in
the augmentation of the
DNA fragment of phage
λ
on
erythrocytes,
bacterial cultures, and
human
foreskin
fibroblasts.

in vitro

- Pt NPs inhibited DNA
replication and impinged on
the
DNA's
secondary
structure
at
higher
concentrations evidenced by
DNA
sequencing,
polymerase chain reaction,
and
DNA
denaturation
experiments.
- Both encapsulated and bare
Pt NPs resulted in lower
oxidative stress in the human
erythrocytes.

Labrador,
-Behavioural
and
et. al. (2018) toxicological properties
of Pt NPs in a HepG-2
liver model

- A high dosage of Pt NPs
induced HepG2 cytotoxicity
while
sub-toxic
concentrations of Pt NPs
elicited
multiple
stress
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in vitro

responses and secretion of
proinflammatory cytokines.
Sustained
cellular
interactions with Pt NPs may
generate long-term health
complications.

Gatto, et. al.
(2018)

- The internalization of
Pt NPs coated with
citrate
into
THP-1
monocytes
and
its
effects on immune cell
responses.

The
presence
of
intracellular
Pt
NPs
effectively reduced ROS
without impinging on the
viability of cells.
in vitro

Nellore, et. - Neuroprotective role
al. (2013)
of Bacopa monnieri
phytochemicals coated in vivo
Pt NPs BME-Pt NPs) in
MPTP-induced
zebrafish PD model
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- Citrate-coated platinum
nanoparticles are non-toxic,
are more effective in
scavenging for ROS and
boast impressive immune
compatibility.
BME-PtNPs
exhibit
antioxidant
and
neuroprotective activities via
the reduction of ROS
generation and scavenging of
free radicals.

CHAPTER 2
INTRINSIC PATHWAY OF APOPTOSIS INDUCED BY SELENIUM
NANOPARTICLES IN PRIMARY MOUSE EMBRYONIC
FIBROBLASTS
2.1 Chapter overview:
Selenium is well reported to inhibit cellular growth at higher doses; however, the
mechanism behind this inhibition varies widely depending on the cell types and selenium
species. In this study, we demonstrate that selenium nanoparticles (SE NPs) induce
intrinsic pathway of apoptosis in primary mouse embryonic fibroblasts (MEFs), at a
minimal concentration of 1 µg Se/ml, without causing necrosis to the primary cells. SE
NPs used in these experiments were synthesized via a chemical reduction of selenium
ions using ascorbic acid as a reducing agent. The physicochemical properties of SE NPs
such as morphology, size distribution, and surface potential were determined. Further, we
have investigated the cytotoxicity of SE NPs in MEFs, which are widely regarded to
behave like cancer cells. SE NPs in a dose- and time-dependent manner inhibited cell
growth and induced intrinsic pathway of apoptosis in MEFs. Thus, our results suggest
that SE NPs may offer a new therapy for some metabolic and neoplastic diseases.
2.2 Introduction
Selenium is a trace element that is essential in small amounts for animals
including human beings. A number of enzymes, termed selenoproteins, require selenium
for appropriate function. There are 25 essential well-known human selenoproteins, many
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Through these selenoproteins, selenium has diverse biological functions and has been
suggested to play preventive roles in various diseases such as cardiovascular disease and
certain carcinomas (Navarro-Alarcon, 2008; Zhang, 2011). Selenium can be introduced
in the human diet in organic and non-organic forms like selenite and as selenomethionine
(Zhang, 2011). Similar to other essential elements, selenium can be toxic at high doses
(Zhang (2011).
Nanoparticle approaches are often explored as a means to reduce toxicity,
enhance bioactivity, and improve targeting of therapeutic agents (Khurana et al., 2019).
Substantial interest has been generated in selenium nanoparticles (SE NPs) as a form of
elemental selenium in nanoscale that can potentially replicate the unique biological
activities and antioxidant properties of non-nanoparticle-derived selenium and can
potentially reduce selenium-associated toxicity (Wang, 2007; Shi, 2011). SE NPs are
typically about 20-50 nanometers in size and with exclusive physiochemical properties
that make them applicable to scientific studies, including biological studies of cellular
physiology (Poborchii, 1999; Manna, 2000; Zhang et al., 2001; Drake, 2006). There is
evidence that SE NPs exhibit low cytotoxicity compared to other forms of selenium
compounds such as selenite (Shi, 2011; Zhang, 2011). SE NPs have been reported to
inhibit the growth of microorganisms at high doses (Tran, 2011) and an in vitro study
found that SE NPs can act as an antineoplastic drug by inducing mitochondria-mediated
pathway, also called intrinsic pathway, of apoptosis (Chen et al., 2008). SE NPs possess
similar efficacy as elemental selenium with regard to increasing antioxidant enzyme
activity. This property makes these to be used as antioxidants, enzyme inhibitors, antitumor and anti-infective agents, cytokine inducers, and immunomodulators (Parnham,
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1991; Sies, 1997; Leonard, 2000). Moreover, SE NPs can act as chemo-preventive agents
at subtoxic doses between 1 ppm and 5 ppm (Wang, 2007; Luca et al., 2010). SE NPs
also prevent cell proliferation in pre-neoplastic and neoplastic lesions prepared from rat
cells (Luca et al., 2010).
While SE NPs are being widely studied as compounds with potential benefits in
relation to many metabolic diseases such as cancer, there is limited research on its side
effects and dose-dependent cytotoxicity (Luca et al., 2010). In addition, there are very
few studies on SE NPs focused on their specific involvement in necrotic or apoptotic
pathways. Several factors including size, shape, surface coating, and source of synthesis
may affect the pathway of cell death due to SE NPs exposure (Chithrani et al., 2006;
Hitchman et al., 2012). This study is based on epidemiological and clinical research,
especially chemotherapeutic trials of the selenium compounds, which indicated high
toxicity in cell culture and animal studies. In addition, this research examines how these
selective ecofriendly developed particles in this study affect the pathway for the
programing of cell death or apoptosis.
In spite of the potential medical importance of SE NPs and their properties, their
application in therapy remains limited. This limited application can be attributed to two
main factors: (1) limited synthesis of cost-effectiveness and efficacy (Li, 2010) and (2)
the instability of SE NPs after synthesis and their thermodynamic transformation, which
causes them to lose their biological activities (Zhang, 2015). It is quit challenging to
control physicochemical properties sufficiently well to prepare SE NPs using a simple
chemical reduction method for medical and therapeutic purposes; the chemical reduction
synthesis of SE NPs using reducing agent and stabilizer may obstruct the functionality of
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synthesized nanoparticles in biological media. Additionally, many known stabilizers may
have a toxic effect due to their chemical nature.
Fibroblasts or fibroblast-like cells exist in almost all, if not all, animal organs
where they contribute to self-renewal, functional maintenance, tissue repair, and
remodeling of these organs (Haniffa et al., 2009). In most organs, fibroblasts are the
primary cell type responsible for production of the extracellular matrix. As such, these
cells have become a therapeutic target in fibrosis and recent studies have illustrated that
targeting these cells may provide a foundation for effective treatment to prevent or
reverse fibrotic conditions (Khalil et al., 2017). For this reason, novel methods for
inducing apoptosis in these cells would be beneficial. The present investigation was
designed to evaluate the effects of SE NPs on apoptosis and other parameters in mouse
embryonic fibroblasts (MEFs). Like cancer cells, MEFs have a relatively short doubling
time that has led to these cells being widely used for studies focused on proliferation, cell
cycle regulation, migration, apoptosis, and other cellular processes (Haniffa et al., 2007;
2009; Lysy et al., 2007; Sun et al., 2007; Oraiopoulou, 2017).
2.3 MATERIALS AND METHODS
2.3.1 Chemicals and molecular biology reagents
The chemicals and reagents used in these experiments were selenite salts (SeO3),
ascorbic acid, sodium citrate, polyvinylpyrrolidone (PVP) (average molecular weight
40k), Cell proliferation kit I (MTT) (purchased from Sigma Aldrich St. Louis, MO,
USA), the BrdU cell proliferation Assay kit from Millipore, Pierce™ LDH cytotoxicity
assay kit (obtained from Thermos Fisher, Waltham, MA, USA), In Situ Cell DeathTMRred detection kit ( purchased

from Sigma-Aldrich, St. Louis, MO, USA).
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Antibodies against Bax, Bcl-2, cytochrome c, cleaved caspase-3, cleaved caspase-7, and
PARP-1 were all purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Antibodies against total p53, phosphorylated p53-Ser15, and β-actin and Signal Fire ECL
Western blotting system were purchased from Cell Signaling Technology (Beverly, MA,
USA).
2.3.2 Synthesis and characterization of SE NPs
In a flask, 1 ml of 5 mM PVP and 1 ml of 1% sodium citrate were added to 10 ml
of 80 mM selenite salt (SeO3). The mixture was stirred for 30 minutes at a speed of 1000
rpm. After 30 minutes of stirring, 8 ml of 100 mM ascorbic acid was added to the
mixture. The suspension was then stirred at 1000 rpm for 30 minutes at room
temperature. The synthesized SE NP suspension was then transferred to a washing cell.
The suspension was then washed four times using 10 ml of cell culture ultrapure
deionized water. The washed synthesized SE NPs were filtered using syringe Nano-filter
(0.1 µm) and stored at 4oC.
2.3.3 UV–Vis absorbance and dynamic light scattering (DLS) spectroscopies
The formation of SE NPs was observed visually by color change as synthesis
progressed. UV–visible spectra were recorded with UV-2600 spectrophotometer from
200 to 800 nm wavelength at room temperature. Distilled water was used as a blank. The
average particle size (hydrodynamic diameter, Z-average) and zeta potential of the
prepared SE NPs were analyzed using Malvern Zetasizer (Zetasizer Nano ZS, ZEN3600
and Malvern, UK). At the same time, particle sizes of SE NPs were derived using the
dynamic light scattering (DLS) measurement.
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2.3.4 Quantification of SE NPs concentration by inductively coupled plasma optical
emission spectrometry (ICP-OES)
Concentration of SE NPs was measured through ultrafiltration method using
inductively coupled plasma optical emission spectrometry-Microtrac Bluewave model
(Varian710-ES-ICPOES). Samples were diluted and digested with Aquaregia. Values
were interpolated in a standard selenium element calibration curve.
2.3.5 Transmission electron microscopy (TEM) analysis
For TEM analysis, the samples were prepared by placing drops of produced SE
NPs on formvar-carbon-coated copper grids and allowing the solvent to partially
evaporate at room temperature. After that, the prepared grids were carefully dipped into
deionized water on three occasions and allowed to air dry. The observation was
performed using Hitachi HT7800 TEM microscopy, and the operation was conducted at
100kV. The deionized water used in the process was treated through ultraviolet radiation
then warmed at 25°C.
2.3.6 Culturing of primary mouse embryonic fibroblasts (MEFs)
The MEFs used for this study were obtained from mice embryo at 13–14 days at
the School of Medicine, University of South Carolina (USC). The primary MEFs were
cultured in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine
serum (FBS), 1% penicillin-streptomycin and 1% glutamine (Hogan et al. 1994; Zhang et
al. 2003). The cells were cultured in Petri dishes until 75–80% confluency and then subcultured at a ratio of 1:3. In this study, MEFs were used prior to passage 7.
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2.3.7 Assessing Acute Toxicity of se nps in MEFs
2.3.7.1 Assessment of cell viability by MTT assay
MEFs were seeded at 500 cells per well in flat bottom, 96-well microplates (tissue
culture grade) in a final volume of 100 μl DMEM containing 10% FBS and antibiotics.
The plate was incubated in a humidified atmosphere (37°C, 5.0 - 6.5% CO2) for 24
hours. The old medium was replaced with fresh 100 μl DMEM containing 0.5% FBS
(starving medium). After 24 hours, incubation was continued in DMEM containing 10%
FBS for another 24 hours. SE NPs were added to the wells at concentrations of 0, 1, 25,
or 50 μg/ml and incubation was continued for 1, 2, 3, 4, and 6 days (24-144 hours).
Analyses were carried out in 3 biological replicates each with 6 technical replicate wells.
Cell viability was measured by the MTT assay [3-(4,5-dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide, Roche]. After the appropriate exposure to SE NPs, 10 μl of
the MTT labeling reagent with a final concentration of 0.5 mg/ml was added to each well.
The plates were incubated for 4 hours in a humidified atmosphere (37°C, 5.0 - 6.5%
CO2) followed by addition of 100 μl of the solubilization solution into each well. The
plate was incubated overnight in a humidified atmosphere (37°C, 5.0 - 6.5% CO2). The
optical density was measured using a microplate reader (Spectra Max M3). The
absorbance was measured at 550 and 690 nm.
2.3.7.2 Assessment of cellular proliferation by bromodeoxyuridine (BrdU) incorporation
MEFs were seeded at densities of 250 cells/well in sterile 96-well tissue culture
plates in 100 μl/well of DMEM containing 10% FBS. The 96-well tissue culture plate
was incubated for 2 days. The DMEM containing 10% FBS was replaced with DMEM
containing 0.5% FBS and incubation was continued for another 2 days. SE NPs were
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added at final concentrations of 0, 1, 25, or 50 μg/ml and incubation was continued for 24
hours. A 20 μl of the diluted BrdU labeling reagent was added to appropriate wells and
incubation was continued for 24 hours. Some control wells did not receive BrdU labeling
reagent. Then, 200 μl/well BrdU fixing solution was added after aspirating the medium
from each well and incubation was continued at room temperature for 30 minutes. The
plate was washed three times with 1x Wash Buffer and blotted dry. Then, 200 μl of BrdU
antibody reagent was then added to each well and incubation was continued for 1 hour at
room temperature. The wells were washed again with 1x Wash Buffer. Then, 100 μl of
1x peroxidase goat anti-mouse IgG was added, and incubation was continued for 30
minutes at room temperature. The previous washing step was repeated, followed by a
final wash using sterile ultrapure deionized water. Then, 100 μl of TMB peroxidase
substrate was added per well and incubated for 30 minutes at room temperature in the
dark. After that, 100 μl of Stop Solution was added to each well. The plate was read using
a plate reader (Spectra Max M3) set at a dual wavelength of 450/550 nm.
2.3.7.3 Assessment of cell membrane damage by lactate dehydrogenase (LDH) assay
MEFs were grown in 96-well microplates in a final volume of 100 μl of DMEM
medium containing 10% FBS per well as indicated above. Following 24 hours of
incubation, the old medium was replaced with fresh 100 μl of DMEM containing 0.5%
FBS and incubation was continued for another 24 hours. After 24 hours, incubation was
continued in DMEM containing 10% FBS and SE NPs (0, 1, 25, and 50 μg/ml) for 24
and 144 hours (6 days). LDH concentration was estimated using Pierce LDH
Cytotoxicity Assay kit (Thermo Scientific) by following the manufacturer’s protocol. The
kit controls included sterile water as spontaneous LDH activity control and positive kit
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controls included sterile water as spontaneous LDH activity control and positive control
as 10x lysis buffer, which referred to as maximum LDH activity control.
2.3.7.4 Determination of apoptosis by TMRred cell death kit (TUNEL Assay)
Apoptotic cells were detected by a TUNEL assay (Cell Death-TMRred kit,
Roche) with the DNA binding fluorescent dye according to the manufacturer’s protocol.
Briefly, the MEFs were grown on Nunc™ Thermanox coverslips (5000 cell/mm2) for 2
days in DMEM containing 10% FBS. Nunc™ Thermanox coverslips are cell culturetreated on one side to ensure optimum cell attachment. The coverslips are also resistant to
most solvents including acetic acid, acetone, and xylene. In this experiment, the medium
was changed to DMEM containing 0.5% FBS and incubation continued for another 2
days to synchronize the cell cycle.
The cells were treated with SE NPs (0, 1, 25, and 50 μg/ml). The medium was
removed, and the coverslips were washed with ice-cold phosphate-buffered saline (PBS)
and fixed in 4% paraformaldehyde for 1 hour at room temperature. The washing was
repeated with cold PBS. The TUNEL reaction mixture was added to the cells at 37oC for
1 hour. The cell nuclei were stained with DAPI (1 μg/ml) for 15 minutes. Then, the cells
were mounted in 50% antifade mounting media, which was a glycerol-based liquid
mountant. Finally, the stained cells were evaluated and photographed by confocal
microscopy (LSM 510 META). Apoptotic cells (red stained nuclei) were determined
relative to the total number of cells (blue nuclei).
2.3.8 Western Blotting for Determination of Levels of proteins involved in Apoptosis
Western blotting was used to determine changes in levels of apoptosis related
proteins (cleaved caspase-3, cleaved caspase-7, total p53, phosphorylated p53-Ser15,
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PARP-1, Bax, Bcl-2, and cytochrome c). After being treated with 0, 1, 25, or 50 g/ml of
SE NPs, the MEFs were washed and protein samples were extracted with a RIPA Lysis
Kit (American Biotechnology Thermo Fisher Scientific). A stock of 100 mM PMSF in
100% ethanol was used to dissolve PMSF (phenylmethylsulfonyl fluoride as protease
inhibitor) in the lysis buffer. The protein concentration of the cytosolic extract was
determined using a BCA Protein Assay kit (Beyotime). An equal amount of each protein
sample was separated by SDS-PAGE and then transferred onto nitrocellulose membranes
(Amersham Biosciences, Pittsburgh, PA, USA).
The membranes were blocked with 5% non-fat milk at room temperature for 1
hour and then washed five times with tris-buffered saline (TBS) containing 0.05% Tween
20 for 5 minutes each time. Afterwards, the membranes were probed at 4°C overnight
with one of the primary antibodies (anti-cleaved-caspase-3, anti-cleaved-caspase-7, antitotal p53, anti-phosphorylated p53-Ser15, anti-PARP-1, anti-Bax, anti-Bcl-2, anticytochrome c, and anti-β-actin). The membranes were then left to incubate with an
appropriate secondary antibody at room temperature for 1 hour. Chemoluminescence was
used to visualize protein bands with a SignalFire ECL reagent (Cell Signaling). The band
density was analyzed by ImageJ software from the National Institute of Health (Bethesda,
MD, USA).
2.3.9 Statistical Analysis
The MTT experiment was performed in six wells with the repetition of treatment
combinations to (replicates, n = 6 / treatment), the (LDH) assay in six wells as replicates
(n = 6 / treatment), and the proliferation assay in five wells as replicates (n = 5 /
treatment). The Western blot band ratio analysis was performed in technical triplicates
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and biological triplicates. Data were reported as the mean of optical density and +/- mean
standard error (MSE). The data were subjected to a two-way analysis of variance
(ANOVA), and the significance of the differences between means was calculated using
the Tukey Kramer using GraphPad prism Insta-3 for Windows, standard version 7.5.1,
and the significance was accepted at p < 0.05.
2.4 Results
2.4.1. Determination of properties of SE NPs
The chemical reduction of selenium ions in water was monitored with the UV2600 spectrophotometer of the solutions after diluting a small aliquot (100 µl) of the
sample to 10 times with ddH2O. The z-average hydrodynamic of the synthesized SE NPs
measured by DLS was 68.83 ± MSE 0.86 nm and the polydispersity index (PDI) was
0.03 (figure2.1-e). The zeta potential was 4.38 mV. The UV-Vis absorbance peak was at
284 nm (figure 2.1-e). The concentration of SE NPs was 175.6 ppm and the dissolved Se
concentration was DF = 0.3 ppm (table A.1-Appendex). SE NPs exhibited spherical
morphology (Figure 2.1a, b, and c) from TEM. The high percentage of SE NPs core size
measured by TEM varied between 36 and 66 nm (Figure 2.1d). The mean core diameter
determined by TEM was 52 ± 12 nm (Figure 2.1d).
2.4.2 Acute toxicity assays
2.4.2.1 Effect of SE NPs on cell viability
SE NPs were used at increasing doses of 0, 1, 25, and 50 µg/ml and the viability
of MEFs were analyzed using the MTT assay after 1, 2, 3, 4, and 6 days of treatment. As
shown in Figure 2.2, treatment of MEFs for 24 hours with PVP-coated SE NPs resulted
in a slight but insignificant reduction in cell viability at all doses tested. After 48 hours of

57

treatment, doses of 25 and 50 µg/ml, reduced the cell viability of MEFs to 56.1% (p ≤
0.05) and 39.2% (p <0.001), respectively. In this experiment, there was a significant
reduction of cell viability following exposure to all doses of PVP-coated SE NPs tested
at 3, 4, and 6 days as compared to untreated cells (negative control, p ≤ 0.001).
2.4.2.2 Analysis of cell proliferation
The BrdU assay is an established colorimetric method for determining cell
proliferation and is based on the measurement of BrdU incorporation during DNA
synthesis (Hall, 1990). In this study, MEFs at a cell density of 250 cells/well were
exposed to 0, 1, 25, and 50 µg/ml concentrations of SE NPs for 24 hours. The cells were
incubated to grow in the presence of BrdU for another 24 hours while still exposed to SE
NPs. The proliferation of MEFs, as determined by the BrdU assay, was significantly
lower after exposure to all doses of PVP-coated SE NPs as compared to the untreated
cells (p ≤ 0.0001) (Figure 2.3).
2.4.2.3 Analysis of cell membrane damage by LDH assay
LDH is a cytoplasmic enzyme that is common in all types of cells. The
extracellular release of this enzyme indicates cell membrane damage (Chan, 2013). To
evaluate cell membrane damage and leakage of LDH into the cell culture medium, the
cells were treated with different concentrations of PVP-coated SE NPs (0, 1, 25, and 50
µg//ml) for 24 hours and 6 days (Figure 2.4). Next, the leakage was quantified as the
amount of formed formazan product using spectroscopy. After 24 hours and 6 days of
exposure to 1, 25, 50 µg/ml of SE NPs, there was no significant difference in LDH
release when compared to the negative control (the SE NPs untreated cells incubated in
media with spontaneous water control) in all treated groups (p ≤ 0.05). On the other
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hand, treatment with any of the concentrations of SE NPs exhibited statistically
significant differences from the positive control (cells treated with lysis buffer, p <
0.0001).
2.4.2.4 Determination of apoptosis in MEFs by TUNEL assay
This study examined whether PVP-coated SE NPs induce cell death via apoptosis
that can be assessed using the TUNEL (terminal deoxynucleotidyl transferase-mediated
dUTP nick end labeling) assay. Measuring the DNA fragmentation appears to be one of
the best techniques for evaluating the induction of apoptosis. To detect apoptotic features
induced by SE NPs, MEFs were treated with 0, 1, 25, and 50 µg/ml PVP-coated SE NPs
and subjected to the TUNEL assay to determine apoptotic DNA fragmentation. The
results, as shown in Figure 2.5, revealed a significant number of TUNEL-positive cells,
representing apoptotic DNA fragmentation following treatment with all three
concentrations of SE NPs (p < 0.0001). There were significant differences in the percent
of TUNEL-positive cells between 1, 25, and 50 µg/ml of SE NPs, which indicated that
the SE NPs induced dose-dependent DNA damage (p < 0.01 to 0.0001).
2.5 Western Blotting For Determining Changes In Expression Of Apoptotic Proteins
The effect of SE NPs on the levels of proteins associated with apoptosis was
analyzed by Western blotting. Caspases are important mediators of apoptosis that can be
induced by a number of stimuli. To address whether effector caspases in cells were
affected due to exposure to SE NPs, the total p53, phosphorylated p53-Ser15, Bax, Bcl-2,
cytoplasmic cytochrome c, cleaved caspase-7, cleaved caspase-3, and poly (ADP-ribose)
polymerase one (PARP-1) were examined in SE NPs-treated cells versus untreated cells
by Western blotting. Results showed that the phosphorylated p53-Ser15 was undetectable
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in control MEFs or after 24 hours exposure to 1, 25 and 50 µg/ml of SE NPs. However,
the total p53 was detected, and it was significantly reduced in all doses of SE NPs used
when compared to the untreated control cells (p ≤ 0.05 to 0.001) (Figure 2.6-a ). The
highest reduction was at 25 µg/ml of SE NPs (p < 0.001) when compared to
concentrations of 1 µg/ml and 50 µg/ml of SE NPs (Figure 2.6-a).
To gain insight into the mechanism by which SE NPs induced cytochrome c
release, the pro-apoptotic Bax expression was studied in MEFs following exposure to SE
NPs. Although it is only one of several members of the Bcl-2 family, increased
expression of pro-apoptotic Bax has been shown to be requisite for induction of apoptosis
in many cell types (Finucane, 1999). Our findings indicated that Bax expression was
elevated considerably in cells in response to treatment with 1, 25 and 50 µg/ml SE NPs
compared to untreated control cells (p < 0.001) (Figure 2.6b). On the other hand, the ratio
of Bcl-2 to Bax decreased considerably in a dose-dependent manner after exposure to 1,
25 and 50 µg/ml concentrations of SE NPs (P < 0.0001) indicating that MEFs were
committed to cell death via induction of intrinsic pathway of apoptosis (Figure 2.6b).
Our data showed that there was a connection between SE NPs and the release of
mitochondrial cytochrome c. To investigate whether cytosolic cytochrome c was
increased during SE NPs-induced apoptosis, western blotting was used to determine
cytochrome c levels in the cytosolic fractions of MEF cells following exposure to 1, 25
and 50 µg/ml of SE NPs. After 24 hours of treatment, cells released a high concentration
of cytochrome c into the cytosol. As shown in our data (Figure 2.6c), cytochrome c
release from mitochondria significantly was increased in a dose-dependent manner after
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exposure to SE NPs compared to untreated cells. There was a statistical significance
between all doses SE NPs used and the untreated control, p < (0.001 to 0.0001).
Western blotting also used with MEFs extracts for cleaved caspase-7 that showed
a significant increase following treatment with 50 µg/ml SE NPs as compared to control
(untreated cells) at 24 hours (p < 0.05) (Figure 2.7a). There was no statistical significance
between the control and 1 ug/ml and 25 ug/ml SE NPs. Nevertheless, cleaved caspase-3
was increased very significantly at 24 hours compared to control in all doses of SE NPs
used (Figure 2.7b). Our results indicated a significant elevation in PARP-1 degradation
product in in MEFs when treated with 1 or 25 µg/ml of SE NPs compared to untreated
controls (Figure 2.6d). Interestingly, treatment with 50 ug/ml SE NPs had no significant
effect on levels of PARP-1 (Figure 2.6d).
2.6 Discussion
The particle size, size distribution, and surface charge of SE NPs were measured
to examine their surface properties. These data (Figure 2.1) indicated that the presence of
PVP-coating keeps the average diameter of SE NPs to about 68.83 nm. After surface
modification with PVP, the zeta potential of particles was −4 mV, suggesting that the SE
NPs exhibited higher colloidal stability and low dissolution than other coating materials
mentioned in other literature. These properties can be inherent features of SE NPs
attributed to steric repulsion described by the large, non-charged polymers (Huynh, 2011,
Tejamaya, 2012). Unlike SE NPs, gold nanoparticles do not interact with organic
macromolecules or depict any aggregation under different environmental conditions
(Hitchman et al., 2012). This property makes gold nanoparticles less stable due to high
mobility in the environment.
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Size, shape, surface charge, coating material, and concentration of nanomaterials
play a crucial role in interactions with cellular biomolecules (Albanese, 2012). In this
study, the SE NPs with a size distribution between 36-66 nm were synthesized by
adjusting the reaction concentrations of sodium selenite. Result revealed that SE NPs that
was modified with PVP-coating presented a homogeneous and mono-disperse spherical
structure with a diameter of approximately an average of 52 nm (Figures 2.1). The
particle size can play a role in the reduction of metabolic effects, proliferation rate, and
apoptosis. Win et al. (2004) reported that SE NPs with a diameter of approximately 55
nm have receptor-ligand interaction that is capable of producing enough energy to result
in an accumulation of the SE NPs inside the cells. This study showed that the cytotoxicity
of SE NPs increases in a time- and dose-dependent manner, which, in turn, might indicate
that the cellular uptake of the selenium would increase with the time due to the size of SE
NPs. Sonkusre et al. (2017) found that biogenic SE NPs with larger sizes of roughly 110
nm can enhance cell death in the prostate cancer PC-3 cells through necroptosis process.
Additionally, the design of the particles, including shape, coating material, and
surface charge, can initiate different interactivities that guide the program of cell death as
well as rate and time of particle uptake. Zhang et al. (2011) have clarified that a
nanoparticle’s shape directly influences absorption into cells. The nanoparticles with an
average size below 100 nm and characterized by spherical shape exhibit a definite
advantage in cellular uptake and interactivities with biomolecules over rods (Chithrani et
al., 2006; Qiu, 2010). Although we measured the cytotoxic effects after 24-144 hours (1
to 6 days), according to literature, the cellular uptake of differently designed SE NPs by
different methods can start earlier and increase with time (Xia, 2015). Sonkusre et al.
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(2017) confirmed that 2µg/ml of biogenic-synthetized SE NPs with spherical shape could
induce necrosis instead of apoptosis. This represents the impact of the design and
synthesized method, which gives the nanoparticles specific interactive characteristics
with biomolecules that, can trigger different cell death pathways.
Nonetheless, the uptake ratio conceivably depends on nanoparticle concentration
and permeability of the cell membrane (Luca et al., 2010). Most embryonic cell lines
such as MEFs have doubling time that mimics many cancer cell lines (Oraiopoulou,
2017) and high permeability, which allows for the uptake of materials from the
surrounding environment, to compensate the high rate of growth and proliferation
(Yusuf, 2013). This might impact the ability of MEFs in taking up the most of PVPcoated SE NPs from surrounding media as well as the increase in uptake in higher
concentration (Yusuf, 2013). It may affects cell viability and proliferation leading to
apoptosis.
To establish the cytotoxic effect of PVP-coated SE NPs in MEFs, we first
investigated the effect on cell viability using the MTT assay. It was apparent that there
was a notable effect on cell viability in all treated doses compared to untreated cells,
which increased during the exposure time (Figure 2.2). The reduction in cell viability was
either in a dose or time-dependent manner. The massive decrease in cell viability was
around 10.8% at 50 µg/ml SE NPs after 6 days of treatment (Figure 2.2). All doses of SE
NPs used were enough to repress about 50% and more of the cell viability of MEF cells
in a time-dependent manner (Figure 2.2). This indicated that the lowest used dose (i.e., 1
ug/ml of SE NPs) was enough to target protective metabolic enzymes that are responsible
for cellular homeostasis, intracellular energy and cell viability. A previous study by
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Sonkusre et al. (2017) showed that the source of intracellular energy (i.e., ATP) was
depleted after exposure to SE NPs. Our result of greater reduction of cell viability may be
attributed to greater ability of MEFs in uptaking our SE NPs. The high activity of SE NPs
under low concentration points to its potential medical applications to cancer therapy for
induction of apoptosis.
Findings of other studies’ reveal that selenium compounds can decrease the rate
of proliferation by reducing DNA synthesis and delaying the entry of cells into the S
phase (LeBoeuf, 1985; Eriksson, 2010). This decrease occurred in a dose-dependent
manner. This scenario can be applied to our data interpretation. SE NPs as a source of
elemental selenium may down regulate the cofactors involved in DNA synthesis and
repair as a pre-apoptotic effect.
Two main mechanisms mediate necrotic cell injury: interference with the energy
supply of the cell and direct damage to cell membranes. This loss of cell membrane
integrity results in the release of the cytoplasmic contents into the surrounding tissue.
LDH is one of the biochemical factors in the cytoplasmic contents that indicate the loss
of cell membrane integrity due to necrosis. Our LDH assay results indicated that there
was no impact on cell membrane integrity with all the doses of SE NPs used.
In this study, the TUNNEL assay was employed to study the apoptotic effect of
SE NPs. After 24 hours of exposure to the nanoparticles, the MEFs were subjected to
TUNEL assay followed by confocal microscopy to count the cell death ratio in each
treatment. The ratio of dead cells in untreated cells was not detectable (ND), whereas the
ratio of dead cells in treated cells were detected and significantly high compared to
untreated cells. Meanwhile, the ratio of dead cells in the 50 µg/ml treatment was
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statistically higher than in 1µg/ml and 25ug/ml concentrations of SE NPs in a dosedependent manner, suggesting that SE NPs significantly induce apoptosis in MEFs. The
percentages apoptosis in MEF cells were 12% + 5.6 in 1 µg/ml, 23% + 12 in 25 µg/ml,
and 78% + 34 in 50 µg/ml SE NPs (Figure 2.5). These results support the hypothesis that
SE NPs repress growth of MEFs mainly by inhibiting cell proliferation and promoting
cell death via apoptosis. Furthermore, it is worth mentioning that in the TUNNEL assay
approach, the cells treated with SE NPs exhibited an impact on cell adhesion, where lots
of adherent cells tending to be detached. The detachment occurred in a dose-dependent
manner, and this might be due to the cytotoxicity of cellular accumulation of SE NPs. Xia
et al. (2015) also reported impacts of SE NPs in cancer cell line and the ability to detach
the surfaces.
Apoptosis exhibits some biochemical modifications in cells such as protein
cleavage (caspases apoptotic cascades) (Hengartner, 2000). Western blotting was used to
investigate the role of SE NPs in the expression of total p53, active phosphorylated p53,
Bcl-2 family proteins (anti-apoptotic Bcl-2 and pro-apoptotic Bax),

cytosolic

cytochrome c, active or cleaved caspase-7, cleaved caspase-3 and PARP-1. Our study
indicated the translocation entry of SE NPs in the cell cytoplasm to turn on the intrinsic
or mitochondria-dependent caspase pathway of apoptosis.
Although our study showed that the phosphorylated p53-Ser15 was undetectable
after 24 hours of exposure to SE NPs, because it was highly unstable and degraded before
16 - 18 hours (Ashcrof, 1999). However, our study was able to detect the total p53
protein and it was significantly reduced in all the used doses of SE NP compared to the
untreated control. One of the important signaling pathways through which proteases can
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cause cell apoptosis is p53 and caspase-3 (Errami, 2013). Our results indicated that the
highest reduction in total p53 in 25 µg/ml of SE NPs might correlate to the reduction in
procaspase-3. It was found that the overexpression of p53 can interfere with the
processing and activation of cytosolic procaspase-3. Our result indicated that the
reduction in total p53 allows procaspase-3 to be activated and consequently converted to
cleaved caspase-3. Our results indicated that the reduction in total p53 protein points to
activation of mitochondrial pathway of apoptosis and not necrosis. Manipulation of
apoptotic functions of p53 by SE NPs can be attractive for cancer therapy.
The anti-apoptotic Bcl-2 protein is one of the regulators that control the
mitochondrial pathway of apoptotic response. As mentioned in previous studies, antiapoptotic Bcl-2 members like Bcl-2 prevent the release of cytochrome c (Kluck, 1997)
whereas pro-apoptotic ones like Bax can cause the release of cytochrome c (Finucane,
1999). It was revealed as a potential biomarker to predict apoptosis in response to
therapies. In this study, we found that the SE NPs may have a complementary effect as a
novel drug that directly targets anti-apoptotic Bcl-2 protein. Our data showed a
significant decrease in anti-apoptotic Bcl-2 protein in a dose-dependent manner and
significant overexpression of Bax protein in a dose-dependent manner. During apoptosis,
Bax can translocate from the cytosol to the mitochondria (Jurgensmeier, 1998; Finucane,
1999) and facilitate mitochondrial outer membrane permeability and cytochrome release
(Jurgensmeier, 1998; Finucane, 1999).
The overexpression of cytochrome c in the cytosol and its release from
mitochondria is an indication of mitochondrial pathway or intrinsic pathway of apoptosis.
In our study, we established that SE NPs induced a dose-dependent increase in the release
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of the mitochondrial respiratory chain protein cytochrome c into the cytosol. The release
of cytochrome c is regulated through the imbalance of the Bcl-2 family of proteins such
as Bax and Bcl-2 proteins. Elevated cytosolic cytochrome c levels were associated with
enhanced expression of Bax protein, suggesting that SE NPs induced expression of Bax
in a dose-dependent manner. Consequently, this causes changes in the inner
mitochondrial membrane and resulting in an opening of the mitochondrial permeability
transition pore and loss of mitochondrial trans-membrane potential. The loss of
mitochondrial trans-membrane potential lead to releases pro-apoptotic cytochrome c
protein from the inter-membrane space into the cytosol in a dose-dependent manner after
exposure to SE NPs. Once cytochrome c is released in the cytosol, it binds and activates
other factors such as Apaf-1 and pro-caspase-9 to form an “apoptosome” (Chinnaiyan,
1999; Hill et al., 2004). Our results suggested that an increase in mitochondrial release of
cytochrome c after 24 hours exposure to SE NPs might play a role in cellular defense
against abnormal growth such in cancer.
Although, the 24 hours of exposure to 1 and 25 µg/ml of SE NPs did not show an
elevation in the cleaved caspase-7, the exposure to 50 µg/ml of the SE NPs significantly
caused elevation in the cleaved caspase-7 (Figure 2.7a). The observation that all doses of
SE NPs used could convert procaspase-3 to cleaved caspase-3 (Figure 2.7b) was
interesting as active caspase-3 could activate other downstream factors such as caspaseactivated DNase or CAD, the translocation of which from cytosol to the nuclei of the
cells could lead to apoptotic DNA fragmentation, as reported in an epoch-making
discovery (Enari et al., 1998).
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Although the introduction of SE NPs was necessary for the activation of caspase3, it was also found that the transition from non-apoptotic to apoptosis stage requires
concentration over four orders of magnitude of caspase-3 (Walters, 2009) and this
magnitude was exceeded in our results after treatment with SE NPs.Elevation in PARP-1
degradation product is an indication of sustained DNA fragmentation and apoptosis. A
study by Yelamos (2011) using either PARP-1 inhibitors or PARP-1 knockout animals
proved the significant role of this enzyme in maintaining DNA integrity. Our results
indicated a significant elevation of PARP-1 fragmentation in 1 µg/ml and 25 µg/ml of SE
NPs but the 50 µg/ml compared to 1 µg/ml and 25 µg/ml was reduced indicating the
overwhelming of PARP-1 fragmentation and fail in DNA repair mechanism (Figure
2.6b). Following DNA damage, PARP-1 can still promote chromatin relaxation and
recruit the base-excision repair proteins that will ensure the DNA repair (Yelamos, 2011).
SE NPs mediated inhibition of PARP-1 can repress tumor growth (Levkoff et al., 2008).
Adding SE NPs to the list of clinical PARP-1 inhibitors calls for more clinical
investigations on mono-therapy or adjuvant therapy to enhance therapeutic effects.
Besides, all used doses of SE NPs in this study did not produce any overexpression or
hyper-activation to PARP-1. The overexpression and hyper-activation of PARP-1 after
DNA damage can lead to necrotic cell death pathway (David, 2009). Our data did not
indicate its overexpression, which suggested that the used doses of PVP-coated SE NPs
induced apoptosis, not necrosis.
2.7 Conclusion
Our study showed that the PVP-coated SE NPs were capable of inducing intrinsic
pathway of apoptosis in MEFs. The data from this study also indicated that SE NPs could
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facilitate the reduction in metabolic activities, cell proliferation, and induce mitochondria
mediated apoptotic activity in a dose- and time-dependent manner. This cell death
mechanism is characterized by decrease in Bcl-2, increase in Bax, release of cytochrome
c from mitochondria without loss of plasma membrane integrity, caspase-3 activation,
and PARP-1 fragmentation. Furthermore, the PVP-coated SE NPs can cause translocation
of Bax from cytosol to mitochondria, which is a mechanism through which SE NPs cause
cytochrome c release. However, the activation of Bax can be induced by other members
of the Bcl-2 family; therefore, one or more of these may be the target of SE NPs. Thus, it
is conceivable that the SE NPs can lead to a significantly higher intracellular interaction
in MEFs for a highly efficient apoptotic activity. This mechanism may be used as
beneficial effect of SE NPs in inducing apoptosis in neoplastic diseases. Further studies
are needed to determine how SE NPs can induce translocation of Bax to the
mitochondria, and whether this is a primary mechanism for SE NP-induced apoptosis.
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Figure 2.1. Physicochemical properties of Selenium NPs: The TEM graph for core
size (a, b, c) & size distribution (d) of mono-dispersed PVP coated selenium
nanoparticles which were between 36-66nm diameters. The mean of frequency of
core size distribution was 52 and MSE ± 12, the hydrodynamic size, zeta potential &
spectral absorbance ( e), Notes: Data were presented as mean ± MSE

70

Figure 2.2. Cell viability of MEF cells after exposure Se NPs: the doses were
1µg/ml, 25µg/ml, & 50µg/ml of Selenium Nanoparticles between 24-hours to 6
days. Notes: Data were presented as normalized mean ± MSE. Asterisks represent (*) P-value <0.05 and (***) P-value <0.001.
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Figure 2.3: Proliferation rate in MEFs after Se NPs treatments: Graphic
representation of the relative BrdU incorporation in MEFs after 24-hours exposure to
1µg/ml, 25µg/ml& 50µg/ml of Selenium Nanoparticles Notes: Data were presented
as mean ± MSE Asterisks (***) represent significantly different P-value < 0.001.
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Figure2.4. Necrosis after Se NPs treatments : (a-b) Membrane integrity: which
represent necrotic effects on MEF cells after 24-hours & 6 days exposure to 1 µg/ml,
25 µg/ml & 50 µg/ml of Selenium nanoparticles compared to negative (only treated
with water as spontaneous LDH control) and positive (lysis buffer) LDH control
indicate here what is the difference between 3a and 3b Notes: Data were presented as
mean ± MSE, Asterisks (****) represent P-value <0.0001; NS = not significant (Pvalue >0.05).
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Figure 2.5 DNA damage after Se NPs treatments: by TUNEL assay, the red cells
represent dead cells (an apoptotic effect) blue cells represent DAPI nuclear stain
(total cells), (a) negative control (untreated cells), (b) cells treated with 1 µg/ml of
Selenium Nanoparticles, (c) cells treated with 25 µg/ml of Selenium Nanoparticles,
(d) cells treated with 50 µg /ml of Selenium Nanoparticles, (e) % of DNA damage in
MEF cells after 24-hours exposure to selenium Nanoparticles. Notes: Data were
presented as mean ± MSE, Asterisks (****) represent extremely significant P-value
<0.0001.
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Figure 2.6 Immunoblotting of apoptotic factors after Se NPs treatments (part1):
Normalized Level of proteins expression in Western blot analysis after exposure to
(0, 1, 25 & 50 µg/ml) of selenium nanoparticles, β-Actin was also measured as the
loading control and used for data normalization: (a) is Level of total p53 expression
to the ratio of b-actin determined by Western blot analysis after 24 hrs. Exposure to
(0, 1, 25 & 50 µg/ml) of selenium nanoparticles. β-Actin was measured as the
loading control and used for data normalization: Total P-53 was significantly reduce
in 1,25 & 50 µg/ml Se NPs treatment. (b) bcl-2/BAX ratio significantly reduced at
all Se NPs treatments. (c) Cytoplasmic Cytochrome C significantly increased in all
Se NPs treatments compared to control. (d) Is Expression of PARP-1 protein as
detected by Western blot analysis after 24 hrs? Exposure to (0, 1, 25 & 50 µg/ml) of
selenium nanoparticles. β-Actin was also measured as the loading control and used
for data normalization: PARP1 was significantly elevated in 1 & 25 & 50 µg/ml of
Se NPs treatment . The graph indicates that 50 ug/ml exposure was not significant.
All values are represented as the means ± MSE. of three independent experiments.
Asterisks represent - * p values < 0.05, ** p values < 0.01 and p values < 0.0001.
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Figure 2.7. Immunoblotting of apoptotic factors after Se NPs treatment (part 2):
Normalized Level of proteins expression in Western blot analysis after exposure to
(0, 1, 25 & 50 µg/ml) of selenium nanoparticles, β-Actin was also measured as the
loading control and used for data normalization: (a) Level of cleaved Caspase 7
increase only significantly in 50µg/ml compared to control. (b) Level of cleaved
Caspase 3 increase significantly in all administered SENPs doses compared to
control; all values are represented as the means ± MSE. Asterisks represent - * p
values < 0.05 and *** p values < 0.001.
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CHAPTER 3
PLATINUM NANOPARTICLES ROLE IN TGFB-1SIGNALLINGS AT
MOUSE EMBRYONIC FIBROBLASTS (MEF) CELLS AND INSIGHT
TO DOUBLE EDGE SWORD IN CANCER AND FIBROTIC DISEASES
3.1 Chapter overview
Platinum nanoparticles may have a crucial role in fibrotic disease and cancer
therapy; it has the ability through induction of Transforming Growth Factor Beta -1
(TGFB-1) signaling pathways on embryonic fibroblast and may lead to differentiation of
myofibroblast and release of extracellular matrix (ECM), causing fibrosis without
initiating inflammatory process.
Methods: Cultured mouse embryonic fibroblasts were pretreated with 1, 25, 50 µg/ml
platinum nanoparticles. Cytotoxicity and intracellular mechanism of platinum
nanoparticles were tested by assessing cell viability, proliferation, necrosis, DNA
damage, and TGFB-1 signaling proteins expression by Immunoblotting.
Results: platinum NPS didn’t induce any toxicity in cell viability or lead to necrosis on
fibroblast but significantly reduce the proliferation percentage to ~ 50% and lower after
24 hours of exposure. Platinum NPs caused differentiation of mouse fibroblast to
myofibroblast by induction of TGFb-1 canonical pathway and production of endogenous
collagen and a-smooth muscle actin (a-SMA). Platinum might serve a big role in the
TGFB-1 signaling pathway in cancer therapy at the early stage, and it may be dangerous
to the patient with fibrotic diseases such as cardiac fibrosis.
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3.2 Introduction
Cancer refers to a broad term that explains the disease, which results when
cellular changes cause uncontrolled growth as well as the division of the cells (Humbert,
2012). More than 100 types of cancer diseases have been identified based on their causes
and tissues affected (Jemal et al, 2009). Among them are breast cancers, prostate cancer,
colon cancer, and lymphoma, among many types (Key, 2001). Due to the complexity of
their causes and mechanisms of control, cancer diseases are becoming the current threat
to human healthcare, with accelerating mortality rates. Moreover, identifying treatment
for cancer diseases has become the most difficult task for medical professionals (Humber,
2012). Despite this, several therapeutic measures are being established to counter a
number of cancer diseases. With several trials in place for cancer treatment, nanomaterial
application in cancer therapy is a new promising method to counter the cancer tragedy
(Shibuya et al, 2014). Platinum compounds application in cancer disease medication has
been proved to lower cancer cells (Morry, 2017). Evading apoptosis is among the
hallmarks of cancer cells that enhance their survival. Cisplatin is an example of platinum
compounds applies for cancer medication.
Cisplatin, a platinum-based family medication, and its analogs have been used as
the first line of cancer therapy, especially ovarian cancer. Cisplatin forms intrastrand
DNA crosslinks, DNA mono adducts, and DNA protein crosslinks that enhances its
cytotoxicity and triggers apoptosis (Gao et al., 2015). Cisplatin, together with
LY2109761, inhibits TGF-β signals by inhibiting TβRI/II kinase receptors and increases
radio sensitivity while reducing clonogenicity in cancer cells and ultimately reducing the
growth of a tumor. LY2109761 inhibits TGF-β1 and TGF-β2 receptors. It targets P-
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Smad2 and 3 activations and inhibits kinase receptors that are related (Connolly et al.,
2011). While cancer cells may be resistant to cisplatin, LY2109761 comes in handy
sensitizing resistant cells to cisplatin. With various cancers becoming resistant to cisplatin
as well as its adverse effects such as hearing loss, severe kidney problems, among others,
other platinum-containing cancer drugs like oxaliplatin and carboplatin have been used
(Gao et al., 2015).
The issue with such platinum compounds the toxicity, formation of excessive
oxidative stress by reactive oxygen species (ROS) and inflammation which trigger
significant adverse effect to cancer patient (Connolly et al., 2011). On the other hands
TGFB signaling pathways are considered the main player of fibrotic diseases such as
liver and cardiac fibrosis. Since TGBs signaling pathways are capable of transforming
the fibroblast to a pathological phenotype called myofibroblast which act under specific
conditions to induce profibrotic inflammatory (includes AKT, ERK1/2, P38, JNK, IKB-α
and NFKβ) and transcription factors (α-smooth muscle actin α-SMA and collagen A)
which may play a role in fibrotic diseases and cancer by depositing extracellular matrix
and form immunosuppression, inflammation, apoptosis and a scarring, that damage the
surrounding tissues (Connolly et al., 2011).
3.2.1Role of TGFβ-1 in Cancer
TGFβ1 plays a crucial role in cancer formation as well as progression regulation.
In early carcinoma and normal cells, TGFβ1 acts as a tumor suppressor as mentioned by
Zhao et. al (2018). However, this role changes in more advanced cancer stages, where it
now promotes tumor progression. TGFβ1 inhibits the cell cycle in the G1 phase exerting
powerful cytostatic effects on its target tissues. It increases P21, P27, and P15 cyclin-
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dependent kinase inhibitors expression inducing G1 phase cell cycle arrest. While the
effects are “Small Mothers against Decapentaplegic” SMAD dependent, they also need
FoxO and SP1 transcription factors. CDK4/6 is directly inhibited by p15, P27, and p21
and displaced from Cyclin-dependent kinase (CDK4/6) complexes. This allows them to
bind, leading to inhibition of CDK2-cyclin A/E complexes (Mishra & Deng, 2014).
TGFβ also causes apoptosis and inhibits the immortalization of cells in various
target tissues (Ruiz-Ortega, 2007). E2F1-pRb-P/CAF pathway is the central pathway in
TGFβ pro-apoptotic effects mediation. This pathway results in TGFβ pro-apoptotic-target
genes transcription in numerous cancers and normal cell types (Neuzillet et al., 2014).
TGFβ, especially in hematopoietic cells, leads to lipid phosphatase SHIP expression
blocking Akt-mediated survival pathways and decreasing the levels of the second
messager PIP3. This leads to cell death in lymphocytes T and B.
Nevertheless, TGFβ inhibits cell immortalization in both cancer and normal cells. Its
tumor-suppressive effects are mediated through JNK, p38, and SMAD pathways. It
requires histone deacetylases recruitment to the telomerase gene promoter, which inhibits
expression of telomerase further and thus inhibiting the immortalization of cells (Kemp el
al, 2008).
3.2.2 Role of TGFβ-1 in fibrotic disease:
TGFB signaling pathways result in various biological functions, leading to
reactive oxygen species (ROS) generation. Growth factors, as well as secretion of
chemokines, release by immune cells during the inflammation phase along with ROS
release has been shown to allow fibroblast activation and deposition of collagen in
fibrosis (Manke, 2013). Among all of these, the most powerful profibrogenic cytokine is
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TGF-β. It is used in the regulation of essentially biological processes that include
epithelial-mesenchymal transition, extracellular matrix production, and cellular
proliferation. In most patients with fibrotic diseases, the expression of TGF-β mRNA has
been seen to be elevated. TGF-β signaling pathways can be activated by ROS, which
signals either through SMAD dependent or independent pathways (Neel, 2012). Elevated
NOX4-generated ROS levels may also be produced from increased TGF-β signaling,
further stimulating pro-fibrotic genes transcriptional activities like NOX4, Collagen I,
and alpha-smooth muscle actin. NOX4-generated ROS presence can also lead to
activation of signaling pathways like NFκB and JNK and trigger the oxidation of DNA,
which leads to differentiation of myofibroblast as well as collagen deposition
accumulation into the extracellular matrix which leads to fibrosis.
3.2.3Tgfb-1 signaling cascades:
Tgfb-1 canonical pathway is where the activation of receptors induces SMADs
transcription factors C-termination phosphorylation. On the other hand, the non-canonical
pathway is where other signaling pathways may be activated without ligation of the
TGFβ receptor (Neuzillet et al., 2014).
3.2.3.1 Canonical pathway
The TGFβ ligand isoforms that include TGF-β3, -β2 precursors bind forming
TGF-β complex (Neuzillet et al., 2014). The TGF-β ligands then bind TGF-β2 receptor
homodimers or TGF-β3 with high affinity after the extracellular activation. The binding
to the TGF-β2 receptor allows TGF-βRI kinase-domain activation, signal transduction
through receptor-regulated SMADs C-terminus phosphorylation and dimerization with
homodimers of TGF-β1 receptor (Neel, 2012). Then, a heterotrimeric complex is formed.
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This complex moves and accumulates in the nucleus. Through SMADs interaction with
various transcription factors, TGF-β dependent signaling can contribute to activation or
repression of hundreds of target genes. Various mechanisms regulate the activities of
SMADs (Neuzillet et al., 2014). They may include inhibitory SMAD6 and 7expression,
Smurf dependent degradation, binding to anchor proteins, or SMAD 2 or 3
nucleocytoplasmic shuttling (Zhan et al, 2001).
3.2.3.2 Non-canonical pathway
TGF-β signaling in the non-canonical pathway triggers SMAD independent
pathways that include MAPK, PI3K/AKT, as well as Abl, Src, FAK, CDc42, Rho/Rac1,
and NF-κB. Also, transversal signaling allows integration of signals from TNF-α, Wnt,
Notch, integrins, signals from cellular processes like apoptosis, cell cycle, as well as
EGF-dependent pathways through TGF-β pathway activation. The TGF-β signaling
pathway, therefore, acquires pleiotropic functions that help to regulate processes such as
angiogenesis, extracellular matrix production, apoptosis, cellular immune response, cell
motility, differentiation, and cell growth (Neuzillet et al., 2014).
3.3 Activity of platinum nanoparticles to target oxidative stress and reactive oxygen
species in fibrotic disease and cancer:
Levels of oxidative stress (ROS) have been traced in fibrotic diseases (trigger
TGFB signaling pathways) and most cancer cell lines. ROS, which is generated by
various sources that include hypoxia conditions, inflammation, radiation, and
chemotherapeutics, has been seen to cause cancer cells genomic instability, invasion,
neovascularization, proliferation, resistance to apoptosis, survival, extravasation and a
distant metastasis site growth (Morry, 2017).Platinum nanoparticles have been verified
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because of their therapeutic potential in clinical research such as anti-aging, and
antioxidant mimicking superoxide dismutase enzyme (SOD1). It has the capability to
protect against inflammation, and apoptosis induced by UV- radiations, ischemia, and
reperfusion injury (Yoshihisa, 2010, Shibuya, 2014).
Platinum nanoparticles are known to possess the antioxidant capacity that can
down-regulate the reactive oxygen species (ROS). The platinum nanoparticle has
catalytic activity gained by its high ratio of electrons to particle surface (Katsumi, 2014)
consequently, this study was designed to investigate the platinum nanoparticle effects on
two of common pathways to target both fibrotic diseases and cancer cells. These
pathways are the inflammatory pathway (which related to non-canonical TGFB
signaling) and the canonical TGFB1 signaling which provide more hope for more cancer
therapies. Nanoparticles such as platinum nanoparticles offer a promising therapeutic
option as they show a tremendous catalytic activity that results from its high electron
ration to particle surface (Morry, 2017). This increases its scavenging ability, which can
help minimize the level of ROS and impair the downstream pathways that may lead to
inflammation. Their potential is based on their ability to deliver drugs, imaging agents as
well as genes as they are in the form of suspension.
3.4 MATERIALS AND METHODS
3.4.1 Chemicals
The chemicals used for these experiments were platinum salt (H2PtCl6), sodium
citrate, Sodium borohydride NaBH4, polyvinylpyrrolidone (PVP) (average molecular
weight 40k), Cell proliferation kit I (MTT) (purchased from Sigma Aldrich St. Louis,
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MO), the BrdU cell proliferation Assay kit from Millipore, Pierce™ LDH cytotoxicity
assay kit (obtained from Thermos Fisher, Waltham, MA).
3.4.2 Preparation as well as Synthesis of platinum nanoparticles
The synthesis of platinum nanoparticles relies on chemical reduction procedures.
In this procedure, the platinum salt (H2PtCl6), which dissolved in water, was chemically
induced to convert to platinum atoms by using a reducing agent such as Sodium
borohydride NaBH4 (Park et al. 2002). Then the platinum metal atoms were merged into
fit supported material to form the platinum nanoparticles. The platinum nanoparticles'
growth was confined by using a stabilizing agent such as polyvinylpyrrolidone (PVP)
(Park et al. 2002). Platinum salt (H2PtCl6) was used as the precursor. A mixture of 0.4M
of H2PtCl6 and 1% sodium citrate was heated to 300 0C under vigorous stirring (600
rpm) for 30 minutes. Then 0.08% of sodium borohydride was used as a reducing agent to
reduce the precursor into ionic form. We will coat the platinum nanoparticle with
Polymeric compounds such as polyvinylpyrrolidone (PVP), which was described as an
effective protective agent to stabilize nanoparticles (Park et al. 2002). The prepared
coated platinum nanoparticles solution was kept covered under the hood at room
temperature at 45 minutes at 600 rpm stirring conditions. After that, the prepared solution
was ready for characterization to determine the presence and size of the nanoparticle.
3.4 3 Characterization of the synthesized platinum nanoparticles
3.4.3.1 UV–Vis absorbance and dynamic light scattering (DLS) spectroscopies
Two ml aliquots of synthesized platinum particles were used to measure the UVVis spectra of the solution using a UV-Vis spectrophotometer at 200nm and 800nm
wavelengths. The color change was then used to track platinum particles. The UV-visible
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spectra were then recorded with a UV-2600 spectrophotometer from 200nm wavelength
at room temperature, with distilled water used as blank. The average particle sizes
together with the zeta potential of the prepared platinum nanoparticles were analyzed
using Malvern Zetasizer Nano SZ, ZEN3600, and Malvern, UK. Moreover, platinum
nanoparticle sizes were derived using the dynamic light scattering (DLS) measurement.
The platinum particles were then quantified using Microtrac Bluewave Model
(Varian710-ES-ICP-OES). The samples were then diluted and digested with Aquaregia.
For scanning transmission electron microscopy (STEM) analysis, the samples were
prepared by placing drops of produced platinum nanoparticles NPs on copper grids
coated with formvar-carbon- and permitting the solvent to vaporize at room temperature
partially. After that, the prepared grids were carefully dipped into deionized water on
three occasions and allowed to air dry. The observation was performed using JEOLJEM2100F STEM microscopy, Department of Engineering, USC, Columbia, SC, and the
operation was conducted at 200kV. The deionized water used in the process was treated
through ultraviolet radiation then warmed at 25°C temperature.
3.4 .4 Primary mouse embryonic fibroblasts MEF cell culture
Primary mouse embryonic fibroblasts (MEFs) were obtained from the Science
Cell Research Laboratories (Catalog #M7570, Carlsbad, CA). The primary MEFs were
cultured using the standard protocol (Hogan et al. 1994; Zhang et al. 2003). The cells
were preserved in liquid nitrogen. The cells thawed at room temperature. The enzymatic
activity was neutralized by adding MEF cells to media containing Dulbecco’s modified
eagle medium (DMEM), with 10% fetal bovine serum (FBS), 1% PenicillinStreptomycin, and 1% glutamine. The cells were cultured in Petri dishes until 75–80%
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confluent and then sub-cultured at a ratio of 1:3. In this study, MEFs were used at
different passages (P1–P7). MEF cells were grown in microplates (tissue culture grade,
96 wells, flat bottom) using a final volume of 100 µl culture DMEM medium per well
and cell seeding density was 500 cells/well, the plate incubated in a humidified
atmosphere (+37°C, 5 - 6.5% CO2). The cell cultures had incubation period of two days
until the cell confluent the bottom of the well.
The 10% fetal bovine serum (FBS) reach DMEM medium replaced with 100 µl
0.5% fetal bovine serum FBS starving medium and incubated in a saturated atmosphere
(+37°C, 5 - 6.5% CO2) in an incubator, for another two days. Platinum nanoparticles
with concentrations (1 µg, 25 µg, and 50 µg/ ml) were loaded in three different 96 wells
plates in 6 replicates and incubated for 24, 48, 72 hours. Another three different 96 wells
plates were seeded with MEF cells (500cells /well) and platinum nanoparticles with
concentrations (1 µg, 25 µg and 50 µg/ ml) were loaded in 6 replicates and incubated for
2, 4 and 6 days in a humidified atmosphere (+37°C, 5 - 6.5% CO2).
3.4.4.1 Cell viability and survival growth rate after exposure to platinum nanoparticles
MTT assays
Cell viability was measured by MTT assay [3-(4,5- dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide, Roche]. After the incubation period of exposed MEF cells
to platinum nanoparticles, 10 µl of the MTT labeling reagent with a final concentration of
0.5 mg/ml was added to each well. The plates were incubated for 4 hours in a humidified
atmosphere (e.g., +37°C, 5 - 6.5% CO2). Then 100 µl of the Solubilization solution was
added into each well. The plate incubated overnight in a humidified atmosphere (e.g.,
+37°C, 5 - 6.5% CO2). The optic density measured by evaluating the plate using a
microplates reader (Artel VMS #8612). The absorbance was set at 570 and 630 nm.
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3.4.4.2 Cellular proliferation assay BrdU
MEF cells were seeded with densities of 500 cells /well, using a sterile 96-well
tissue culture plate in 100 μL/well of DMEM media. Some wells on the plate should be
set aside for blank (do not receive cells- media alone) and wells contain cells without
BrdU reagent (assay background). The 96-well tissue culture plates were incubated for
two days. The reach DMEM medium replaced with a starving DMEM medium for
another two days. The platinum nanoparticles with concentrations (1, 25 and 50 μg/ ml)
loaded in wells in 5 replicates. The 96-well tissue culture plate will be incubated for 24
hours. Then 20 μL of the diluted 1X BrdU label was added to the appropriate wells and
incubated for 24 hours. Next, 200μL/well BrdU fixing solution was added after aspirating
the medium from each well and incubating at room temperature for 30 minutes. The
plates were washed three times with 1X Wash Buffer and blotted dry, then 200μL of
Detector Antibody reagent was added per well and incubated for one hour at room
temperature. Previous washing steps applied 100 µL of 1X Peroxidase Goat Anti-Mouse
IgG was added and incubated for 30 minutes at room temperature. Previous washing
steps were used plus a final wash with sterile ultrapure deionized water. Finally, 100 µL
of TMB Peroxidase substrate was added per well and then plates were incubated for 30
minutes at room temperature in the dark. Then, 100 µL of Stop Solution added to every
well and readings were taken using a plate reader set at a dual-wavelength of 450/550
nm.
3.4.4.3 Cellular membranes damages by lactate dehydrogenase (LDH) assay:
Lactate dehydrogenase (LDH) was measured using a kit (Thermo Scientific),
following the test protocols. MEF cells were seeded in tissue culture 96 wells flat bottom
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with density (500 cells/ well) in 100μL of DMEM medium six replicates wells. Each
plate was then incubated at 37°C, 5% CO2 overnight. 100μL of platinum nanoparticles
with concentrations (1 µg, 25 µg and 50 µg/ ml) was added to each six replicates well of
cells. The plate incubated at 37°C, 5% CO2 for 24 hours. 10μL of each negative (water)
and positive (lysis buffer-10X) controls were added in triplicates wells of cells and
incubated at 37°C, 5% CO2 for 45 minutes. A 50μL of each sample medium was shifted
to a new 96-well flat-bottom plate. A 50μL of Reaction Mixture was transferred to each
sample well and mix using a multichannel pipette. The plate with the contents was
incubated in the dark at room temperature for 30 minutes.
3.4.4..4 Determination of apoptosis in MEF cells by TUNEL cell death kit:
Apoptotic cells were spotted by staining using a cell death kit (Roche) using the
DNA binding fluorescent dye, Fluorescein Isothiocyanate (FITC). The MEF cells were
proliferated on glass coverslips (1 9 106 cm-2) for two days. The media was replaced
with a starving medium and incubated for another two days to synchronize the cell cycle.
The cells were treated with platinum nanoparticles with concentrations (1 μg, 25 μg, and
50 μg/ ml). The medium was removed, and the coverslips were washed with ice-cold
PBS and fixed in 4 % paraformaldehyde for one hour at room temperature. Repeat
washing using cold PBS, and the cells were stained using cell death kit reagents. The
cells were mounted in 50 % mounting media, and the nuclear staining was evaluated by
fluorescent microscopy, using BoliOptiocs (FM03020303) Fluorescent microscope.
Those cells with luminously stained abridged chromatin or nuclei were recognized as
apoptotic cells.
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3.5 Western blot -determination of activation of inflammatory factors (non-canonical
tgfb-1 signaling) and canonical tgfb1signaling proteins
Changes in the level of inflammation were determined through immunoblotting
using related proteins (ERK1/2, P-ERK1/2, P38, P-P38, JNK, P-JNK, AKT, P-AKT,
IKB-⍺, P-IKB-⍺) as well canonical TGFB-1 proteins (TGFB-1, smad2/3, p-smad2/3, aSMA, and Colla). Upon treatment with 0, 1, 25 or 50mg/ml of SE NPs, the MEFs were
washed and protein extracted with a RIPA Lysis Kit (American Biotechnology Thermo
Fisher Scientific). A stock of 100 mM PMSF in 100% ethanol was used to dissolve
PMSF (phenylmethylsulfonyl fluoride as protease inhibitor) in the lysis buffer. BCA
Protein Assay kit (Beyotime) was applied to determine the protein concentration of the
cytosolic extract. An equal amount of the protein was separated by SDS-PAGE and then
transferred onto nitrocellulose membranes (Amersham Biosciences, Pittsburgh, PA,
USA). The membranes were blocked with 5% non-fat milk at room temperature for one
hour and then washed five times with TBS containing 0.05% between 20 for 5 minutes
each time. Afterward, the membranes were probed at 4°C overnight with one of the
primary antibodies that included anti-(ERK1/2, P-ERK1/2, P38, P-P38, JNK, P-JNK,
AKT, P-AKT, IKB-⍺, P-IKB-⍺, TGFB-1, smad2/3, p-smad2/3, a-SMA, Col-1A and antiβ-actin. The membranes were then left to incubate with a complementary antibody at
room temperature for one hour. Chemiluminescence was used to visualize protein bands
with a Signal Fire ECL reagent (Cell Signaling). The Image J software from the National
Institute of Health (USA) was used to analyze band density.
3.6 Statistical analysis
MTT experiment was conducted among six wells by repeated combinations,
while six wells were used for proliferation assays. Moreover, the technical triplicates, as
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well as the biological triplicates, were used as the immunoblot band ratios. These optical
density data were then statistically analyzed and descriptive statistics were calculated
including mean and mean of standard error ± (MSE). These data were then subjected to a
two-way analysis of variance (ANOVA). The value of the differences between means
was calculated using the Turkey Kramer by Graphpad prism Insta-3for windows. The
standard version 7.5.1 was used and the value accepted at p values of <0.05 was the
minimal level used to determine significant differences between treatments and both
positive and negative controls.
3.7 RESULTS
3.7.1 Physicochemical properties of platinum nanoparticles
The hydrodynamic size of synthesized PVP coated platinum nanoparticles was
15nm, and polydispersity was 0.03, with the average core size being 12nm ± 3 while the
spectral absorbance was 220 nm by UV-vis. Nevertheless, the zeta potential was -12.4.
(See figure 3.1)
3.7.2 Cell viability and survival growth rate after exposure to platinum nanoparticles
MTT assays
Upon exposure to platinum nanoparticles, it was observed that all administered
doses (1, 25, and 50 ug/ml) didn’t induce any significant changes in cell viability
compared to control (non-treated cells) in all administered period of time between 24 144 hours (1 to 6 days). All p-values were > 0.05 and were not significantly different, as
shown in the figure 3.2.
3.7.3 Cellular proliferation assay BrdU:
The cellular proliferation rate was significantly reduced in a dose-dependent
manner in all administered doses compared to controls (non-treated cells). Proliferation
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rates were reduced by 51%, 42.3% and 32.7% for 1, 25 and 50 µg/ml respectively and
were significantly different, with p-values < 0.0001 as illustrated in figure 3.3-a.
3.7.4 Cellular membranes damages by lactate dehydrogenase (LDH) assay:
Neither the evidence of necrosis nor cellular damage produced by platinum
nanoparticles of all administered doses (1,25, and 50 µg/ml) was noted after exposure for
24 hours and six days compared to water treated cells (negative control),P-value >0.05
unlike in the lysis buffer treated cells (positive control). There were significant
differences between lysis buffer treated cells (positive control) and water treated cells
(negative control) and all administered platinum nanoparticles doses at –p-value<0.000
as illustrated in figure 3.4 (a-b).
3.7.5 Determination of apoptosis in MEF cells by TUNEL cell death kit:
Neither proof of DNA DAMAGE nor apoptosis produced by platinum
nanoparticles was observed for all platinum nanoparticles administered doses (1, 25, and
50 µg/ml) upon a 24-hour exposure (see figure 3.3-b).
3.7.6 Western blot -Determination of activation of inflammatory factors (non-canonical
TGFB-1 signaling) and canonical TGFB1Signaling proteins:
3.7.6.1 First: Inflammatory factors (non- canonical TGFB-1 signaling)
In all platinum nanoparticles administered doses (1, 25, and 50 ug/ml), there were
no significant change in the ratio between the phosphorylated and inactive AKT protein
in all doses when compared to control, with p values > 0.05 (see figure 3.5-a.). In all
platinum nanoparticles administered doses (1, 25 and 50 ug/ml), there were no significant
changes in the ratio between the phosphorylated and inactive P38 protein in all platinum
nanoparticles doses and controls, with p values of > 0.05 (see figure 3.5-d). In all
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platinum nanoparticles administered doses (1, 25 and50 ug/ml), there were no significant
changes in the ratio between the phosphorylated and inactive ERK1/2 protein in treated
cells compared to controls, with p values of > 0.05 (see figure 3.5-c). In all platinum
nanoparticles administered doses (1, 25 and 50 ug/ml), there were no significant changes
in the ratio of the phosphorylated and inactive JNK protein in comparisons between all
platinum nanoparticle treated cells and controls, with p values of > 0.05 (see figure 3.5b).
In all platinum nanoparticles administered doses (1, 25 and 50 ug/ml), there were
no significant changes in the ratio of the phosphorylated and inactive IKB-ALPHA
protein in comparisons between all platinum nanoparticle treated cells and controls, with
p values of > 0.05 (see figure 3.6-a). However, the rate of NFKB phosphorylation was
significantly different in the higher platinum nanoparticle doses (25 and 50 ug/L) than
controls (non-treated cells). Similarly, there were differences between different platinum
doses as the 1 µg/ml dose was signicantly different when compared to 25 and 50 µg/ml
platinum nanoparticles doses, with p values < 0.05. There were no significant differences
between the control and 1ug/ml (the p value was > 0.05), but the phosphorylation rate of
NFKB was thus significantly reduced in both the 25 and 50 ug/ml compared to the
control and 1 ug/ml (see figure 3.6-b)
3.7.6.2 Second: Activation of canonical TGFB1Signaling proteins:
The rate of TGFβ -1 expression in control and the dose of 1ug/ml was not
significant and the p-value >0.05, but It was clear that the rate of TGFβ -1 expression
significantly increased in the doses of 25 and 50 µg/ml, the p-value <0.05 (see figure 3.7a) The phosphorylation of smad2/3 not significant between control (non-treated cells) and
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1ug/ml and 25ug/ml of platinum nanoparticles and the p-value >0.05. The smad2/3
activation was only significantly high at dose 50ug/ml of platinum nanoparticles treated
cells compared to control, 1ug/ml and 25µg/ml, the p-value<0.05(see figure 3.7-b).There
was no significant difference between control (non-treated cells) and dose 1ug/ml, and pvalue >0.05. However There was a significant increase in a-smooth muscle actin (aSMA) expression in dose 25ug/ml and 50 µg/ml compared to control and 1ug/ml, the pvalue<(0.001-0.005)(see figure 3.7-c) Compared to control (non-treated cells), there was
a significant elevation in collagen A production in all administered doses and the p-value
<0.05 (see figure 3.7-d)
3.8 Discussion
3.8.1 Characterization of the synthesized platinum nanoparticles (physicochemical
properties)
The results of this study have indicated that the small hydrodynamic (15nm) and
core size of produced PVP coated platinum nanoparticles averaged 11.7nm. Smaller
nanoparticles can more easily penetrate the cells and hence reach the target organ to
attain the desired function (Porcel et al, 2010). Nanoparticles size also can depend on
cellular uptake and cell permeability (Bratlie, et al, 2007). Often, these smaller-sized
particles are associated with increased potency or toxicity (Hartmann et al, 1999).
Research has also shown that nanoparticle cellular uptake may depend on the
nanoparticle shape (Bratlie et al, 2007). STEM analysis indicated that the produced
platinum nanoparticles have spherical shape. Some studies have reported that spherical
shaped nanoparticles record the highest uptake in terms of the weight, while the rod-like
nanoparticles often have the highest uptake in terms of the quantity (Stutz et al, 2011).
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The platinum spherical nanoparticles increase the cellular uptake for the heavier
molecules that are transferred across the membranes (Hartmann et al, 1999).
In this study, a Polyvinylpyrrolidone (PVP) coating polymer was used to cover the
platinum nanoparticles. The coating of nanoparticles is necessary to enhance
stabilization, modification as well as functionalization of the nanoparticles (Stutz et al,
2011). Each coating is conducted to achieve a particular physico-chemcial property. PVP
is a commonly used water-soluble polymer and is widely used as it is well known for
being antigenic, as well as biocompatible for most pharmaceutical formulations (Kondo
et al, 1991). The respective coating material can regulate the dissolution of nanoparticle
in the biological medium (Stutz et al, 2011). The coating is, therefore, a regulation for
distribution as well as interaction for the biological compounds (Stutz et al,
2011).Although the zeta potential of synthetized platinum nanoparticles was -12Mv, the
platinum nanoparticles were as a result stable and that might be due in part to the steric
stability obtain from PVP coating. Steric stability refers to the mechanism that elucidates
the ability of certain additives to prevent the coagulation of suspensions (March &
Napper, 1997). Nanoparticle zeta potential is essential in determining the stability of the
nanoparticle. The nanoparticles with values > +25 mV or < -25 mV are considered to be
highly stable (Cogston & Patri, 2011). The platinum nanoparticle synthesized in this
study had zeta values that fell within these zeta ranges for acceptable stability.
3.8.2 Cell viability and survival growth rate after exposure to platinum nanoparticles
MTT assays:
The platinum nanoparticles used in this study did not result in loss of viability
based on the synthetized shape and size for cellular uptake. It is worth noting that this
might in part be due to metabolic activities of the cells that may lead to use of the

94

platinum nanoparticle as source supplement for their essential cellular functions and rapid
clearance of the nanoparticles inside the cells, which reduces the chances of cytotoxicity,
and enhancing cell viability (Rice-Evans et al, 1997, Sadowska-Bartosz, 2014).
3.8.3 Cellular proliferation assay BrdU
Drastic reduction in the cells proliferation rates to 50 % and less were observed in
a dose dependent manner which may have resulted from the ability of platinum
nanoparticles to inhibit cellular growth and division. Platinum nanoparticles can trigger
cytotoxic effects within the highly dividing cells such as cancer cells and fibrotic
associated fibroblasts. This inhibition of cell growth may be due in part to the arrest of
the cell cycle as a result of the interaction with the SMAD pathway (Mishra et al, 2018).
3.8.4 Cellular membranes damages by lactate dehydrogenase (LDH) assay:
Platinum nanoparticles did not induce cellular membrane damages suggesting that their
cytotoxic effects are minimal compared to other platinum compounds such as
chemotherapeutic drug cisplatin. Cisplatin can result in cell necrosis due to aborted
apoptosis linked to effecs on caspase 3. (Zhang et al, 2007). This lack of effect may also
be attributed to the unique physicochemical properties of the platinum nanoparticles such
as their shape, and size. These results clearly indicate that platinum nanoparticles
designed similar those used in this study can be potentially used to target fibrosis
associated fibroblast and cancer cells.
3.8.5 Determination of apoptosis in MEF Cells by TUNEL cell death kit
Results from the TUNEL Assay indicated that the platinum nanoparticle did not
induce DNA damage as a marker of apoptosis. Research has shown that some
nanoparticles have the capability to reduce oxidant mediated apoptosis (Sanpui et al.,
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2011). This can also be due to the ability of some nanoparticles to deactivate the
caspases, which are responsible for the initiation of apoptosis (Sanpui et al., 2011).
3.8.6 Western blot -Determination of activation of inflammatory factors (non-canonical
TGFB-1 signalling) and canonical TGFB1Signaling proteins
3.8.6.1 First: Inflammatory factors (non- canonical TGFB-1 signaling)
Platinum nanoparticles did not induce any of the inflammatory factors such as
(AKT, P38, JNK, ERK1/2, IKB-α, NFKB) that can trigger non canonical TGFB pathway.
Some of the primary factors initiating these inflammatory factors are oxidative stress and
reactive oxygen species (ROS). TGF-β signaling pathways can be activated by ROS,
which signal either through SMAD dependent or independent pathways (Neel et al.,
2012). Elevated NOX4-generated ROS levels may also be produced from increased TGFβ signaling, further stimulating pro-fibrotic genes transcriptional activities like NOX4,
Collagen I, and alpha-smooth muscle actin. NOX4-generated ROS can also lead to
activation of signaling pathways like NFκB and JNK and trigger the oxidation of DNA,
which leads to differentiation of myofibroblast as well as collagen deposition
accumulation into the extracellular matrix which may lead to fibrosis (Petrov et al.,
2001). In this study, the platinum nanoparticles exhibited catalytic activity that increased
its scavenging ability, which would help reduce the level of reactive oxygen species
(ROS) thus impairing the downstream pathways that may lead to inflammation. Thus
platinum nanoparticles offer a promising therapeutic option for some cancers and in
fibrosis. Platinum nanoparticles have enhanced antioxidant capacities that may exceed
the abilities of natural enzymes and can easily adjust to changes in the environment.
Research has also evaluated oxidative related stress disorders that may be linked to the
free radical scavenging material by nanoparticle activites at a cellular level (Seddon et al,
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2007). Platinum nanoparticles were found to also facilitate the recovery of oxidative
stress-mediated disease effects (Moglianetti et al, 2016).
3.8.6.2 Second Activation of canonical TGFB1Signaling proteins:
This study indicated that the higher doses (25 and 50 µg/ml) of platinum
nanoparticles targeted canonical TGFB-1 signaling pathway and initiated the downstream
cascade by phosphorylating smad2/3 and allowing translocation inside the nucleus to
produce endogenous α-SMA and collagen A. Because TGFB1 is considered one of
double sided agents in cancer growth and progression based in cancer stages, we might
use the platinum nanoparticles capability to induce TGFB1 signaling as a therapeutic
agent especially at early stages of cancer. In early stages of cancer, the TGFβ1 inhibits
cell cycle in the G1 phase exerts powerful cytostatic effects on target tissues. It increases
P21, P27, and P15 cyclin-dependent kinase inhibitors expression, inducing G1 phase cell
cycle arrest. While these effects are SMAD dependent, they also need FoxO and SP1
transcription factors to be effective. CDK4/6 is directly inhibited by p15, P27, and p21
and displaced from CDK4/6 complexes. This allows them to bind, leading to inhibition of
CDK2-cyclin A/E complexes (Mishra et al, 2018). TGFβ also causes apoptosis and
inhibits the immortalization of cells in various target tissues (Ruiz-Ortega, 2007). E2F1pRb-P/CAF pathway is the central pathway in the mediation of TGFβ pro-apoptotic
effects. This pathway results in TGFβ proapoptotic-target genes transcription in
numerous cancer and normal cell types.
In later stages of cancer, TGF-β signaling activation can serve as a cancer cell
growth and metastasis agent. TGF-β signaling has been linked as key cancer driver,
promoting tumor formation. Moreover, increases in TGF-β signaling enhance the
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expression of malignancy. Studies have found that TGF-β down regulation enhances the
phosphorylation of SAPKs as well as production of ROS, adding to the inactivation of
Akt & NOX4 (Porcel et al, 2010). The application of platinum nanoparticle therefore can
either trigger tumor formation or prevent its formation depending on the stage of cancer.
This study demonstrates that application of platinum nanoparticle at an early stage may
prevent tumor formation.
This study also found significant expression of smad 2/3 (at the 50ug/ml dose),
alpha smooth muscle actin (at both the 25 and 50ug/m doses) and collagen A (at the 1, 25
and 50ug/ml doses) after exposure to platinum nanoparticles. In normal tissues, the alpha
smooth muscles actin is often found in the stroma cells, muscle fibers and blood vessels.
Fibroblast, in pathological conditions such cardiac fibrosis and tumor tissues, also
express alpha smooth muscle actin. Alpha smooth muscle actin may play a role in
fibrosis, cancer growth, metastasis and aggressiveness (Taniguchi et al, 2001). This may
result in platinum not being an acceptable and effective treatment for cancer, especially at
the later stages. Alpha smooth muscle actin is present in both the myofibroblasts as well
as epithelial to mesenchymal transition cells. EMT is indicative ofprogressive metastasis.
Increased alpha smooth muscle actin expression resulted in neoplasm development in
ovarian tissues (Anggorowati et al, 2017). In cancer therapy, platinum nanoparticles may
enhance the formation of α-SMA which may lead to tumor progression and lead to
fibrosis in fibrotic diseases.
Recent studies have linked SMAD-3 role in promoting apoptosis while inhibiting
cell proliferation. Nevertheless, SMAD-3 has been shown to induce TGF- β immune
suppression as well as regulating transcriptional responses (Millet & Zhang, 2007). This
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further indicates that platinum nanoparticles may be used to target smad3 protein for
early stage cancer therapy. Studies indicate that ROS can activate TGF-β pathways that
trigger activation of SMAD-3 pathway, leading to the activation of tumor progression by
signaling JNK and ROS pathways. In the extracellular matrix, collagen has been shown
to be a key structural protein that has been linked to fibrotic disease and cancer
development as well as metastasis. For example, collagen type I alpha has been expressed
in breast cancer cells and has been linked to play critical role in tumor progression (Liu et
al, 2018). Analysis of differing therapeutic effects among different platinum nanoparticle
doses used in this study, indicated that there was fine line between effectively using
platinum nanoparticles in treating early stage cancers versus late stage cancers where it
can worsen the manifestations of fibrotic diseases.
3.9 Conclusion
Most cancer treatments are hard to facilitate due to the challenges in detection.
Early detection of cancer cells is vital for the treatment and management processes.
Nanoparticles have been applied in many different cancer treatments successfully. There
has been unclear awareness of the cytotoxicity linked to certain platinum nanoparticle
application in cancer treatment. The findings of this study pave the way for the use of
platinum nanoparticles application in early stage cancer treatment. Platinum may serve a
big role in targeting the TGFB-1 signaling pathway in cancer therapy during early stages.
However, it use may be dangerous to patients during late stages or patient with fibrotic
diseases such as liver and cardiac fibrosis. In this study, platinum NPs did not induce any
toxicity in cell viability or lead to necrosis in fibroblasts but significantly reduced
proliferation to 50% or lower after 24 hours of exposure. Platinum NPs caused
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differentiation of mouse fibroblast to myofibroblast by induction of TGFB-1 canonical
pathway and production of endogenous collagen and a-smooth muscle actin (a-SMA).
Although the study revealed no cytotoxicity effects on the normal cells, a high level of
caution is therefore necessary for the application of platinum nanoparticles in cancer
therapy and in fibrotic diseases.
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Figure 3.1 Physicochemical properties of the Platinum Nanoparticles: (a) TEM core
size & distribution analysis & (b) TEM image of monodispersed spherical in shape
PVP coated platinum nanoparticles with average core size 12 nm synthesized in
ultrapure cell culture water. (c) overall average hydrodynamic size of platinum
nanoparticles equals to 15 nm determined, by DLS, zeta potential by Zetasizer &
spectral absorbance 260 nm by UV-vis measurement
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Figure 3.2. Cell viability of MEF cells after exposure to Platinum NPs: the doses
were 1µg/ml, 25 µg/ml, & 50 µg/ml, of platinum Nanoparticles between 24-hours to
6 days exposure. There were no significant changes in cell viability at all
administered doses of platinum nanoparticles compared to non- treated cells
(control) Notes: Data were presented as normalized mean ± MSE. P-value >0.05
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Figure 3.3 Effects of platinum NPs on cell proliferation & DNA damage: (a)
Graphical representation of the relative BrdU incorporation in MEFs after 24-hours
exposure to 1, 25 & 50 µg/ml, of platinum nanoparticles, compared to non-treated
cells (controls). There were significant reductions in proliferation rates in all
platinum nanoparticles administered doses versus controls with a clear dose-response
effect noted; (b) DNA damage and apoptosis was not detected by the TUNEL assay.
Data are presented as mean ± Mean Standard Error (MSE). Asterisks (***) indicated
highly significant different between platinum nanoparticle treatments and controls
with P values of <0.0001
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Figure 3.4. Necrotic effects of platinum NPs on MEF Cells: (a-b) Results of
membrane integrity assessment which indicated a significant necrotic effects on
MEF cells after 24 and 144 hours (6 days) following exposure to 1, 25 & 50 µg/ml
of platinum nanoparticles compared to negative control (only treated with water as
spontaneous LDH control) and positive (lysis buffer) LDH control. There were no
significant differences between the negative control and all administered doses of
platinum nanoparticle in both 24 and 144 hours (6 days) time periods, indicating that
platinum nanoparticles didn’t induce cellular damage or necrosis. These data
presented indicate significant differences between all administered doses of platinum
and the lysis buffer (positive control). Data are presented as mean ± Mean Standard
Error (MSE) for each treatment. Asterisks (***) indicated highly significant
differences between controls and treatments with P value <0.0001. Treatments that
were Not Significantly different (NS) had p values of > 0.05, as all platinum
nanoparticle treatments and the negative control were not significantly different.
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Figure 3.5 Immunoblotting of non-canonical factors after Pt NPs treatments (part1):
Normalized Level of non-canonical proteins expression in WB analysis after
exposure to platinum nanoparticles: the doses (0, 1,25 & 50 µg/ml) of platinum
nanoparticle, β-Actin was measured as the loading control and used for data
normalization.(a-d). There were no significant differences in the phosphorylation
ratio between non-treated cells (control) and all doses of platinum nanoparticles
treated cells for (AKT, JNK, ERK1/2, and P38 proteins) p values >0.05, indicating
non-induction of inflammation within the MEF cells.
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Figure 3.6 Immunoblotting of non-canonical factors after Pt NPs treatments (part2):
Normalized Level of continuous non-canonical proteins expression in WB analysis
after exposure to platinum nanoparticles: The doses (1, 25 and 50 µg/ml) of
platinum nanoparticles, β-Actin was also measured as the loading control and used
for data normalization: (a) there were no significant differences in the
phosphorylation ratio of IKBα between non-treated cells (control) and all doses of
platinum nanoparticles treated cells, with p values of >0.05; (b) there were
significant reductions in phosphorylation ratio of NFKB at 25and 50 µg/ml doses of
platinum nanoparticles treated cells compared to the controls and 1 µg/ml dose
platinum nanoparticle dose, with p values of <0.05, indicating non-induction of
inflammation at the lower dose. Asterisks (*) were significantly different at p values
of < 0.05. Not Significant (NS) differences were observed between controls and the
1 µg/L platinum nanoparticle dose
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Figure 3.7 Immunoblotting of canonical factors after Pt NPs treatments :
Normalized levels of canonical pathway proteins after exposure to platinum NPs:
The doses (1, 25 and 50 µg/ml) of platinum nanoparticles. β-Actin was also
measured as the loading control and used for data normalization: (a) there were
significant increase in the expression of TGFB at the 25 and 50 µg/ml doses of
platinum nanoparticles treated cells compared to controls and 1 µg/ml dose. This is
indicative of canonical activation of TGFB signal. (b) There were significant
increases in the expression of smad2/3 at the 50 µg/ml dose of platinum
nanoparticles treated cells compared to controls and the 1 and 25 g/ml doses,
indicating canonical activation of the TGFB signal. (c) There were significant
increases in the expression of α-SMA at the 25 µg/ml and 50 µg/ml doses of
platinum nanoparticles treated cells compared to controls and the1 µg/ml dose,
indicating canonical activation of the TGFB signal. (d) There were significant
increases in collagen-1A at all doses (1, 25 and 50 µg/ml) of platinum nanoparticles
treated cells compared to controls. Asterisks (* and **) had a p values of < 0.05, and
< 0.01, respectively.
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CHAPTER 4
CERIUM OXIDE NANOPARTICLES DOWN REGULATE TGFB-1
SIGNALING PATHWAY IN MOUSE EMBRYONIC FIBROBLASTS A
PROMISING THERAPEUTIC AGENT IN CARDIAC FIBROTIC
DISEASES
4.1 Chapter 4 overview
Cerium oxide Nanoparticles (Nanoceria) are considered a promising therapeutic
agent in cardiac fibrosis and cellular damages to cardiac cells where under certain
pathological conditions, as the fibroblast differentiate to myofibroblast under initiation of
inflammation and TGFB-1 signaling pathways. Our finding indicated that cerium oxide
nanoparticles (Nanoceria) are potentially capable of inhibiting TGFB-1 signaling through
inhibition of smad2/3 and downstream factors expression and inflammation progression
in mouse embryonic fibroblast without induction of adverse effect in in vitro study.
4.2 Introduction
In the field of medicine, cardiac fibrosis is described as the deposition of excess
extracellular matrix within cardiac muscles (Travers, et al., 2016). Other than such a
definition, cardiac fibrosis can further refer to the thickening of valves of the heart
abnormally (Travers et al., 2016). Such pathological effects can occur due to the
accumulation of cardiac fibroblasts and myofibroblasts. Treatment of cardiac fibrosis
may entail prevention of the manufacture of serotonin, the utilization of stimulatory drugs
or even surgery to replace tricuspid valves (Travers et al., 2016). TGFβ has indicated to
cause cardiac hypertrophy, cardiomyocyte apoptosis, as well as cardiac fibrosis (Aihara
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et al., 2011). In TGFβ signaling, TGFβ binds to the TGFβRII receptor, recruiting
TGFβRI receptors. TGFβ canonical signaling pathway involves SMADs activation,
which then translocate into the nucleus where extracellular matrix production and
formation of myofibroblast occurs through transcriptional reprogramming, which
eventually leads to cardiac fibrosis (Pardali, 2012). In myocardial infarction, levels of
TGFβ are elevated, causing further myocardial injury, which may lead to heart failure
(Frangogiannis, 2017).
Through TGFB signaling pathways there are overproduction and release of
extracellular matrix rich in proteins. Overproduction of fibroblasts and differentiation of
myofibroblasts fuel the release of collagen to the tissues by increasing the rate of its
synthesis (Hsiao et al., 2015). The utilization of nanomaterials is essential for purposes of
treating fibrosis as such aspects make it possible to deliver molecules incorporating
specific biological components at a sustained as well as controlled rate to particular
tissues in a specific way (Mohanraj, 2006). Cerium oxide nanoparticles have been of
interest in some medical therapies, due to certain properties that they exhibit, including
their ability to reduce the rate at which oxidative stress occurs in a cell by inhibiting both
the release of reactive oxygen (ROS) and the inflammation cascade (Serebrovska, 2017).
This feature allows the cerium oxide nanoparticles to prevent cell apoptosis and also
increases their growth and viability. Consequently, cerium oxide (CeO2) NPs are also
able to alter the TGFB signaling pathway which is essential in cutting down the
production of collagen and myofibroblasts that cause cardiac fibroblasts. There were no
confirmed studies about application of cerium oxide nanoparticles might be helpful for
purposes of treating fibrotic diseases. (Mohanraj, 2006; Serebrovska, 2017)
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TGF-B Signaling pathway can be induced by inflammation. The design of this
study focused on the study of the ability of cerium oxide nanoparticles and their crucial
roles in targeting the canonical and non-canonical TGF-B Signaling pathways, as it is
critical to inhibit its actions (Mohanraj, 2006). Consequently, inhibiting the actions of the
TGF-B signaling pathways by cerium oxide nanoparticles thus might help in protecting
against cardiac injuries induced through inflammation and fibrosis. Moreover, by
inhibiting the signaling pathway, cerium oxide helps reduce the progress of cardiac
fibrosis as TGF-B serves as an activating component of this medical condition.
4.3 Materials and methods
4.3.1 Chemicals
The chemicals required for the experiment are Cerium nitrate hexahydrate, with
purities exceeding 99% was used as the precursor material (Ce(NO3)36H2O, Sigma
Aldrich),polyvinylpyrrolidone (PVP) (average molecular weight 40k), Cell proliferation
kit I (MTT) (purchased from Sigma Aldrich St. Louis, MO, USA), the BrdU cell
proliferation Assay kit from Millipore, Pierce™ LDH cytotoxicity assay kit (obtained
from Thermos Fisher, Waltham, MA, USA), In Situ Cell Death-TMRred detection kit (
purchased

from Sigma-Aldrich, St. Louis, MO, USA). ). Antibodies against AKT,

pAKT, ERK1/2, pERK1/2 ,P38, pP38, JNK, pJNK, IKBα, pIKBα, NFKB, pNFKB,
TGFB1, SMAD2/3, SMAD2/3, COL1-A, and α-SMA were all purchased from American
Biotechnology (Thermo Fisher Scientific, Santa Cruz Biotechnology (Santa Cruz, CA,
USA) and β-actin and Signal Fire ECL Western blotting systems were purchased from
Cell Signaling Technology (Beverly, MA, USA).
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4.3.2 Chemical synthesis of Cerium nanoparticles
The PVP-coated cerium oxide nanoparticles NPs were synthesized as described
previously (Merrifield et al., 2013). The Hydrothermal synthesis was carried out in closed
vessels and at constant water volume. Cerium nitrate hexahydrate, with purities
exceeding 99% was used as the precursor material (Ce(NO3)36H2O, Sigma Aldrich).
Polyvinylpyrrolidone (PVP) was used as the capping agent (MW = 29,000 g/mol, Sigma
Aldrich). Deionized water was used as the solvent. The PVP (0.05 g/mL) was dissolved
in 100 mL of deionized water to prepare the polymer solution before adding 0.2 mmol of
the cerium nitrate. Then the solution constantly stirred for two hours with the help of a
magnetic stirrer until the solution turned homogeneous. Later, the combined solution was
transferred to a close vesseland subjected to a temperature of 300 C for 3 hours. After
that, the synthesized nanoceria kept to cool under the hood overnight. The synthesized
Nanoceria was transferred to test tubes and washed with acetone (ratio1:1) under
2000rpm centrifugation for 30 minutes. The precipitate of Nanoceria was collected and
washed four times using 10 ml of ultrapure deionized water. The washed synthesized
Nanoceria filtered using syringe Nano-filter (0.1 µm) and stored at 4oC.
4.3.3 Characterization of the synthesized cerium oxide nanoparticles
4.3.3.1UV–Vis absorbance and dynamic light scattering (DLS) spectroscopies
The formation of cerium oxide nanoparticles was observed visually by color
change as synthesis progressed. UV–visible spectra were recorded with UV-2600
spectrophotometer from 200 to 800 nm wavelength at room temperature. Distilled water
was used as a blank. The average particle size (hydrodynamic diameter, Z-average) and
zeta potential of the prepared cerium oxide NPs were analyzed using Malvern Zetasizer
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(Zetasizer Nano ZS, ZEN3600 and Malvern, UK). At the same time, particle sizes of
cerium oxide NPs were derived using the DLS measurement. Concentration of cerium
oxide NPs was measured through ultrafiltration method using Microtrac Bluewave model
(Varian710-ES-ICPOES). Samples were diluted and digested with Aquaregia. Values
were interpolated in a standard cerium element calibration curve.
4.3.3.2 Scanning Transmission electron microscope analysis:
For scanning transmission electron microscopy (STEM) analysis, the samples
were prepared by placing drops of produced cerium oxide nanoparticles NPs on copper
grids coated with formvar-carbon- and permitting the solvent to vaporize at room
temperature partially. After that, the prepared grids were carefully dipped into deionized
water on three occasions and allowed to air dry. The observation was performed using
JEOL-JEM2100F STEM microscopy, Department of Engineering, USC, SC, and the
operation was conducted at 200kV. The deionized water used in the process was treated
through ultraviolet radiation then warmed at 25°C temperature.
4.3.4 Primary mouse embryonic fibroblasts MEF cell culture and seeding with cerium
oxide nanoparticles in96 wells plate:
Primary mouse embryonic fibroblasts (MEFs) - Catalog #M7570 was obtained
from the Science cell Research Laboratories, Carlsbad, CA. The primary MEFs were
cultured using the standard protocol (Hogan et al. 1994; Zhang et al. 2003). The cells
were preserved in liquid nitrogen. The cells thawed at room temperature. The enzymatic
activity was neutralized by adding MEF cells to media containing Dulbecco’s modified
eagle medium (DMEM), with 10% fetal bovine serum (FBS), 1% PenicillinStreptomycin, and 1% glutamine. The cells were cultured in Petri dishes until 75–80%
confluent and then sub-cultured at a ratio of 1:3. In this study, MEFs were used at
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different passages (P1–P7). MEF cells were grown in microplates (tissue culture grade,
96 wells, flat bottom) using a final volume of 100 μl culture DMEM medium per well
and cell seeding density were250 and 500 cells/well, the plate incubated in a humidified
atmosphere (+37°C, 5 - 6.5% CO2).
The cell cultures had incubation period of two days until the cell confluent the
bottom of the well. The 10% fetal bovine serum (FBS) reach DMEM medium replaced
with 100 μl 0.5% fetal bovine serum FBS starving medium and incubated in a saturated
atmosphere (+37°C, 5 - 6.5% CO2) for another two days. Cerium oxide nanoparticles
with concentrations (1 μg, 25 μg, and 50 μg/ ml) were loaded in with the cells in
different 96 wells plates in 6 replicates and incubated for 24, 48, 72, hours,4 and 6 days.
Another three different 96 wells plates were seeded with MEF cells (500cells /well) and
cerium oxide nanoparticles with concentrations (1 μg, 25 μg and 50 μg/ ml) were loaded
in 6 replicates and incubated for 24 hours and 6 days in a humidified atmosphere (+37°C,
5 - 6.5% CO2).
4.3.5 Assessing acute toxicity of cerium oxide NPs in MEFs
4.3.5.1 Assessment of cell viability by MTT assay
MEFs were seeded at 500 cells per well in flat bottom, 96-well microplates (tissue
culture grade) in a final volume of 100 μl DMEM containing 10% FBS and antibiotics.
The plate was incubated in a humidified atmosphere (37°C, 5.0 - 6.5% CO2) for 24
hours. The old medium was replaced with fresh 100 μl DMEM containing 0.5% FBS
(starving medium). After 24 hours, incubation was continued in DMEM containing 10%
FBS for another 24 hours. Cerium oxide NPs were added to the wells at concentrations
of 0, 1, 25, or 50 μg/ml and incubation was continued for 1, 2, 3, 4, and 6 days. Analyses
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were carried out in 3 biological replicates each with 6 technical replicate wells. Cell
viability was measured by the MTT assay [3-(4, 5-dimethylthiazol-2-yl)-2, 5
diphenyltetrazolium bromide, Roche]. After the appropriate exposure to cerium oxide
NPs, 10 μl of the MTT labeling reagent with a final concentration of 0.5 mg/ml was
added to each well. The plates were incubated for 4 hours in a humidified atmosphere
(37°C, 5.0 - 6.5% CO2) followed by addition of 100 μl of the solubilization solution into
each well. The plate was incubated overnight in a humidified atmosphere (37°C, 5.0 6.5% CO2). The optical density was measured using a microplate reader (Spectra Max
M3). The absorbance was measured at 550 and 690 nm.
4.3.5.2Assessment of cellular proliferation by bromodeoxyuridine (BrdU) incorporation
MEFs were seeded at densities of 250 cells/well in sterile 96-well tissue culture
plates in 100 μl/well of DMEM containing 10% FBS. The 96-well tissue culture plate
was incubated for 2 days. The DMEM containing 10% FBS was replaced with DMEM
containing 0.5% FBS and incubation was continued for another 2 days. Cerium oxide
NPs were added at final concentrations of 0, 1, 25, or 50 μg/ml and incubation was
continued for 24 hours. A 20 μl of the diluted BrdU labeling reagent was added to
appropriate wells and incubation was continued for 24 hours. Some control wells did not
receive BrdU labeling reagent. Then, 200 μl/well BrdU fixing solution was added after
aspirating the medium from each well and incubation was continued at room temperature
for 30 minutes.
The plate was washed three times with 1x Wash Buffer and blotted dry. Then, 200
μl of BrdU antibody reagent was then added to each well and incubation was continued
for 1 hour at room temperature. The wells were washed again with 1x Wash Buffer.
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Then, 100 μl of 1x peroxidase goat anti-mouse IgG was added, and incubation was
continued for 30 minutes at room temperature. The previous washing step was repeated,
followed by a final wash using sterile ultrapure deionized water. Then, 100 μl of TMB
peroxidase substrate was added per well and incubated for 30 minutes at room
temperature in the dark. After that, 100 μl of Stop Solution was added to each well. The
plate was read using a plate reader (Spectra Max M3) set at a dual wavelength of 450/550
nm.
4.3.5.3Assessment of cell membrane damage by lactate dehydrogenase (LDH) assay
MEFs were grown in 96-well microplates in a final volume of 100 μl of DMEM
medium containing 10% FBS per well as indicated above. Following 24 hours of
incubation, the old medium was replaced with fresh 100 μl of DMEM containing 0.5%
FBS and incubation was continued for another 24 hours. After 24 hours, incubation was
continued in DMEM containing 10% FBS and cerium oxide NPs (0, 1, 25, and 50 μg/ml)
for 24 and 144 hours (6 days). LDH concentration was estimated using Pierce LDH
Cytotoxicity Assay kit (Thermo Scientific) by following the manufacturer’s protocol. The
kit controls included sterile water as spontaneous LDH activity control and positive
control as 10x lysis buffer, which referred to as maximum LDH activity control.
4.3.5.4 Determination of apoptosis by TMRred cell death kit (TUNEL Assay)
Apoptotic cells were detected by a TUNEL assay (Cell Death-TMRred kit,
Roche) with the DNA binding fluorescent dye according to the manufacturer’s protocol.
Briefly, the MEFs were grown on Nunc™ Thermanox coverslips (5000 cell/mm2) for 2
days in DMEM containing 10% FBS. Nunc™ Thermanox coverslips are cell culturetreated on one side to ensure optimum cell attachment. The coverslips are also resistant to
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most solvents including acetic acid, acetone, and xylene. In this experiment, the medium
was changed to DMEM containing 0.5% FBS and incubation continued for another 2
days to synchronize the cell cycle. The cells were treated with cerium oxide NPs (0, 1,
25, and 50 μg/ml).
The medium was removed, and the coverslips were washed with ice-cold
phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde for 1 hour at room
temperature. The washing was repeated with cold PBS. The TUNEL reaction mixture
was added to the cells at 37oC for 1 hour. The cell nuclei were stained with DAPI (1
μg/ml) for 15 minutes. Then, the cells were mounted in 50% antifade mounting media,
which was a glycerol-based liquid mounting. Finally, the stained cells were evaluated and
photographed by confocal microscopy (LSM 510 META). Apoptotic cells (red stained
nuclei) were determined relative to the total number of cells (blue nuclei).
4.3.6 Western blot -Determination of activation of inflammatory factors (non-canonical
TGFB-1 signaling) and canonical TGFB1Signaling proteins:
Changes in the level of inflammation were determined through Immunoblotting
using related proteins (ERK1/2, P-ERK1/2, P38, P-P38, JNK, P-JNK, AKT, P-AKT,
IKB-⍺, P-IKB-⍺) as well canonical TGFB-1 proteins (TGFB-1, smad2/3, p-smad2/3, aSMA, and Colla). Upon treatment with 0, 1, 25 or 50 µg/ml of CeO2 NPs, the MEFs
were washed and protein extracted with a RIPA Lysis Kit (American Biotechnology
Thermo Fisher Scientific). A stock of 100 mM PMSF in 100% ethanol was used to
dissolve PMSF (phenylmethylsulfonyl fluoride as protease inhibitor) in the lysis buffer.
BCA Protein Assay kit (Beyotime) was used to determine the protein concentration of the
cytosolic extract. An equal amount of the protein was separated by SDS-PAGE and then
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transferred onto nitrocellulose membranes (Amersham Biosciences, Pittsburgh, PA,
USA).
The membranes were blocked with 5% non-fat milk at room temperature for one
hour and then washed five times with TBS containing 0.05% between 20 for 5 minutes
each time. Afterward, the membranes were probed at 4°C overnight with one of the
primary antibodies that included ERK1/2, P-ERK1/2, P38, P-P38, JNK, P-JNK, AKT, PAKT, IKB-⍺, P-IKB-⍺) TGFB-1, smad2/3, p-smad2/3, a-SMA, Col-1A and anti-β-actin.
The membranes were then left to incubate with a complementary antibody at room
temperature for one hour. Chemiluminescence was used to visualize protein bands with a
Signal Fire ECL reagent (Cell Signaling). The Image J software from the National
Institute of Health (USA) was used to analyze band density.
4.3.7 Statistical analysis
The MTT experiment was performed in six wells with the repetition of treatment
combinations to (replicates, n = 6), the (LDH) assay in six wells as replicates (n = 6), and
the proliferation assay in five wells as replicates (n = 6). The Western blot band ratio was
performed in technical triplicates and biological triplicates. Data were reported as the
mean of optical density and Mean standard error ± (MSE). The data were subjected to a
two-way analysis of variance (ANOVA), and the significance of the differences between
means was calculated using the Tukey Kramer using Graphpad prism Insta-3 for
Windows, standard version 7.5.1, and the significance was accepted at p < 0.05.
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4.4 Results
4.4.1 Physicochemical properties of cerium oxide nanoparticles
The hydrodynamic size of synthesized PVP coated cerium oxide nanoparticles
was 14 nm, and polydispersity was 0.3, with the average core size being 11.8 nm -+ 3.6
while the spectral absorbance was 279 nm by UV-vis. Nevertheless, the zeta potential
was -0.54. (See figure 4.1-a-c)
4.4.2 Effect of cerium oxide NPs on cell viability (MTT assays)
Upon exposure to cerium oxide nanoparticles between 24 hours and till 6 days, it
was observed that all administered doses didn’t induce any significant changes in cell
viability compared to control (non-treated cells). The p-value is > 0.05, as shown in the
figure 4.2
4.4.3 Analysis of Cellular proliferation (BrdU assay):
After 24 hours exposure, the cellular proliferation rate didn’t induce any
significant changes in all administered doses of cerium oxide nanoparticles compared to
control (non-treated cells). The p-value > 0.05 as illustrated in figure 4.3-a
4.4.4 Analysis of cell membrane damage by LDH assay:
Neither the evidence of necrosis nor cellular damage produced by cerium oxide
nanoparticles of all administered doses (1,25, and 50 µg/ml) was noted after exposure for
24 hours and six days, unlike in the lysis buffer treated cells (positive control). There
were significant differences between all administered doses at –p-value<0.0001 for
cerium oxide nanoparticles and lysis buffer (positive control) -p-value <0.05, as
illustrated in figure 4.4.
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4.4.5 Determination of apoptosis in MEFs by TUNEL assay
Neither proof of DNA damage nor apoptosis produced by cerium oxide
nanoparticles was observed for all administered doses of cerium oxide nanoparticles (1,
25, and 50 ugs/ml) upon a 24 hour exposure. (See figure 4.3-b)
4.5.6 Western blot -Determination of activation of inflammatory factors (non-canonical
TGFB-1 signaling) and canonical TGFB1Signaling proteins:
4.4.5.1 First: Inflammatory factors (non- canonical TGFB-1 signaling)
In all cerium oxide nanoparticles administered doses (1, 25, 50 µg/ml), there were
no significant changes in the ratio between the phosphorylated and inactive AKT protein
in all doses and compared to control, p-value >0.05 (see figure 4.5-a). In all cerium oxide
nanoparticles administered doses (1, 25, 50 µg/ml), there were no significant changes in
the ratio between the phosphorylated and inactive P38 protein in all doses and compared
to control, p-value >0.05 (see figure 4.5-d). In all cerium oxide nanoparticles
administered doses (1, 25, 50 µg/ml), there were no significant changes in the ratio
between the phosphorylated and inactive ERK1/2 protein in all doses and compare to
control, p-value >0.05 (see figure 4.5-c).
In all cerium oxide nanoparticles administered doses (1, 25,50 µg/ml), there were
no significant changes in the ratio between the phosphorylated and inactive JNK protein
in all doses and compared to control, p-value >0.05 (see figure 4.5-b). In all cerium oxide
nanoparticles administered doses (1, 25, 50 µg/ml), there were no significant changes in
the ratio between the phosphorylated and inactive IKB-ALPHA protein in all doses and
compared to control, p-value >0.05 (see figure 4.6-a). The rate of NFKB phosphorylation
was significantly high at control (non-treated cells) compared to 50 µg/ml. There was no
significant difference between the control, 1µg/ml and 25 µg/ml, (the p-value >0.05), but
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there was a significant difference between control, and 50 µg/ml where p-value <0.05.
The phosphorylation rate of NFKB was less in 50 µg/ml compared to the control and 1
µg/ml and 25 µg/ml (see figure 4.6-b).
4.4.5.2 Second: Activation of canonical TGFB1Signaling proteins:
The rate of TGFβ -1 expression in control compared to allcerium oxide
nanoparticles doses was not significant and the p-value >0.05 (see figure 4.7-a). The
expression of smad2/3 were extremely significant between control (non-treated cells) and
1µg/ml, 25 µg/ml and 50 µg/ml, the p-value <0.0001. The smad2/3 ratio of
phosphorylation reduced significantly at all doses compared to control, the pvalue<0.0001(see figure 4.7-b). There was no significant difference between control (non
treated cells) and the dose 1µg/ml, and p-value >0.05. But there was a significant
reduction in

-smooth muscle actin ( -SMA) expression at the doses 25 µg/ml and 50

µg/ml the p-value<0.0001 compared to control and 1µg/ml (see figure 4.7-c). Compared
to control (non-treated cells), there was a significant absent in collagen expression in all
administered doses and the p-value <0.0001 (see figure 4.7-d)
4.5 Discussion
4.5.1 Physicochemical properties of cerium oxide nanoparticles
The results of this study indicated that the cerium oxide nanoparticles were small
and in average size of 11.8 nm (STEM). The size of particles is crucial as it determines
the interaction of materials in a biological setting. Small particles have a large surface
area to volume ratio, transforming the surface of the nanomaterial to react on itself as
well as surrounding elements (Gatoo et al., 2014). The size of a particle and surface area
reveals the reaction of the system, distribution, and elimination of materials. Various
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biological processes are influenced by the surface of the particle, such as cellular uptake,
endocytosis, and efficiency of particle processing. The toxicity of nanoparticles based on
their size depends on their ability to enter a biological system and affect the structure of
several macromolecules, thus affecting critical biological processes (Gatoo et al., 2014).
Therefore, whereas surface area and size determine the biological effects of
nanoparticles, their intrinsic cellular activities may also depend on other factors like
chemical composition. (Gatoo et al., 2014).
In this study, the STEM graph presented a spherical shape to the produced cerium
oxide nanoparticles. The biological effects of nanomaterial based on shapes affects
different factors such membrane-nanoparticles interaction, biological proteins interaction
and induce certain biological Spherical nanoparticles experience faster and easier
endocytosis compared to fiber-like or rod-shaped nanoparticles (Gatoo et al., 2014). Also,
spherical nanoparticles are comparatively less toxic regardless of their heterogeneous or
homogenous nature (Gatoo et al., 2014). Also the uptake of spherical nanomaterials is
comparatively higher compared to non- spherical nanoparticles (Gatoo et al., 2014).
The toxicity of nanoparticles may also depend on their surface properties since it
determines how they interact with cells and other biological elements. Surface coating
affects cytotoxic properties due to their ability to change their physiochemical features
like electric, optical, magnetic, and chemical reactivity (Gatoo et al., 2014). Also, surface
coating may alter pharmacokinetics, accumulation, toxicity, and distribution of
nanoparticles.
In this study we used PVP coating polymer to stabilize the cerium oxide
nanoparticles and interestingly the produce nanoceria didn’t induce cellular toxicity
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through impacting cell viability, cellular membrane integrity and DNA strand. This is
might be that PVP surface coating eliminates and prevents adverse effects caused by
cerium oxide nanoparticles. Specifically, proper surface coating may stabilize
nanoparticles as well as evade the release of harmful ions from nanoparticles (Gatoo et
al., 2014). Generally, surface coatings are necessary as they enhance the core’s resilience,
averting ion leaching, and increase the dispersibility of media such water (Gatoo et al.,
2014).
In this study the zeta potential of synthesized cerium oxide nanoparticles was
0.54 1. The coating agent also determines nanoparticle charges. Nanoparticle charges
may affect their toxicity. (Gatoo et al., 2014). Nanoparticles charge can affect the cellular
uptake and determines the strength of the interaction between nanoparticle and the cells
and also enhances cell adhesion (Gatoo et al., 2014).
4.5.2 Cell viability and survival growth rate after exposure to cerium oxide nanoparticles
MTT assays
Through the MTT assay, cell viability was investigated in the presence of (1, 25,
50

g/ml) doses of cerium oxide nanoparticles. These cerium oxide nanoparticles were

found to be non-toxic since they did not impact the cell viability. This result provided us
that the cerium oxide nanoparticles safe to use on the cells.
4.5.3 Cellular proliferation assay BrdU
In this study cerium oxide nanoparticles didn’t initiate changes in cellular
proliferation rate. This means that the cerium oxide nanoparticles didn’t target the
receptors and proliferation pathways in the cells. In fibrosis, the fibroblast cells should
proliferate in high and sufficient number before differentiation to get to produce the
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necessary extracellular matrix proteins (ECM) which increase the fibrosis through the
TGFβ signaling pathway (Kendall, 2014). In this study the case, those cerium oxide
nanoparticles didn’t initiate the proliferation process on fibroblasts hence producing antiinflammatory signals which prevent fibrosis or inflammation.
4.5.4 Cellular membranes damages by lactate dehydrogenase (LDH) assay
The cerium oxide nanoparticles did not induce necrosis. Since inflammation and
reactive oxygen species (ROS) initiated necrosis (Walkey et al., 2015). Cerium oxide
nanoparticles might deactivate the potential of the cells to produce inflammation and
reactive oxygen. The inflammation and ROS derive the cellular membrane damage and
release the lactase dehydrogenase as a biomarker for necrosis (Walkey et al., 2015.)
4.5.5 Determination of apoptosis in MEF Cells by TUNEL cell death kit
Our data showed that cerium oxide nanoparticles were not initiating apoptotic
pathways or DNA damage. For DNA damage to occur there must be some endogenous
or exogenous factors such reactive oxygen species (ROS) and inflammation (Walkey et
al., 2015), which in our study were rendered unreactive by the presence of cerium oxide.
The same principle applies to cells that undergo apoptosis. Therefore, the absence of
reactive oxygen species induces the anti-inflammatory proteins in the cells thus
preventing the death of fibroblasts (Benameur et al., 2015). As a result, we can conclude
that cerium nanoparticles are safe therapy for patients with cardiac fibrosis.
4.5.6 Western blotting for determination of levels of proteins involved in inflammation
and TGFB-1 signaling
4.5.6.1 First: The inflammatory (non-canonical TGFB-1 signaling) proteins
There are certain inflammatory factors that can initiate TGFB signaling and
described them as non smads dependent factors (Zhang, 2008). These factors include
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AKT, ERK1/2 P38, JNK, IKB-α and NFKB. Our data indicated that cerium oxide
nanoparticles did not induce inflammation through activation of inflammatory factors
such (AKT, ERK1/2 P38, JNK, IKB-α and NFKB). The results were not significant
compared to control (untreated cells) except for NFKB factor at cerium oxide
nanoparticles dose 50µg/ml, where it was significantly decreased. This confirmed the
anti-inflammatory properties of the cerium oxide nanoparticles and made cerium oxide
nanoparticles sufficient agent in treating cardiac fibrosis. Also, Smad2/3 proteins were
seen to be phosphorylated independently with the availability of reactive oxidative
oxygen (ROS) (Tan et al., 2015). In this case, it might be possible the increase
inflammation in the absence of cerium oxide nanoparticles.
4.5.6.2 Second: Canonical TGFB1Signaling proteins:
Our data indicated that the cerium oxide nanoparticles didn’t interact directly or
significantly interfere with the TGFB-1 protein compared to control. Still some studies
showed that, TGFB-1 protein can play a preventive role to reduce myocardial cells death
(Euler, 2015) because it attacks activin receptor like kinase (ALK) proteins, which are
responsible for the necrosis or apoptosis of myocardia (Euler, 2015). In this study it has
been achieved, that cerium oxide didn’t interfere with the level of TGFB-1 expression
and that can help in keeping functionality of TGFB in the right position. Although cerium
oxide nanoparticles didn’t interfere with the level of TGFB protein, the still cerium oxide
nanoparticles affects the manifestation of the smad2/3 protein.
Cerium oxide nanoparticles might have ability to block the signal communication
between the TGFB-1 and smad2/3. Additionally, the study showed those cerium oxide
nanoparticles at dose 25 µg/ ml and 50 µg/ml were capable to shut down the expression
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of alpha-SMA-positive myofibroblast. This could indicate that cerium oxide
nanoparticles might protect from myofibroblast formation and fibrosis which give chance
to cardiac cells regeneration of the mammalian heart hence protecting the heart from
rupturing. Our data indicated the role of cerium oxide nanoparticle to swithch of
production of collagen A. this considered cerium oxide nanoparticles as a promising
therapeutic agent to treat cardiac fibrosis. Fibroblasts collagen that speed the conversion
of fibroblast into myofibroblasts whereas myofibroblasts produce collagen that acts as
fibrosis marker (Fan et al., 2012)
4.6 Conclusion
To conclude, the cerium oxide nanoparticles have proven to show promising
results in the drug therapy used for treating cardiac fibrosis. Cerium oxide nanoparticles
can be incorporated with proteins responsible about

TGFB-1 signaling. When the

cerium oxide nanoparticles are present, they regulate the TGFβ signaling pathways which
in return switch down the cells that produce extracellular matrix (ECM) proteins in the
TGFβ-SMAD signaling pathways. Thus, the cerium oxide nanoparticles can be used to
treat cardiac fibrosis since it causes the reduction of inflammatory proteins responsible
about the activation of the TGFβ signaling pathways to downplay the production of αSMA and collagen. So, the cerium oxide nanoparticles can be used to administer drugs
for patients with cardiac fibrosis. This will retard the fibroblast growth and differentiation
to myofibroblast and releases of collagens.
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Figure 4.1. Physicochemical properties of Nanoceria: (a) TEM core size distribution
analysis & (b) TEM image of Monodispersed spherical in shape PVP coated cerium
oxide nanoparticles with average core size 11.8 nm synthesized in ultrapure cell
culture water. They are capped with a polymer coating (polyvinylpyrrolidone) to
stabilize and prevents their aggregation, (c ) overall average hydrodynamic size of
cerium oxide nanoparticles equals to 14 nm determined, by DLS , zeta potential by
Zetasizer and spectral absorbance 279 nm by UV-vis measurements.
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Figure 4.2. Cell viability of MEF cells after exposure to Nanoceria: Cell viability of
MEF cells after exposure to 1µg/ml, 25µg/ml, & 50µg/ml of cerium oxide
nanoparticles between 24-hours to 6 days. There were no significant changes in cell
viability at all administered doses of cerium oxide nanoparticles compared to nontreated cells (control)Notes: Data were presented as normalized mean ± MSE. Pvalue >0.05
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Figure 4.3. Effects of Nanoceria on cell proliferation & DNA damage: (a) Graphic
representation of the relative BrdU incorporation in MEFs after 24-hours exposure to
1µg/ml, 25µg/ml& 50µg/ml of cerium oxide nanoparticles, compared to non-treated
cells (control), there were no significant difference in proliferation rate in all cerium
oxide nanoparticles administered doses. (b) The DNA damage and apoptosis not
detected by TUNEL assay. Notes: Data were presented as mean ± MSE, Pvalue>0.05
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Figure 4.4. Necrotic effects of Nanoceria on MEF Cells: (a-b) Membrane integrity
which represent necrotic effects on MEF cells after 24-hours & 6 days exposure to 1
µg/ml, 25 µg/ml & 50 µg/ml of cerium oxide nanoparticles compared to negative
control (only treated with water as spontaneous LDH control) and positive(Lysis
buffer) LDH control. The data indicated no difference between the negative control
and all administered doses of platinum nanoparticle in both 24 hours and 6 days’
time period which indicating that platinum nanoparticles didn’t induce cellular
damage or necrosis. The data presented significant differences between all
administered doses of platinum and the lysis buffer (positive control). Notes: Data
were presented as mean ± MSE (***) extreme significant P-value <0.0001, Ns =not
significant , P-value >0.0
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Figure 4.5.Immunoblotting of non-canonical factors after Nanoceria treatments
(part1): Normalized Level of proteins expression in Western blot analysis after
exposure to (0, 1,25 & 50 µg/ml) of cerium oxide nanoparticles, β-Actin was also
measured as the loading control and used for data normalization.(a-d ) there were no
significant differences in the phosphorylation ratio between non-treated cells
(control) and all doses of cerium oxide nanoparticles treated cells for (AKT ,
JNK,ERK1/2,P38 proteins) p-value >0.05, indication of non-induction of
inflammation.
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Figure 4.6.Immunoblotting of non-canonical factors after Nanoceria treatments
(part2):Normalized Level of proteins expression in Western blot analysis after
exposure to (0, 1,25 & 50 µg/ml) of cerium oxide nanoparticles, β-Actin was also
measured as the loading control and used for data normalization.(a) there were no
significant differences in the phosphorylation ratio of IKB- between non-treated
cells (control) and all doses of cerium oxide nanoparticles treated cells p-value
>0.05, (b) there were significant reduction in phosphorylation ratio of NFKB at the
doses of 50 g/ml of platinum nanoparticles treated cells compared to control , 1
g/ml dose ,and 25 g/ml (*) p-value <0.05, indication that cerium oxide not
inducing inflammation.
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Figure 4.7.Immunoblotting of canonical factors after Nanoceria treatments :
Normalized Level of proteins expression in Western blot analysis after exposure to
(0, 1,25 & 50 µg/ml) of cerium oxide nanoparticles, β-Actin was also measured as
the loading control and used for data normalization.(a) there was no significant
difference in the expression of TGFB at all dosses of cerium oxide nanoparticles
treated cells compared to control (b) there was significant inhibition of smad2/3
phosphorylation at all dosses of cerium oxide nanoparticles treated cells compared
to control. (c) There were significant decrease in the expression of -SMA at the
doses of 25 g/ml and 50 g/ml of cerium oxide nanoparticles treated cells
compared to control and 1 g/ml dose, indication of inhibition of canonical
activation of TGFB signal. (d) There was significant inhibition of collagen-1A
expression at all doses of cerium oxide nanoparticles treated cells compared to
control. (*) p-value <0.05, (**) p-value<0.01, (***) p-value<0.001
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CHAPTER 5
CONCLUSIVE SUMMARY AND CONSIDERATION
5.1 Conclusion
The rise of the field of nanotechnology has significantly changed drug
development and discovery perception by addressing gaps that existed in the
pathophysiology of diseases as well as the advancement of new treatment options.
Although nanoparticles such as selenium, platinum, cerium oxide, among others, have
been used commercially developed and used successfully in research as drug delivery
carriers and used as therapeutic agents, still their properties and biological behaviors not
hoelistically knownw. Based on results form this study and other

research on the

nanoparticle's physiochemical characteristics of nanoparticles and their respective
dosimetry, certain nanoparticles can produce reactive oxygen species that can regulate
many cellular functions such as growth, proliferation, and autophagy. They can also
modulate the fate of various cells, including mitotic catastrophe, apoptosis, necroptosis,
and necrosis (Mohammadinejad et al. 2019). Our research was focused on defining some
of its biological impacts on a cellular level by using mouse embryonic fibroblast cell line
(MEF) to add to the existing literature to provide benefit scientists in public health and
biomedical field. It is hoped that our research help address the importance and application
of these nanoparticles in the field of therapy for diseases such as cancer &fibrosis.
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Our findings indicated that these nanoparticles are essential when it comes to
targeting diseases. Results from our selenium nanoparticles exposures clearly indicated
their abilities to kill cells and inhibit massive growth of MEF cells, which might be a
good outcome insome cancer therapies to induce intrinsic or mitochondria apoptosis.
Selenium nanoparticles serve as the most promising nanoparticles because of their good
biocompatibility and high anticancer activity. Many reports show the role of selenium
compounds in cancer cells apoptosis induction, causing some massive side effects such
inflammation, oxidative stress and necrosis (Khurana et al. 2019). In our study, the
selenium nanoparticles have been shown to cause apoptosis in a time and dose-dependent
manner without the aforementioned side effects. We found that selenium nanoparticles
cause apoptosis by initiating mitochondrial pro-apoptotic and apoptotic proteins such
caspase 3 and caspase 7 inductions. Anticancer effects in these nanoparticles have been
reported at doses close to toxic levels. Cells that are exposed to a dose of 1microgram/ml
die after just 2 days.
Previous research has show that selenium nanoparticles cause necrosis or
necroptosis. ataResults from our research, however, indicated that selenium nanoparticles
induced intrinsic apoptosis and no necrosis. The reason for this in part may bethe
different methods used in the synthesis of our selenium nanoparticles as the chemical
synthesis used in our experiments may have contributed to some of the results observed.
Besides, the structural properties, both the surface coat and size of the selenium
nanoparticles, may also play a crucial role. Selenium nanoparticles may cause different
cell death mechanisms based on their compactness, structure, size, bioavailability, and
presence of selenium nanoparticles' functional groups.
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Convectional necroptosis pathways are generally triggered by various
inflammatory signals such as toll-like receptors (TLRs) and tumor necrotic factor-alpha
(TNFα). These processes are caspases independent and may be triggered by a necrosome
complex that contains RIP1 and 2 (Sonkusreand Cameotra, 2017). For the occurrence of
necroptotic cell death, MLKL has to be phosphorylated through RIPK3. However, no
such expression was observed in our research, which is the one of the primary reasons no
necrosis occurred. Our chemical synthesized selenium nanoparticles might give hope to
chemotherapeutics for their ability to exhibit differential activity against normal and
malignant cells. With anticancer molecules, selenium nanoparticle offers a novel method
to treat cancer.
Platinum nanoparticles have also been indicated to have the capacity to enter cells
(Yamada et al., , 2015). Their mode of action mechanism in cancer therapy is linked to
their DNA crosslinking ability and thus causing damage to DNA and, ultimately,
apoptosis. On the other hand, TGF-β, a regulatory peptide, plays a significant role where
it controls various cellular function aspects such as apoptosis, immune surveillance,
angiogenesis, migration, survival, differentiation, adhesion, and cellular proliferation
(Lebrun, 2012). Platinum nanoparticles are also strong catalysts because of their large
surface area (Shibuya et al., 2014). They may induce anti-inflammatory responses
(Acton, 2011). Results from our studies suggest that platinum nanoparticles initiated the
TGFB-1 canonical Smads dependent pathway but did not induce the non-canonical
pathway and inflammation.
These results are important for -TGFB-1 SIGNALING, especially when cancer is
in the early stages. In this stage, TGF-β mainly acts as a tumor suppressor, where it
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induces apoptosis or inhibits the proliferation of premalignant cells (Sun et al., 2016). In
later more advanced cancer progression stages, care should be taken when using platinum
nanoparticles. This is because, at these late stages of cancer development, TGF-β, unlike
in earlier stages of cancer, promotes metastasis. It also triggers epithelial-mesenchymal
transition, which results in more cancer cell invasion and by inducing genes facilitating
secondary organ sites spread such as brain, liver, bone, and lung metastatic colonization
(Sun et al., 2016).
Platinum nanoparticles may also be vital in the treatment of patients with fibrosis
because of their ability to of initiate TGFB signaling. They are intrinsic antioxidants that
scavenge free radicals formed and inhibit deleterious reactive oxygen species (ROS)
downstream inflammatory effects (Morry et al.,

2017). Therefore, since TGFB-1

signaling induction in fibrotic diseases will worsen tfibrosis and the resulting health of
patients . Platinum nanoparticles clearly help protect cells against oxidative stress. Their
antioxidant properties may be used to offer targeted therapy. But this will need more
targeted studies in the future to better differentiate the fine line between platinum
nanoparticles beneficial therapeutic activities versus their risk of toxicity and/or disease
progressions.
Cerium oxide nanoparticles have many commercial applications, such as catalytic
converters in automotive and oxygen sensors, among others. These nanoparticles have
recently gotten more attention today for their good catalytic properties derived from fast
oxidation state mutation between Ce3+ and Ce4+. (Xu and Qu, 2014). More recently
cerium nanoparticles have been employed in modulating oxidative stress in biological
systems. Their anti-inflammatory and antioxidant properties have made them highly

136

effective as therapeutic agents (Davidson et al., 2015). Our research results demonstrated
that these nanoparticles play a huge role in the shutdown as well as downregulation of the
TGF-β1 signaling pathway and do not induce inflammatory responses, which might
cause cardiac fibrosis. This is very important given the wide spread obesity in the many
developed nations of the world including the U.S.
TGF-β may contribute to cardiac fibrosis as it can contribute to cardiac
hypertrophy and cardiomyocyte apoptosis (Liu et al., 2017). Activin receptor-like kinase
(ALK1) in canonical signaling pathway activates Smads 1 and Smad 5 while Smad2 and
SMAD3 areactivated by ALK5 (Walton et al., 2017). These Smad pairs bind to Smad 4
after the formation of a corresponding complex and translocate into the nucleus where the
extracellular matrix is produced and myofibroblast formed through transcriptional
programming (Liu et al., 2017). This eventually leads to cardiac fibrosis and disease.
Reactive oxygen species in fibrosis enhances activation as well as the proliferation of
myofibroblast and fibroblasts, which lead to activation of the TGF-β pathway.
Unfortunately, only a few therapeutic fibrosis management strategies exist. One of the
logical fibrosis therapeutic interventions is using ROS which generates
oxidases inhibitors, enzymes, and antioxidant supplements (Morry et al.,

NADPH
2017).

According to our research results, cerium oxide nanoparticles may helpto protect against
cardiac fibrosis progression as well as remodeling by myocardial oxidative stress
attenuation and inflammatory processes since they possess antioxidant properties. The
clear conclusion for our research is that through TGF-β1 signaling modulation, cerium
oxide nanoparticles might help to protect against injury resulting from inflammation and
thus help cardiac fibrosis patients to reduce the risk of fibrosis in the disease.
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5.2 Future Recommendations
In conclusion, besides the interesting results of our study and the comparisons
with other published stidies it is very clear that further research on these three
nanoparticles needs to be conducted. Moving from in vitro cellular studies to more
robust in vivo animal models will be vital in that it will give more robust information
about the inherent organ system toxicity, fibrosis and inflammation as well as the
important therapeutic effects of these nanoparticles. Since there are contradictive data
about each nanoparticles, for example selenium nanoparticles (see figure 5.1& 5.2
e.g.comparative adverse outcomes), it should be tested in different cancer cells types and
evaluated for the same outcomes. We should also reduce the doses below 1ug/ml, and
reduce the exposure times (4-6 hrs) and asses toxicity outcomes compared to what has
been previously found in the literature. For platinum nanoparticles (see figure 5.3: e.g.
comparison of different synthetized Pt nanoparticles in cell viability) we should asses the
toxicity at similar conditions described in other studies and we should use cancer cell
models such liver cancer,since fibrosis associated with Non Alcoholic Liver Disease is
part of liver cancer progression. For cerium oxide since there are some contradicting data
about toxicity (see figure 5.4), we need to apply existing models of cardiac fibroblast and
myofibroblast under pathological conditions, adding TGFB as positive control to quantify
the differences in expression of fibrotic factors.
All of these suggestions fall to the next line of public health and biomedical
researchers who will help us continue to more fully explore the universe of nanomaterial
therapeutics and human diseases to which nanoparticles can help provide therapeutic
treatments and cures. This is highly transdisiplanary science requiring the skills of
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nanomaterial chemists, molecular biologist and biomedical toxicologists to continue this
quest. My research has been a small part of this journey and I am very thankful for the
results we have obtained for everyone who helped guide this research forward.
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Figure 5.1. Doses comparisons between PVP- Se NPs & other studies: Biological
effects in dose and type dependent manner following 24 - 48 hours exposure to
selenium obtained from different studies and compared to PVP-Se NPs produced in
this study. Proportions in each pie represent comparisons of doses used in each
study, (a) effect of doses in necrosis (b) effect of doses in apoptosis (c ) effect of
doses in cell viability, proliferation and DNA damage. (a) Sufficient doses of
Biogenic Selenium (110 nm), 2ug/ml (Sonkusre et.al , 2017 ) and Chitosan (CS) -Se
NPs (40-60 nm) 10 ug/ml (Heras et. al, 2014) which induced necrosis after 24 hours
exposure, where PVP-Se NPs (in this study) and SPS-Se NPs (20-50 nm), 1.3 ug/ml
(Chen et.al,2012) didn’t induce necrosis after 24 hours exposure.(b) 1µg/ml was the
minimum dose of 68 nm PVP-Se NPs (this study) needed to induce apoptosis after
24 hours of exposure compared to SPS-Se NPs (20-50 nm), 1.3 ug/ml (Chen
et.al,2012) after 24 hours; Biogenic Selenium ( 110 nm), 2ug/ml (Sonkusre et.al ,
2017) after 24 hours, and Chitosan (CS) -Se NPs (40-60 nm), 10 ug/ml (Heras et. al,
2014) after 24 hours exposure. (c) 1µg/ml was the minimum doses of 68 nm PVP-Se
NPs (this study) need to reduce cell viability, proliferation and DNA damage after 72
hours compared to SPS-Se NPs (20-50 nm), 1.3 ug/ml (Chen et.al,2012) after 24
hours; Biogenic Selenium ( 110 nm), 2ug/ml (Sonkusre et.al , 2017 ) after 24 hours,
and Chitosan (CS) -Se NPs (40-60 nm), 10 ug/ml (Heras et. al, 2014) after 24 hours
exposure. These comparisons with our results clearly indicate the importance of
particle size and type as well as dose in inducing therapeutic effects and illustrate
that our findings are in keeping with results from other studies.
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Figure 5.2. Adverse outcome comparisons between PVP- Se NPs & other studies:
Differences in cellular adverse outcomes at different exposure time [24-144 hours (6
days)] induced by different Se NPs, obtained from different studies compared to
lowest dose of (1ug/ml) of PVP-Se NPs (this study). In our study cell viability was
not reduced until 72 hours at the 1ug/ml of PVP-Se NPs dose; Necrosis in our study
was not observed after 6 days compared to Biogenic Selenium ( 110 nm), 2ug/ml
(Sonkusre et.al , 2017 ) and Chitosan (CS) -Se NPs (40-60 nm) 10 ug/ml (Heras et.
al, 2014) which induce necrosis after 24 hours. Whereas there was significant
apoptosis progress by PVP-Se NPs after 24 hours.
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Figure 5.3. Cell Viability comparisons between PVP- Pt NPs & other studies:
Comparison on % of cell viability after (24h-6 days) exposure to PVP-Pt NPs (this
study) compared to other platinum produced nanoparticles obtained from other
studies. Both PVP-Pt NPs (this study) at 50ug/ml and Pt NPs (Kutwin, et al. 2014)
didn’t induce any significant reduction at viability compared to other studies results
after exposure time between 24 -144 hours(6 days)
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Figure 5.4. Cell Viability comparisons between Nanoceria & other studies:
Comparison on % of cell viability after (24h-6 days) exposure to PVP-Ce NPs (this
study) compared to other cerium oxide produced nanoparticles obtained from other
studies. PVP-CeNPs (this study) at 50 ug/ml and Ce NPs (Oostingh, 2011) at
200ug/ml didn’t induce any significant reduction on % of viability compared to other
studies after exposure time between 24 -144 hours (6 days).
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APPENDIX A
ADDITIONAL DATA OF CHAPTER 2
In this study the selenite salt toxicity assisted (include cell viability (MTT assay,
proliferation (BrdU assay) and necrosis (LDH assay), the protocol of assessment is
typical to protocol of assessing the selenium nanoparticles in this study:

Figure A.1. Cell Viability (MTT assay) of selenium salt (selenite): Selenite used to
produce Selenium nanoparticles: In this study, the results of (MTT assay), and the
selenite salt induce extreme reduction in cell viability in dose and time dependent
manner. The reduction rate in viability started immediately after 24 hours exposure
to selenite and increased significantly within the time compared to the non-treated
cells (control), p-value < 0.0001. The selenite administered doses induced toxic
effect earlier than selenium nanoparticles, p-value < 0.05(see figure 1). All values
are represented as the means ± MSE. Asterisks (***) indicated p values of < 0.001,
which were extremely significantly different from controls (unexposed MEF cells).
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Figure A.2. Cell proliferation (BrdU assay) after Selenium salt exposure: In the
proliferation rate (BrdU), there were significant reduction in proliferation rate after
24 hours exposure to selenite salt compared to non- treated cells (control), p-value
<0.001. Compared to selenium nanoparticles, the reduction after exposure to
selenite were not significant, p-value >0.05. Both the salt and the nanoparticles
within the same rhythm of reduction in proliferation (see figure 2).All values are
represented as the means ± MSE
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Figure A. 3. Necrotic effect of selenite salt: In this study and similar to selenium
nanoparticles effect, the selenite salt didn’t induce cellular membrane damage or
necrosis after 24 hours and 6 days compared to water treated cells (negative control),
p-value > 0.05. Where there was significant difference between all administered
doses of selenite and the Lysis buffer treated cells (positive control), p-value <
0.0001. (See figure 3-a &b). All values are represented as the means ± MSE
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Figure A. 4. The UV-VIS absorbance and energy band of Se NPs: (a) UV-visible
absorption spectra of our synthetized PVP- Se NPs in cell culture water suspension.
(b)Table of calculated energy gap band of our synthetized PVP-Se NPS compared to
other selenium species from (Jiang, 2017).
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Table A. 1 ICPOES concentration analysis before and after exposure to selenium NPs
Synthesized Selenium NPs initial concentration in cell
culture water
Se dissolve fraction

Initial
administer
ed dose (
µg/ml)

Non
treated
cells
(–ve
control)

Total Cell
density/
treatment
(10^6)

2.7*10^6

Final
ICPOES
detected
concentrati
ons of Se
NPs / total
cells of
each
treatment (
C ) µg/ml

0.00008

Dilution
volume of
ICPEOS (V)
ml

6

175.6 g/ml
0.3 g/ml

Final mass
(M) of Se
NPs /cells
(M=C*V)

Final mass
(M) of Se
NPs /cells
density
(M=C*V)

0.00048

0.00048 µg
/ 2.7*10^6
cells

1 µg/ml

1.6*10^6

0.85

6

5.1

25 µg/ml

1.4*10^6

21.8

6

130.8

50 µg/ml

1.2*10^6

42.5

6

255
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5.1 µg /
1.6*10^6
cells
130.8 µg /
1.4*10^6
cells
255 µg /
1.2*10^6
cells

Table A.2: Lists of primary and secondary antibodies used in selenium study
Primary antibody
Name

Company

Product #

Dilution

ß-Actin

Cell
signaling

A5441

1:3000

Application
WB

P53

Cell
signaling 2524

1:1000

Bax

Cell
signaling

9292

1:1000

Bcl-2

Santa Cruz

16910-50

1:1000

WB

Caspase-3

Cell
Signaling

9665

1:1000

WB

Caspase-7

Cell
Signaling

9661

1:200

WB

Cytochrome C

Santa Cruz

7159

1:1000

WB

PARP-1

Santa Cruz

74470

1:1000

WB

Secondary antibody
Name

Company

Product #

Dilution

Application

ECL anti-mouse IgG
HRP linked

Cell
Signaling

7076

1:2500

WB
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WB
WB

APPENDIX B
ADDITIONAL DATA OF CHAPTER 3
In this study the platinum salt toxicity assisted (include cell viability (MTT assay,
proliferation (BrdU assay) and necrosis (LDH assay), the protocol of assessment is
typical to protocol of assessing the nanoparticles in this study.

Figure B.1. Cell viability (MTT assay) after exposure to platinum salt:
Chloroplatinic acid used to produce platinum nanoparticles: After 48 hours exposure
to platinum salt, the cell viability was significantly reduced at the dose 25and 50
ug/ml, and significantly continue to reduce in all administered dose from 72 hours
tell 6 days, p-value < (0.00-0.001). Compared to platinum nanoparticles, there were
significant differences where platinum nanoparticles didn’t induce any changes in
cell viability in all administered doses and times, p-value <0.0001.

192

Figure B.2. Cell proliferation (BrdU assay) after exposure to platinum salt:
Compared to platinum nanoparticles, both salt and nanoparticles significantly reduce
the proliferation rate in all administered doses compared to non-treated cells
(control), p-value (0.001-0.0001).
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Figure B.3. Necrotic effect of platinum salt: In this study and similar to platinum
nanoparticles effect, the platinum salt didn’t induce significant cellular membrane
damage or necrosis after 24 hours compared to water treated cells (negative control,
p-value > 0.05. Where there was significant difference between all administered
doses of salt and the Lysis buffer treated cells (positive control), p-value < 0.0001.
After 6 days exposure to platinum salt, there was significant necrosis appeared in all
administered doses compared to the water treated cells (negative control), p-value<
0.001. Compared to platinum nanoparticles, the salt significantly induced necrosis
after 6 days, p-value <0.0001.
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Table B.1 ICPOES concentration for platinum NPs before and after exposure
Platinum NPs initial concentration in ultrapure
cell culture water
Pt dissolve fraction
Initial
Total Cell
Final
Dilution
administ
density/
ICPOES
volume of
ered
treatment
detected
ICPEOS (V)
dose
concentration
ml
( µg/ml)
s of Pt NPs /
total cells of
each
treatment (C)
µg/ml
Control
2.7*10^6
0
6
(0
µg/ml)
1 µg/ml
1.8*10^6
0.24
6
25 µg/ml 1.3*10^6
14.66
6
50 µg/ml 1.2*10^6
23.26
6
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66.04 g/ml
0.094g/ml
Final mass (M) of Pt NPs
/cells density (M=C*V)

0.0 µg/ 2.7*10^6 cells

1.44 µg/ 1.8*10^6 cells
87.96 µg/ 1.3*10^6 cells
139.56 µg/ 1.2*10^6 cells

Table B. 2 Lists of primary and secondary antibodies in platinum NPs study
Name

Company

Product #

Dilution

Application

Akt

Santa Cruz

93856

1:1000

WB

p Akt

Cell Signaling

4051

1:1000

WB

Jnk

Cell Signaling

9661

1:200

WB

p-Jnk

Cell signaling

9261

1:1000

WB

Erk

Cell Signaling

9108

1:1000

WB

p Erk

Cell Signaling

9106

1:1000

WB

P38

Cell signaling

MA3-023

1:3000

WB

pp38

Cell signaling

4631

1:1000

WB

NF-кB

Santa Cruz

372

1:1000

WB

Cell signaling

4692

1:1000

WB

1:1000

WB

1:1000

WB

1:1000

WB

1:1000

WB

1:3000

WB

IкB-α

44-244G
Smad2/3

Thermofisher
PA5-36125

p-Smad2/3 Thermofisher
α-SMA

Thermofisher

Col-1-A-1

Santa Cruz

ß-Actin

Cell signaling

14-9760-82
59772
A5441
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APPENDIX C
ADDITIONAL DATA OF CHAPTER 4
In this study the cerium salt toxicity assisted (include cell viability (MTT assay,
proliferation (BrdU assay) and necrosis (LDH assay), the protocol of assessment is
typical to protoco l of assessing the nanoparticles in this study

Figure C.1. Cell viability (MTT assay) of cerium salt: Cerium nitrate hexahydrate
used to produce Selenium nanoparticles: Similar to cerium oxide nanoparticles, the
cerium salt didn’t induce any changes to cell viability in all administered doses and
times, p-value >0.05

197

Figure C.2. Cell proliferation (BrdU assay) after exposure to cerium oxide salt:
Similar to cerium oxide nanoparticles, the cerium salt didn’t induce any changes in
proliferation rate in all administered doses after 24 hours exposure, p-value >0.05.
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Figure C.3. Necrotic effect of cerium salt: Similar to cerium oxide nanoparticles, the
cerium salt didn’t induce any changes in cellular membrane or causes any necrosis in
all administered doses after 24 hours and 6 days, p-value >0.05 (see figure above (a
& b)
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Figure C. 4. Additional figures of cerium oxide NPs by Hitachi HT7800 TEM
microscopy
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Table C.1 ICPOES concentration before and after exposure to cerium oxide NPs
Cerium oxide NPs initial concentration in
cell culture water
CeO2 dissolve fraction
Initial
administ
ered
dose
( µg/ml)
Control
(0
µg/ml)

Total Cell
density/
treatment

2.8*10^6

Final detected
ICPEOS
concentrations of Ce
NPs / total cells of
each treatment ( C )
µg/ml

0

151.74 g/ml
0.004g/ml
Dilution
volume of
ICPEOS
(V) ml

final mass
(M) of Ce
NPs /cells
(M=C*V)

6

0.0 µg /
2.8*10^6
cells

6

2.1786
µg/1.6*10^6
cells

6

111.02694
µg/
1.5*10^6
cells

6

171.33 µg/
1.5*10^6
cells

0.3631
1 µg/ml

1.6*10^6

18.50449
25 µg/ml

1.5*10^6
28.555

50 µg/ml

1.5*10^6
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Table C. 2 List of primary and secondary antibodies in cerium oxide study
Name
Akt
p Akt
Jnk
p-Jnk
Erk
p Erk
P38
pp38
NF-кB
IкB-α

Company
Santa Cruz
Cell Signaling
Cell Signaling
Cell signaling
Cell Signaling
Cell Signaling
Cell signaling
Cell signaling
Santa Cruz

Product #
93856
4051
9661
9261
9108
9106
MA3-023
4631
372

Dilution
1:1000
1:1000
1:200
1:1000
1:1000
1:1000
1:3000
1:1000
1:1000

Application
WB
WB
WB
WB
WB
WB
WB
WB
WB

Cell signaling

4692

1:1000

WB

1:1000

WB

1:1000

WB

1:1000

WB

1:3000

WB

pSmad2/3

Thermofisher

α-SMA

Thermofisher

Col-1-A-1

Santa Cruz

ß-Actin

Cell signaling

PA5-36125
14-9760-82
59772
A5441
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